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"It is widely believed that misjudgment produces dysfunction. Certainly, 
gross miscalculation can create problems. However, optimistic self-
appraisals of capability that are not unduly disparate from what is possible 
can be advantageous, whereas veridical judgments can be self-limiting. 
When people err in their self-appraisals, they tend to overestimate their 
capabilities. This is a benefit rather than a cognitive failing to be 
eradicated. If self-efficacy beliefs always reflected only what people could 
do routinely, they would rarely fail but would not mount the extra effort 
needed to surpass their ordinary performances". 
 ALBERT BANDURA (1989) 
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Presentation 
This doctoral thesis is a compendium of research articles. At the moment 
of the preparation of this thesis, four of these papers have already been 
published, and the rest have been submitted to indexed scientific journals 
for its publication.  
Following Royal Decree 99/2011, which sets forth the regulations about 
doctorate studies in Spain, in order to obtain the degree of International 
Doctor, the current doctoral thesis has been fully written in English.   
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This chapter presents a general preface to the doctoral thesis. The 
main goal of this thesis was to develop and test in a randomized controlled 
trial a psychological intervention for anxiety and depressive disorders (i.e. 
emotional disorders) in Spanish public specialized mental health care. To 
this end, two general approaches were undertaken. The first is the use of 
Information and Communication Technologies (ICTs) and, more 
specifically, the Internet, to provide psychological interventions. The 
second is the adoption of a mechanistically, cognitive behavioral therapy 
(CBT) transdiagnostic approach to the treatment of emotional disorders.  
The general introduction starts highlighting the burden of emotional 
disorders, as well as the need for evidence-based treatments to address 
this alarming public health problem. Next, a review of the literature about 
the efficacy of disorder-specific CBT is briefly outlined, followed by a 
description of the barriers for the use of these protocols. This is followed 
by a section that underscores the challenges of current public mental 
health services regarding the treatment of emotinal disorders, both 
globally and in Spain. The next sections focus on transdiagnostic 
treatments and Internet-delivered interventions, and in how they can help 
to decrease the burden of anxiety and depressive disorders, with a 
particular emphasis in public specialized mental health care. The general 
introduction ends with a description of the general aim and the specific 
aims pursued in each chapter.  
The burden of emotional disorders 
Anxiety and depressive disorders (referred to as emotional 
disorders) negatively affect the lives of millions of people across the globe 
(Baxter, Scott, Vos, & Whiteford, 2013; Kohn, Saxena, Levav, & Saraceno, 
2004; Steel et al., 2014). Regarding anxiety, the lifetime prevalence of an 
anxiety disorder has been estimated at 28.8% (Kessler et al., 2005), 
whereas the 12-month prevalence has been estimated at 18.1% (Kessler, 
Chiu, Demler, Merikangas, & Walters, 2005). Anxiety disorders are 
associated with important costs (Andlin-Sobocki & Wittchen, 2005), 
disability (Baxter, Vos, Scott, Ferrari, & Whiteford, 2014; Hendriks et al., 
2014), and worse psychosocial functioning and quality of life (Mendlowicz 
& Stein, 2000; Rapaport, Clary, Fayyad, & Endicott, 2005). Along with 
anxiety disorders, depressive disorders are some of the most prevalent 
and disabling psychological disorders among the adult population (Ferrari 
et al., 2013). Only for major depressive disorder, the literature has shown 
a lifetime prevalence of 16.6% (Kessler et al., 2005a) and a 12-month 
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prevalence of 6.7% (Kessler et al., 2005b). Similarly to anxiety disorders, 
depression is associated with substantial impairment (Ferrari et al., 2013), 
chronicity (Andrews, 2001; Richards, 2011), and increased mortality 
(Cuijpers & Smit, 2002), as well as high personal, social, and economic 
costs (Cuijpers, Beekman, & Reynolds, 2012). In Spain, the lifetime 
prevalence for mood and anxiety disorders among patients attending 
primary care settings has been estimated at 35.8% and 25.6%, 
respectively (Roca et al., 2009). 
Another important characteristic related to emotional disorders is 
the high comorbidity rates among these conditions (i.e. when two or more 
psychological disorders co-occur in the same patient). The literature has 
shown the high current and lifetime comorbidity rates between anxiety 
disorders (Kroenke, Spitzer, Williams, Monahan, & Löwe, 2007), and 
between anxiety and depression (Brown, Campbell, Lehman, Grisham, & 
Mancill, 2001), with estimates that range from 40 to 80%. Moreover, 
higher comorbidity rates usually lead to greater severity (Kessler et al., 
2005b), poorer quality of life (Rapaport et al., 2005), higher chronicity rates 
(Hofmeijer-Sevink et al., 2012), and a worse clinical course (Bruce, 
Machan, Dyck, & Keller, 2001; Sherbourne & Wells, 1997). Thus, the 
development of assessment and treatment strategies for patients with 
anxiety and depression, as well as for patients with comorbid 
presentations of these disorders, is of paramount importance for research 
and clinical practice.  
In the past few decades, research efforts have been devoted to 
developing and testing evidence-based psychological treatments for 
different mental health problems. From the range of treatment 
approaches, Cognitive Behavioral Treatments (CBT) are those with the 
most evidence found for their efficacy and effectiveness in the treatment of 
multiple mental disorders, with a substantial proportion of this research 
focused on the treatment of depression and anxiety disorders. Data on the 
efficacy and effectiveness of these interventions have been shown in 
numerous systematic reviews for both traditional (i.e. face-to-face 
psychotherapy) (Cuijpers, van Straten, & Warmerdam, 2007; Hofmann & 
Smits, 2008; Olatunji, Cisler, & Deacon, 2010) and computerized CBT (i.e. 
computer- and Internet-delivered treatments) (Andrews et al., 2018; 
Richards & Richardson, 2012; Spek et al., 2007; Warmerdam, Van 
Straten, Twisk, Riper, & Cuijpers, 2008) and summarized in books and 
manuals about evidence-based treatments (Nathan & Gorman, 2015). 
There is extensive research showing the efficacy and effectiveness of 
disorder-specific CBT (i.e. a specific protocol to target a specific disorder) 
for the treatment of depression (Cuijpers, van Straten, Andersson, & van 
Oppen, 2008; Hollon & Ponniah, 2010), generalized anxiety disorder 
(GAD) (Borkovec & Ruscio, 2001; Covin, Ouimet, Seeds, & Dozois, 2008), 
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panic disorder (PD) and agoraphobia (AG) (David H. Barlow, Craske, 
Cerny, & Klosko, 1989; Mitte, 2005), social anxiety disorder (SAD) (Mayo-
Wilson et al., 2014), and obsessive-compulsive disorder (OCD) (Öst, 
Havnen, Hansen, & Kvale, 2015). Data on the efficacy and effectiveness 
of CBT protocols have been shown across age groups and settings, such 
as community samples and university students, as well as primary and 
specialized care (Cartwright-Hatton, Roberts, Chitsabesan, Fothergill, & 
Harrington, 2004; Cuijpers et al., 2013; Stewart & Chambless, 2009).  
 
Disorder-specific CBT protocols are effective but have 
important shortcomings  
In the past few decades, a large number of CBT protocols for both 
anxiety and depressive disorders have been developed and tested in 
clinical trials. However, whereas disorder-specific CBT has shown its 
efficacy for anxiety and depressive disorders, there are a number of 
barriers regarding these protocols that limit their utility. The first drawback 
stems from the high comorbidity rates observed among the emotional 
disorders. Because each disorder-specific treatment focuses on a specific 
set of symptoms, comorbid disorders are not directly targeted in these 
protocols (McManus, Shafran, & Cooper, 2010). Although several ways to 
address comorbidity have been proposed (e.g. sequential application of 
treatments), the literature does not support the utility of these strategies 
(e.g. McManus et al., 2010). Second, subthreshold symptoms of clinical 
entity that do not meet diagnostic criteria for one disorder or another are 
not usually targeted by disorder-specific protocols (Barlow, Allen, & 
Choate, 2004). Third, disorder-specific protocols do not target disorders 
that do not fit a specific nosological category, i.e. anxiety and depression 
“not otherwise specified” (NOS), even though these disorders may also 
have clinical significance and, therefore, should be addressed with 
appropriate treatment (Brown et al., 2001). Finally, disorder-specific 
protocols are costly in terms of training because clinicians have to be 
trained in one specific protocol for each of the different emotional 
disorders (McHugh, Murray, & Barlow, 2009).  
 
The barriers to the treatment of emotional disorders in 
public specialized mental health care 
In Spain, the two main public providers of mental health care are 
primary and specialized care. Mental health care in our country is based 
on a model in which the patient has a first consultation with a primary care 
general practitioner (GP), who typically prescribes medication (e.g. 
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antidepressants or anxyolitics), even when the patient presents with mild 
to moderate levels of anxiety or depression. When the medication is not 
effective or when the GP judges that the case is difficult or severe enough 
to require specialized attention, the patients are referred to specialized 
mental health care or mental health units, where they receive treatment 
from a psychiatrist and/or a clinical psychologist. This model differs from 
the so-called stepped care model, in which patients with mild to moderate 
depression and anxiety disorders are prescribed low intensity 
interventions, such as guided self-help and computerized CBT. This model 
has been successfully implemented in countries such as the United 
Kingdom in response to the movement Improving Access to Psychological 
Therapies (IAPT) (Clark et al., 2009). Specialized mental health care in 
Spain is provided by psychiatrists and clinical psychologists with the 
highest degree of specialization in the assessment, diagnosis, and 
treatment of psychological disorders. Therefore, patients in this setting 
receive the best therapeutic option that can be provided by the national 
public health system. However, current mental health units face a number 
of barriers that affect both the quantity and quality of the services delivered 
in these centers. First, in Spain, most of the patients attending public 
mental health services, such as mental health units, suffer from anxiety 
and depressive disorders (Montilla, González, Retolaza, Dueñas, & 
Alameda, 2002). Second, the literature has shown that a lack of resources 
tends to characterize mental health services in developed countries, 
resulting in limitations in providing adequate treatment or follow-up care 
(Wang et al., 2007). For instance, compared to other European countries, 
in Spain, the number of clinical psychologists in the public mental health 
care system is very low, with a ratio of around 4 of these professionals per 
100000 inhabitants (Palacios, Fraga, Hoyas, Laíz, & Rodríguez, 2006). It 
is therefore not surprising that the data in Spain show that a substantial 
proportion of patients have to wait longer than 45 days until the first 
consultation with a clinical psychologist or a psychiatrist (Martín-Jurado, 
de la Gándara, Carbajo, Moreira, & Sánchez-Hernández, 2012). Likewise, 
a study by Fernández et al. (2006) concluded that only one third of the 
treatments provided to patients who attend public services to seek mental 
health treatment in Spain meet minimal adequacy criteria. Finally, other 
authors have highlighted the treatment gap present in mental health care, 
that is, the proportion of patients with mental disorders who do not receive 
treatment in mental health services, especially those with anxiety and 
mood disorders (Fernández et al., 2006; Kohn et al., 2004). In sum, these 
data point to the need to improve the quality of mental health services. In 
this task, the role of clinical research in this setting is of vital importance.  
On the other hand, the barriers mentioned in the previous section 
regarding disorder-specific protocols might be particularly evident when 
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these protocols are administered in clinical contexts such as public 
specialized mental health care. First, because it is an ecological setting 
(i.e. patients are not selected based on eligibility criteria), the clinical 
presentations of the patients attending these centers are generally more 
heterogeneous, including more patients with comorbidity, subthreshold 
symptoms, and NOS diagnoses (i.e. anxiety and depression NOS), which 
impedes their adequate treatment using disorder-specific protocols. 
Second, patients attending mental health units normally have to face long 
waitlists to receive treatment. In this sense, the literature shows that most 
disorder-specific evidence-based treatments for anxiety and depression 
work, among other reasons, because they are delivered regularly (e.g. on 
a weekly basis) (Nathan & Gorman, 2015). However, the frequency of the 
visits in mental health units is generally lower. For instance, in Spain the 
frequency of the sessions for patients attending these units is around once 
a month (González-González et al., 2014). Thus, this lower frequency of 
sessions may negatively impact the effective delivery of manualized 
evidence-based treatments in these centers. Finally, the work of clinical 
psychologists in mental health units in Spain is not restricted to anxiety 
and depressive disorders, but rather includes a wide range of clinical 
presentations (Echeburúa, Salaberría, de Corral, & Cruz-Sáez, 2012), 
which means that these professionals require the knowledge and skills to 
treat a myriad of psychological problems. Therefore, training clinicians in 
the different disorder-specific protocols required for each emotional 
disorder can become a real challenge under these circumstances. In fact, 
it does not come as a surprise that training clinicians has been highlighted 
as a major difficulty in the dissemination and implementation of evidence-
based treatments in clinical settings (McHugh & Barlow, 2010). In 
response to the limitations of disorder-specific protocols, new lines of 
research have emerged that could help to overcome some of these 
challenges. A characteristic example of this research is the transdiagnostic 
approach for the treatment of emotional disorders, which has experienced 
rapid growth in the past fifteen years. This approach is described in the 
following sections.  
 
The transdiagnostic approach to the treatment of emotional 
disorders  
In recent years, there has been great interest in treatment 
strategies (referred to as transdiagnostic treatments) that might be more 
widely effective across these diverse mental health disorders. 
Transdiagnostic treatments “apply the same underlying treatment 
principles across mental disorders, without tailoring the protocol to specific 
diagnoses” (McManus et al., 2010, p. 4). In general terms, unlike disorder-
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specific protocols, transdiagnostic treatments are based on the premise 
that the commonalities of psychological disorders outweigh their 
differences, and that the observed differences (symptoms) are specific 
manifestations of broader, underlying common psychopathological 
processes (Barlow, Sauer-Zavala, Carl, Bullis, & Ellard, 2013; Barlow et 
al., 2004; Harvey, Watkins, Mansell, & Shafran, 2004; Mansell, Harvey, 
Watkins, & Shafran, 2009; Meidlinger & Hope, 2017). Research on 
transdiagnostic treatments and processes has attracted researchers’ 
interest in recent years, and this interest has been manifested in several 
ways. For example, a special issue entitled “Transdiagnostic Approaches” 
was published in the Journal of Anxiety Disorders, which presented a 
series of articles focused on recent developments in the field of 
transdiagnostic treatments for emotional disorders (Norton, 2017). 
Similarly, in our country some researchers have manifested their 
interested in this topic (Sandín, 2012), and a number of randomized 
controlled trials are currently being conducted to study the efficacy of 
transdiagnostic treatments in both community (Díaz-García et al., 2017) 
and specialized care settings (Osma et al., 2018). Finally, at the 
“Conference on Transdiagnostic Approaches to Mental Health 
Challenges”, held in Cambridge, UK, on September (2018), the most 
recent advances and future research directions were presented by leading 
researchers in the field of transdiagnostic treatments, helping to 
consolidate the interest in the study of the transdiagnostic approach to the 
scientific understanding, assessment, and treatment of emotional 
disorders.  
The transdiagnostic approach has directly influenced both research 
focused on common psychopathological processes across diagnoses 
(Harvey et al., 2004) and the development of treatments and their 
application in multiple randomized controlled trials over the past fifteen 
years (e.g. Barlow et al., 2017; Dear et al., 2015; Erickson, Janeck, & 
Tallman, 2007; Farchione et al., 2012; Norton & Hope, 2005). Several 
meta-analytic reviews have shown that transdiagnostic treatments are 
effective in comparison with control groups (Newby, McKinnon, Kuyken, 
Gilbody, & Dalgleish, 2015; Newby et al., 2016; Păsărelu, Andersson, 
Bergman Nordgren, & Dobrean, 2017; Reinholt & Krogh, 2014), with 
pooled effect sizes (Hedges’ g) in the moderate to large range for overall 
measures of anxiety (.65 to .82) and depression (.79 to .84), and moderate 
effects on quality of life measures (.46 to .56). In addition, another meta-
analysis revealed that there are no differences in efficacy between 
transdiagnostic treatments and disorder-specific protocols (Pearl & Norton, 
2017). There is, therefore, a growing body of evidence indicating that 
transdiagnostic treatments are effective in improving anxiety and 
depression, as well as quality of life.  
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The first author to apply a transdiagnostic approach was Fairburn 
(Fairburn & Harrison, 2003), with a particular focus on the transdiagnostic 
treatment of eating disorders. For instance, within this model, the 
overvaluation of shape and weight is viewed as a core process that is 
common to all the eating disorders (i.e. bulimia nervosa, anorexia nervosa, 
and atypical eating disorders), and therefore the treatment is developed to 
directly address this common vulnerability. The counterpart for emotional 
disorders is the Unified Protocol (UP) developed by Barlow (Barlow et al., 
2004; Ellard, Fairholme, Boisseau, Farchione, & Barlow, 2010). Both the 
theoretical rationale and the treatment protocol are described below.   
Transdiagnostic treatments can be classified according to several 
characteristics. First, regarding the number of disorders that 
transdiagnostic protocols cover, these treatments may range from those 
targeting two disorders (Bolton et al., 2014; Wetherell et al., 2009) to those 
targeting multiple anxiety and/or depressive disorders (Boettcher et al., 
2014; Farchione et al., 2012). Second, whereas some transdiagnostic 
protocols focus on the treatment of anxiety disorders alone (Nordgren et 
al., 2014), others address both anxiety and depressive disorders (Titov et 
al., 2011). Transdiagnostic treatments may also be classified according to 
other characteristics, such as the delivery format (e.g. face-to-face vs. 
Internet-delivered treatments; group vs. individual); however, one of the 
most important features in classifying transdiagnostic protocols is probably 
the treatment approach used.  
According to Sauer-Zavala et al. (2017), transdiagnostic protocols 
can be classified in three broad categories depending on the treatment 
approach adopted by each: a) transdiagnostic treatments based on 
universally applied therapeutic principles; b) transdiagnostic modular 
treatments; and c) transdiagnostic treatments based on shared 
mechanisms. In short, transdiagnostic interventions within the first 
approach are top-down strategies to be applied across a wide range of 
diagnoses. However, they do not pay attention to the specific mechanisms 
underlying these disorders. Rather, the distinct characteristic of this 
approach is that a theoretical model is first developed and then applied to 
a wide range of psychological disorders. Examples of this approach 
include humanistic, psychodynamic, and “third wave” therapies (e.g. 
Mindfulness-based treatments, and Acceptance and Commitment 
Therapy). In contrast, the main characteristic of transdiagnostic modular 
treatments is that the treatment is developed based on the selection of 
evidence-based strategies and techniques. However, as in the first 
approach, the rationale for modular treatments is not the selection of 
treatment strategies based on mechanisms underlying all the emotional 
disorders. Instead, this approach to treatment is based on the selection of 
treatment strategies that have been shown to work for each problem. An 
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example of a treatment in this category is CETA (Common Elements 
Treatment Approach), a modular treatment designed for depression and 
anxiety (Murray et al., 2013). In CETA, the treatment strategies are 
selected from a bank of empirically supported components as varied as 
psychoeducation, behavioral activation, relaxation, exposure, and suicide 
management. Moreover, the specific strategies and their dose, as well as 
the order in which they are implemented, depend on the characteristics of 
each patient. Finally, unlike the other two approaches, the goal of 
transdiagnostic treatments based on shared mechanisms is to address the 
common psychopathological processes responsible for the development 
and maintenance of a specific range of disorders, assuming a causal 
relationship between these processes and the manifestation of the 
emotional, cognitive, and physiological phenomenology characteristic of 
each emotional disorder. The most representative example of a treatment 
based on a mechanistically transdiagnostic approach is probably the 
Unified Protocol (UP) (Barlow et al., 2011a, 2011b). A number of 
advantages have been attributed to transdiagnostic treatments based on 
this approach. First, the assumption of a core psychopathology across 
emotional disorders can help to explain the high levels of comorbidity 
among these disorders and provide a treatment strategy with the potential 
to more effectively treat comordid presentations (Mansell, Harvey, 
Watkins, & Shafran, 2008). Second, only one protocol is needed for a 
range of disorders, which means lower costs in terms of training and is 
consequently beneficial for both dissemination and implementation 
(McEvoy, Nathan, & Norton, 2009). Third, rather than focusing on 
disorder-specific symptoms, mechanistically transdiagnostic treatments 
address core processes that are hypothesized to be responsible for the 
maintenance vulnerability processes across emotional disorders. It is 
assumed that by targeting these common processes, larger and more 
lasting clinical changes can be expected in these disorders (Sauer-Zavala 
et al., 2017).   
A more detailed review of the different transdiagnostic approaches 
is beyond the scope of this work (for a comprehensive review see Sauer-
Zavala et al., 2017). Thus, this dissertation will focus on the last approach 
described, that is, the mechanistically transdiagnostic approach. Because 
the principal objective of the current doctoral thesis was to test a 
transdiagnostic intervention mainly focused on the dimension of 
neuroticism and the regulation of negative affectivity, in the following 
sections we describe the rationale and specific psychopathological 
processes and intervention strategies supporting the transdiagnostic 
treatment protocol designed and tested in this work. First, the Theory of 
triple vulnerability is presented as the theoretical model underlying the 
treatment approach adopted in this doctoral thesis, as well as the links 
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between this model and the difficulties in emotion regulation shown in 
emotional disorders. Second, the Unified Protocol, a treatment protocol 
derived from this theoretical model, is described. Third, the utility of 
Dialectical Behavior Therapy (DBT) for the transdiagnostic treatment of 
emotional disorders is outlined. Finally, as a secondary objective we also 
establish the basis for including components focused on the regulation of 
positive affectivity. Specifically, a pilot study was conducted to explore the 
utility of adding intervention modules targeting positive affectivity to a 
transdiagnostic protocol with traditional components for the regulation of 
negative affectivity (e.g. cognitive restructuring, exposure procedures). 
The last section explains the rationale for this approach.  
 
The theory of triple vulnerability  
A number of cognitive, behavioral, and emotional constructs have 
been found to play a transdiagnostic role in emotional disorders. These 
processes include, but are not limited to, intolerance to uncertainty 
(Mahoney & McEvoy, 2012), thought suppression (Aldao & Nolen-
Hoeksema, 2010), rumination (Ehring & Watkins, 2008), perfectionism 
(Egan, Wade, & Shafran, 2011), anxiety sensitivity (Boswell et al., 2013), 
and behavioral avoidance and safety behaviors (Clark, 2009; Schmidt et 
al., 2012). Among these constructs, neuroticism is a transdiagnostic 
process that has been consistently associated with both anxiety and 
depressive disorders (Barlow, Ellard, Sauer-Zavala, Bullis, & Carl, 2014; 
Brown & Barlow, 2009; Harvey et al., 2004).  
The Theory of triple vulnerability, formulated by Barlow (2000), is a 
dimensional model that integrates the personality construct of neuroticism 
as a key feature to understand both the origin and the perpetuation of 
emotional disorders. This model provides a conceptual framework for 
understanding emotional disorders, with contributions from the fields of 
genetics, personality, cognitive research and neuroscience, and emotion 
and learning theories. According to this theory, three types of 
vulnerabilities or diatheses can be distinguished that influence both the 
onset and maintenance of emotional disorders. The first, a general 
biological vulnerability, is described as a genetically or heritable tendency 
to experience negative emotions (also called neuroticism or “general 
neurotic syndrome”). The second, a general psychological vulnerability, is 
caused by early childhood experiences in stressful environments, leading 
to a sense of unpredictability and uncontrollability that interferes with the 
development of effective coping strategies and self-efficacy. Finally, the 
third vulnerability is a specific psychological vulnerability, by virtue of 
which an individual learns that some situations, objects, or internal states 
(e.g. thoughts, physical sensations) are dangerous, even when there is no 
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reasonable association between them. The combination of these three 
diatheses would account for the emergence of the different anxiety and 
depressive disorders.  
These vulnerabilities or diatheses have been intimately linked to the 
difficulties in emotion regulation shown by individuals with emotional 
disorders, especially with regard to neuroticism (Barlow, Sauer-Zavala, 
Carl, Bullis, & Ellard, 2013) and low positive affect (Carl, Soskin, Kerns, & 
Barlow, 2013). Emotion regulation has been defined as an individual’s 
attempts to affect the types of emotions experienced, and when and how 
these emotions are expressed and experienced (Gross et al., 1998). In 
addition, an individual may use emotion regulation to increase or maintain 
an emotion (i.e. up-regulation) or to decrease his/her emotions (i.e. down-
regulation). The strategies used to regulate emotion may be behavioral 
(e.g. problem solving, avoidance) or cognitive (reappraisal, suppression), 
and they can be more or less adaptive for the individual’s psychological 
and interpersonal functioning. For instance, reappraisal is a cognitive 
emotion regulation strategy used to change the meaning of an emotion-
eliciting situation in a way that promotes adaptation, whereas suppression 
entails the attempt to hide, inhibit, or decrease ongoing emotion-
expressive behavior, leading to increased distress and worse 
psychological functioning (Gross & John, 2003). Difficulties in the 
regulation of both negative and positive emotions have emerged in 
research as a common feature in depression and anxiety disorders 
(Campbell-Sills & Barlow, 2007; Campbell-Sills, Ellard, & Barlow, 2014; 
Sloan, Moulding, Bryce, Mildred, & Staiger, 2017). Based on this 
theoretical framework, David H. Barlow developed The Unified Protocol 
(UP), a transdiagnostic CBT protocol for anxiety and depressive disorders 
(Ellard et al., 2010) that emphasizes the role of emotion regulation in the 
maintenance of these disorders. A detailed description of the protocol, as 
well as the evidence supporting its efficacy, is summarized in the following 
section.  
 
The Unified Protocol 
The Unified Protocol for the Transdiagnostic Treatment of 
Emotional Disorders (UP) is a manualized, mechanistically transdiagnostic 
CBT protocol for the treatment of anxiety and depressive disorders, whose 
principal goal is to teach patients adaptive ways to regulate their emotions.  
The UP contains the following five core treatment modules: a) present-
focused emotional awareness, b) cognitive flexibility, c) identification and 
prevention of emotional avoidance patterns, d) increasing awareness and 
tolerance of physical sensations, and e) graded (interoceptive and 
situational) exposure. The protocol includes two additional modules, 
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focused on motivation for change and psychoeducation about emotional 
experiences, and a relapse prevention module at the end of the treatment. 
UP manuals for both patient and therapist have been published (Barlow et 
al., 2011a, 2011b) and translated into Spanish (Barlow et al., 2016). 
The efficacy of the UP has been shown in two randomized 
controlled trials. The first compared the efficacy of the UP to a waitlist 
control group. At post-treatment, the between-group comparison yielded a 
moderate effect size for anxiety (Hedges’s g = .56) and a large effect for 
depression (Hedges’s g = 1.11) and work and social adjustment (Hedges’s 
g = 1.09), and these effects were maintained in the long term (Bullis, 
Fortune, Farchione, & Barlow, 2014). Five years later, the results of a 
second larger randomized controlled trial comparing the UP to disorder-
specific CBT protocols showed that there were no differences in efficacy 
between the transdiagnostic and disorder-specific approaches on generic 
measures of anxiety and depression (Barlow et al., 2017), as well as on 
measures of comorbid anxiety disorders (Steele et al., 2018). Moreover, 
preliminary data have been published that support the efficacy of the UP in 
improving the temperament dimensions of behavioral inhibition and 
behavioral activation (Carl, Gallagher, Sauer-Zavala, Bentley, & Barlow, 
2014).  
The UP has also been tested in other populations and using 
different delivery formats. For instance, there is preliminary evidence 
suggesting the efficacy of the UP for anxiety and depression delivered in a 
group format (Bullis et al., 2015; Laposa, Mancuso, Abraham, & Loli-Dano, 
2017), for comorbid bipolar disorders and anxiety (Ellard et al., 2017), and 
for the treatment of anxiety and depression in adolescents (Ehrenreich-
May et al., 2017). Furthermore, cross-cultural studies with the UP have 
been carried out (de Ornelas Maia, 2015; Ito et al., 2016; Mohsenabadi, 
Zanjani, Shabani, & Arj, 2018), and ongoing randomized controlled trials 
are being conducted to study the efficacy of the UP, for example, in Spain 
(Osma et al., 2018) and Japan (Ito et al., 2016). In summary, the literature 
on the UP suggests that a mechanistically transdiagnostic approach can 
be effective across categories of emotional disorders, outcome measures, 
delivery formats, and age groups.  
 
Using Dialectical Behavioral Therapy to regulate emotions in anxiety 
and depressive disorders  
Emotion regulation difficulties play a pivotal role under the umbrella 
of Dialectical Behavioral Therapy (DBT) (Linehan, 1993). Although DBT 
was initially developed as a theoretical model and treatment strategy for 
understanding and treating borderline personality disorder, more recently, 
it has been proposed that DBT may also be useful for treating patients 
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with anxiety and depressive disorders because these individuals show 
patterns of emotion dysregulation that may benefit from the emotion 
regulation skills present in DBT (Neacsiu, Bohus, & Linehan, 2015; 
Neacsiu, Herr, Fang, Rodriguez, & Rosenthal, 2015). For instance, one of 
the targets in DBT is the regulation of emotion expression and the action 
tendencies linked to these emotions. A DBT technique proposed to 
improve this regulation strategy is the opposite action. This strategy is 
based on the idea that, in order to change the nature and intensity of a 
specific emotion, individuals have to engage in behaviors or actions 
opposite to those associated with the unwanted emotions. Another skill 
central to DBT is mindfulness. For instance, mindfulness skills in DBT 
include “what skills” (observing, describing, and participating) and “how 
skills” (non-judgmentally, one-mindfully, and effectively). Overall, these 
techniques are aimed at teaching the ability to observe and describe one’s 
emotional experiences in a nonjudgmental way, trying to focus on the 
present moment (Linehan, 1993). In this regard, another important 
element of DBT linked to mindfulness skills is the concept of radical 
acceptance. This concept implies that, in order to reduce unnecessary 
emotional suffering, individuals should aim for the complete and 
nonjudgmental acceptance of experiences, embracing reality “as it is” 
(Linehan, 1993). DBT skills have been adapted and applied to different 
emotional disorders, including post-traumatic stress disorder (Bohus et al., 
2014), depression (Berking, Ebert, Cuijpers, & Hofmann, 2013), and mixed 
anxiety and depression (Neacsiu et al., 2014), suggesting that the 
inclusion of treatment strategies based on the emotion regulation DBT 
skills may be used transdiagnostically to improve symptoms of anxiety, 
depression, and emotion dysregulation in patients suffering from anxiety 
and depressive disorders.  
 
The regulation of positive affectivity as a treatment target in 
transdiagnostic treatments  
In the previous sections, the role of pathological factors such as 
neuroticism or emotion dysregulation in anxiety and depressive disorders 
has been highlighted. However, a more complete picture for 
understanding and treating these disorders is not possible without the 
consideration of positive affectivity (Carl et al., 2013; Eisner, Johnson, & 
Carver, 2009; Headey, Kelley, & Wearing, 1993; Watson, Clark, & Carey, 
1988).  
There is a growing body of research linking positive affectivity to 
anxiety and depressive disorders. First, low levels of positive affectivity 
have been associated with most emotional disorders (Kotov, Gamez, 
Schmidt, & Watson, 2010). For instance, structural equations have shown 
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the association between low levels of positive affectivity and emotional 
disorders such as depression (Clark & Watson, 1991), social anxiety 
disorder (Brown, Chorpita, & Barlow, 1998), and agoraphobia (Rosellini, 
Lawrence, Meyer, & Brown, 2010). Second, individuals with depression 
are more prone to using maladaptive strategies to regulate positive 
affectivity. For example, a study found that depressed individuals tend to 
engage in dampening (i.e. an emotion regulation strategy used to 
decrease the intensity of positive emotional states) more frequently than 
healthy individuals (Werner-Seidler, Banks, Dunn, & Moulds, 2013). Third, 
deficits in the regulation of positive affectivity seem to worsen the clinical 
course of individuals with depression (Shankman, Nelson, Harrow, & 
Faull, 2010). Fourth, a review focused on positive emotion regulation in 
emotional disorders revealed different patterns of disturbances with regard 
to the regulation of positive emotions in individuals with anxiety and 
depression. For example, the review showed that whereas patients with 
depression are more likely to exhibit deficits such as decreased reward 
sensitivity and positive imagery difficulties, individuals with anxiety and 
related disorders (e.g. generalized anxiety disorder, agoraphobia, panic 
disorder, social anxiety, and obsessive-compulsive disorder) more often 
display deficits such as stronger biases toward negative stimuli and 
increased avoidance motivation (Carl et al., 2013). A comprehensive 
review of the deficits in emotion regulation shown by both anxiety and 
depressive disorders can be found in Carl et al. (2013). 
The study of protective factors is not new in the literature. The 
emphasis on promoting these factors has long been acknowledged by 
leading researchers in the field (Bandura, 1977; Rutter, 1985; Seligman & 
Csikszentmihalyi 2000; Taylor, & Brown, 1988). With regard to positive 
affectivity, its study in relation to different indicators of health and optimal 
functioning is abundant in the literature. For instance, positive affectivity 
has been associated with better physical (Cohen & Pressman, 2006) and 
psychological health (Livingstone & Srivastava, 2012), general well-being 
(Lyubomirsky, King, & Diener, 2005), healthier lifestyles (Kobau et al., 
2011), better interpersonal functioning (Garland et al., 2010), and 
enhanced cognitive performance (Rowe, Hirsh, & Anderson, 2007). 
Additionally, the promotion of positive emotion functioning has been linked 
to increased resilience (Tugade & Fredrickson, 2007), i.e., the ability of 
individuals to cope with and learn from stressful events in life, a factor that 
is believed to play a protective role across psychopathologies, including 
anxiety and depressive disorders (Luthar, Cicchetti, & Becker, 2000; 
Southwick, Vythilingam, & Charney, 2005). Furthermore, recent efforts to 
identify protective factors have linked positive affectivity to the construct of 
Openness to the future, a prospective protective factor defined by the 
authors as “an active cognitive-affective mood state that involves positive 
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expectations about what life may bring, a sense of competence and ability 
to cope with events, the anticipation, planning and perseverance to reach 
an outcome even in the face of adversity, and the acceptance of what 
cannot be resolved or predicted” (Botella et al., 2018 p. 2). Based on the 
breadth of the data, it appears logical that the development of treatment 
strategies to up-regulate positive affectivity should not be neglected. 
To date, research on the transdiagnostic approach has mainly 
focused on deficits and negative psychological functioning (Barlow et al., 
2017; Dear et al., 2015; Norton & Hope, 2005; Titov et al., 2011), and less 
attention has been paid to the promotion of flourishing and protective 
factors such as positive affectivity. However, more recently, the study of 
positive affective regulation from a transdiagnostic perspective has gained 
renewed interest among researchers. For instance, Taylor, Lyubomirsky, 
and Stein (2017) pilot-tested the efficacy of a transdiagnostic intervention 
based on positive psychology interventions (PPIs) for anxiety and 
depressive disorders, with results suggesting their usefulness on 
measures of anxiety and depression, as well as positive and negative 
affectivity. Another possible strategy is to add strategies to up-regulate 
positive affectivity to the existing transdiagnostic protocols, mainly focused 
on down-regulating negative affectivity. A study by Carl, Gallagher, and 
Barlow, (2018) illustrates this point. In this study, the authors presented a 
module for the regulation of positive affectivity to be applied 
transdiagnostically across anxiety and depressive disorders. According to 
the authors, the module can be implemented in a flexible way, either 
integrated into a modular treatment program, or as an adjunct for patients 
who show deficits in positive emotions at post-treatment. Although 
promising, the results of this emerging research are only preliminary, and 
thus more research is needed to further explore the potential of these 
strategies in improving emotional disorders.  
 
The use of Information and Communication Technologies 
to improve mental health: Internet-delivered interventions 
The main objective of this doctoral thesis was to explore the 
effectiveness of a transdiagnostic Internet-delivered protocol for emotional 
disorders. Therefore, in the following sections, both the rationale and the 
most relevant research on the topic of Internet interventions are set forth.  
Research on Internet-delivered psychological interventions has 
blossomed in the past two decades (Andersson, 2016, 2018). The number 
of clinical trials testing the efficacy and effectiveness of Internet-delivered 
CBT (ICBT) has increased exponentially in recent years. A number of 
meta-analyses have shown that Internet-delivered treatments are effective 
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for both anxiety and depressive disorders in comparison with control 
groups (Andrews et al., 2018; Richards & Richardson, 2012; Spek et al., 
2007), and that there are no differences in efficacy between ICBT and 
face-to-face CBT (Carlbring, Andersson, Cuijpers, Riper, & Hedman-
Lagerlöf, 2018).  Moreover, in terms of cost-effectiveness, the literature 
has shown promising data in favor of Internet-delivered interventions, 
compared to more traditional ways of delivering therapy (e.g. face-to-face 
treatments) (Donker et al., 2015). In Spain, a number of studies have 
shown the efficacy of Internet-delivered treatments for depression (Mira et 
al., 2017; Montero-Marín et al., 2016), and others for the treatment of 
anxiety and depression are underway (e.g. Campos et al., 2016; Díaz-
García et al., 2017; Rachyla et al., 2018). In sum, there is extensive 
evidence in the literature indicating the efficacy and (potential) cost-
effectiveness of these treatments.  
Internet-delivered interventions have been found to have several 
advantages for users, clinicians, and researchers. For users, the most 
commonly mentioned advantages include increased access to evidence-
based treatments (e.g. individuals living in rural areas) (Griffiths & 
Christensen, 2007), the possibility of receiving treatment without the 
stigma typically associated with mental disorders (Griffiths, Lindenmeyer, 
Powell, Lowe, & Thorogood, 2006), a shorter waiting time to receive 
treatment (Spurgeon & Wright, 2010), and greater convenience compared 
to other delivery formats such as face-to-face psychotherapy (e.g. patients 
do not have to attend a center or facility to receive treatment) (Griffiths et 
al., 2006). For researchers and clinicians, the potential advantages of 
Internet interventions include, but are not limited to, easier participant 
recruitment and data collection about the patients (Andersson & Titov, 
2014), reductions in the workload of mental health professionals (Musiat & 
Tarrier, 2014), and increased cost-effectiveness (Donker et al., 2015). 
An important aspect of Internet-delivered treatments is the type and 
degree of guidance provided to the patients. ICBT can be delivered with 
some type of clinician or therapist support or completely self-guided. 
Moreover, support in guided ICBT can be provided in many ways, such as 
phone calls, emails, chat, and/or videoconference. In general terms, the 
literature suggests that guided ICBT frequently leads to better outcomes 
than unguided ICBT (Baumeister, Reichler, Munzinger, & Lin, 2014; 
Palmqvist, Carlbring, & Andersson, 2007). In this regard, a systematic 
review on the efficacy of Internet-delivered treatments for depression 
showed a linear relationship between the degree of clinician contact and 
the magnitude of the outcomes, with the largest effect sizes observed for 
the treatments where there was therapist contact both before and during 
the treatment, and the smallest effect sizes for those where there was no 
contact between patients and the providers of support (Richards & 
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Richardson, 2012). Although there is research indicating that unguided 
ICBT can lead to similar results as guided ICBT, at least for some patients 
(Karyotaki et al., 2017), in general, it is widely assumed that Internet 
interventions work better if some type of support is delivered to the 
patients. In addition, the degree of support or contact provided to the 
patients has also been linked to the rates of adherence and attrition from 
these treatments, as dropout rates have been found to be higher in 
unguided Internet-delivered treatments (Richards & Richardson, 2012). 
Apart from the indicators of efficacy, which are of undeniable importance, 
given the higher drop-out rates in Internet-delivered interventions 
compared to face-to-face treatments (van Ballegooijen et al., 2014), 
indicators of adherence and attrition should be given equal importance in 
research on these treatments. In order to enhance the value of Internet-
delivered interventions, efforts should be made to decrease the 
percentage of participants who decide to drop out from these treatments. 
In the field of transdiagnostic treatments for emotional disorders, 
the literature has shown the efficacy of Internet-delivered treatments in 
comparison with control groups (Newby et al., 2016), and that 
transdiagnostic Internet-delivered treatments might be as effective as 
transdiagnostic face-to-face treatments (Newby et al., 2015). However, 
most of the evidence about the efficacy and effectiveness of 
transdiagnostic treatments comes from studies conducted in community 
settings (e.g. Farchione et al., 2012; Dear, et al., 2015) and, less 
commonly, in primary care (e.g. Berger et al., 2016). However, in spite of 
the compelling data showing the prevalence and lack of adequate 
coverage of anxiety and depressive disorders in specialized mental health 
care, to our knowledge, the way transdiagnostic Internet-delivered 
treatments work in this setting has not yet been explored in the literature. 
Hence, the aforementioned problems associated with the delivery of 
mental health services in public specialized mental health (e.g. long 
waiting times to access therapy, low number of clinical psychologists in 
public mental health services, and so on) strongly suggest that a change 
in the way mental health services are provided is needed. Some authors 
have highlighted the usefulness of ICTs, such as the Internet, to bridge 
this gap, in order to provide evidence-based treatments that are more 
accessible for all of the population in need (Kazdin, 2015; Kazdin & Blase, 
2011). Consistent with this view, the benefits of a transdiagnostic 
approach (i.e. less training is needed because only one treatment protocol 
is used to address various psychological disorders, which might lead to 
greater coverage of the demand for treatments in these services) may be 
enhanced by using an Internet-delivered format in order to improve access 
by people for whom face-to-face treatments are not available.   
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Aims of the current doctoral thesis  
 
General aim  
With the aforementioned in mind, the general aim of this doctoral 
thesis was to develop a transdiagnostic Internet-delivered protocol for the 
treatment of emotional disorders to be tested in an RCT, compared to 
treatment as usual as provided in public specialized mental health care.  
 
Specific aims  
The specific aims of the current doctoral thesis are described in 
the following lines. First, a systematic review focused on transdiagnostic 
treatments for anxiety and depressive disorders is presented in Chapter 2. 
It sought to answer the following research questions: a) whether treatment 
response to comorbidity is evaluated in transdiagnostic treatments; b) 
what diagnoses are targeted in transdiagnostic treatments; and c) what 
the real distribution of the diagnoses is at baseline in these studies. 
Second, Chapter 3 presents the study protocol of the RCT conducted in 
this doctoral thesis. Third, two validation studies were carried out to 
analyze the psychometric properties of two short scales delivered online 
for the assessment of the impairment and severity associated with anxiety 
and depression in Spanish clinical samples, namely, the Overall Anxiety 
Severity and Impairment Scale (OASIS), and the Overall Depression 
Severity and Impairment Scale (ODSIS). These scales are included as 
assessment tools in the RCT presented in the current doctoral thesis and 
presented in Chapters 4 and 5. Fourth, an RCT was conducted to 
analyze the effectiveness and acceptability of a transdiagnostic Internet-
delivered protocol compared to treatment as usual in public specialized 
mental health care. The results of the RCT are presented in Chapter 6. 
The protocol is based on the treatment components of the UP (i.e. 
present-focused emotional awareness, cognitive flexibility, emotional 
avoidance and emotion driven behaviors, and interoceptive and situational 
exposure). Moreover, a greater emphasis is placed on the component that 
addresses present-focused emotional awareness by adapting some of the 
strategies and techniques used in the emotional regulation DBT skills (e.g. 
“what” and “how” techniques). Unlike most previous transdiagnostic online 
treatments, it is designed to be broadly applicable to a wide range of 
anxiety and depressive disorders, including MDD, DD, depression NOS, 
GAD, PD, AG, SAD, anxiety NOS and OCD. Finally, a pilot study was 
conducted to explore a transdiagnostic protocol that adds a component for 
the regulation of positive affectivity to the traditional CBT components for 
the regulation of negative affectivity. In order to analyze the utility of 
including treatment modules focused on the regulation of positive 
affectivity, the feasibility of these two treatment conditions was explored in 
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terms of preliminary acceptability and differential efficacy, with a particular 
focus on measures of positive and negative affectivity, depression, and 
anxiety. This study is presented in Chapter 7. The thesis ends with 
Chapter 8, which includes a general discussion of key findings, 
implications of the current work, strengths and limitations, future 
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The advantages of transdiagnostic protocols for emotional disorders (ED) 
(anxiety and depression) include the ability to treat multiple psychological 
disorders using the same treatment protocol, and the capacity to better 
address comorbidity. Comorbidity in ED has been associated with higher 
rates of severity, functional impairment, and chronicity. However, no 
attempts have been made in the literature to systematically review 
whether these studies include assessments to evaluate the treatment 
response in comorbid diagnoses, in addition to the principal diagnosis. 
Moreover, transdiagnostic treatments have been developed for a range of 
ED, but to date no study has analyzed the real distribution of diagnoses in 
these studies. The current study aimed to analyze: a) whether treatment 
response in comorbidity is evaluated in transdiagnostic treatments for ED; 
b) what diagnoses are targeted in transdiagnostic treatments for ED; and 
c) the real distribution of the diagnoses at baseline in these studies. A 
systematic search of the literature was conducted in PsycINFO, PubMed, 
EMBASE, and the Cochrane Library. Fifty-two randomized controlled trials 
were identified, with a total of 7007 adult participants. The results showed 
that, although most of the studies reported data on comorbidity at 
baseline, only 40% of them examined the effects of the intervention on the 
comorbid disorders. The most commonly targeted diagnoses in 
transdiagnostic protocols were panic/agoraphobia, generalized anxiety, 
social anxiety, and depression. Other disorders, such as obsessive-
compulsive disorder, posttraumatic stress disorder, and 
anxiety/depression not otherwise specified, were marginally included in 
these studies. Regarding the distribution of diagnoses at baseline, 
generalized anxiety, panic/agoraphobia, social anxiety, and depression 
were the most frequently observed, whereas depression not otherwise 
specified was the least represented. The results highlight the importance 
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of assessing comorbidity in addition to the principal diagnoses in 
transdiagnostic treatments, in order to draw conclusions about the true 
potential of these interventions to improve comorbid symptoms. 
Implications of the current study and directions for future research are 
discussed.  
Introduction 
Emotional disorders (ED) (depression and anxiety disorders) are 
common mental health conditions and one of the main causes of suffering 
and impairment worldwide [1, 2]. In the past few decades, a large number 
of disorder-specific cognitive-behavioral treatments (CBT) have been 
developed for ED and tested in clinical trials, with evidence found for their 
efficacy and effectiveness [3-7]. However, although disorder-specific 
treatment protocols have been shown to work effectively, there are still 
some barriers related to these protocols. One of them stems from the high 
comorbidity rates observed in ED, ranging between 40 and 80% for these 
disorders [8, 9].  
Comorbidity in ED has been associated with greater severity and 
impairment [8], worse quality of life [10], and higher chronicity rates [11]. 
The literature has proposed different ways to manage comorbidity, such 
as combinations of treatments or the sequential application of treatments 
[12]. Another strategy involves applying a protocol to target one of the 
disorders and expecting an impact on the comorbid disorders. 
Nevertheless, the effective use of these strategies is not well supported by 
the existing empirical evidence (for a review of the evidence, see 
McManus et al., 2010) [12]. A more recent development to deal with 
comorbidity is the application of treatments based on a transdiagnostic 
perspective. Although the term transdiagnostic has been employed to refer 
to different treatment approaches [13], the common denominator of these 
treatments is that one protocol is applied to address various psychological 
disorders [14]. Research on transdiagnostic treatments for ED has 
increased in recent years [15-17], with a noteworthy rise in the number of 
trials assessing the efficacy and effectiveness of transdiagnostic 
treatments in the past 15 years [18-27]. Several advantages have been 
attributed to transdiagnostic treatments. The first and most important is the 
ability to address multiple ED using the same treatment protocol. Thus, 
these disorders can be treated in a more cost-effective way because 
clinicians only have to be trained in one protocol that addresses various 
psychological disorders [13, 15]. Second, training clinicians in one 
treatment approach, rather than in a different protocol for each ED, may 
facilitate the dissemination of evidence-based treatments for these specific 
problems [15].  This approach could be of particular interest in ecological 
settings such as public services, where clinicians have to treat patients 
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with diagnostically heterogeneous presentations, which makes the 
adequate selection of protocols and techniques difficult [13].  Third, 
another important advantage is that comorbid mental disorders can be 
more adequately targeted because these protocols usually focus on what 
these disorders have in common, rather than on disorder-specific 
symptom variations [17, 22, 26, 28]. For instance, extensive research 
shows the key role played by neuroticism in the onset and maintenance of 
both anxiety and depressive disorders, indicating its relevance in research 
and clinical practice [15-17, 29, 30]. In this regard, the “shared 
mechanisms approach”, described by Sauer-Zavala et al. [13], is based on 
the assumption that there are core mechanisms underlying both anxiety 
and depressive disorders, and that, consequently, in order for the specific 
symptoms to improve (e.g. symptoms of panic, symptoms of social 
anxiety, and so on), treatment should focus on addressing these common 
processes. Based on this approach, some authors have argued that a 
transdiagnostic treatment may be appropriate for a wide range of 
disorders, including all the anxiety and unipolar mood disorders, and even 
somatoform and dissociative disorders [15,22], while facilitating the 
treatment of patients with comorbidity (12). There are, nevertheless, other 
transdiagnostic approaches to the treatment of ED (including the treatment 
of comorbid presentations), such as individually-tailored CBT [20] or “third 
wave” therapies (e.g. mindfulness and acceptance and commitment 
therapy) [31-33]. Finally, transdiagnostic treatments also have the 
potential to address “not otherwise specified” (NOS) diagnoses for which 
there are no evidence-based treatments in the literature (e.g. anxiety 
NOS) [13]. 
There is a growing body of literature on the efficacy and 
effectiveness of transdiagnostic treatments for ED.  To date, various meta-
analyses have shown the efficacy of these treatments in adults with ED, 
compared to control conditions, on measures of overall anxiety [34-38] 
and disorder-specific anxiety [38], as well as depression [35-38] and 
quality of life [36-38]. Moreover, a meta-analysis of the efficacy of these 
protocols, compared to disorder-specific CBT, found no significant 
differences in the efficacy of these two treatment approaches on anxiety 
outcomes [39]. Nevertheless, no prior study has examined how 
comorbidity is reported and assessed in trials analyzing transdiagnostic 
protocols, despite the importance of comorbidity in aspects such as the 
clinical severity, the clinical course, and the rate of relapse in patients with 
comorbid anxiety and depressive disorders [8, 10, 11]. Some studies on 
transdiagnostic treatments for ED have assessed treatment effects on 
comorbid symptoms, as well as the symptoms primarily targeted in the 
study. For instance, some studies include self-reported measures to 
assess a range of comorbid disorder-specific symptoms [21, 40, 41], and 
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others assess the impact of the intervention in terms of the number of 
comorbid disorders, in addition to the number of principal diagnoses [22]. 
However, this aspect has not yet been systematically analyzed in the 
literature on transdiagnostic treatments for ED.  
Regarding the types of diagnoses targeted by transdiagnostic 
treatments, the transdiagnostic treatments published to date may range 
from those targeting only two disorders [42-44] to those addressing a 
larger number of ED [45-47]. Moreover, transdiagnostic treatments may 
focus on anxiety disorders alone [48-50], or anxiety disorders along with 
depressive disorders [51-53]. There is, therefore, great disparity in the 
types and frequencies of anxiety and depressive disorders targeted in 
transdiagnostic treatments. However, to our knowledge, the real 
distribution of specific diagnoses in these interventions, i.e. the classes of 
disorders and the most frequent and infrequent disorders targeted in 
transdiagnostic treatments for ED, has not yet been analyzed. 
Taking all this into consideration, a systematic review was 
conducted to answer the following research questions: a) Are comorbid 
disorders evaluated in transdiagnostic treatments for emotional disorders? 
b) What diagnoses are targeted in transdiagnostic treatments for
emotional disorders? and c) What is the real distribution of the diagnoses 
at baseline in transdiagnostic treatments for emotional disorders? 
Methods 
Search strategy, data extraction, and coding 
A systematic search of the peer-reviewed literature was conducted 
through the following databases: PsycINFO, PubMed, EMBASE and the 
Cochrane Register of Controlled Trials. The following terms were 
combined to conduct the search: “transdiagnostic”, “unified”, “mixed 
anxiety and depression”, “mixed depression and anxiety”, “heterogeneous” 
“depression”, “anxiety”. The deadline for inclusion of studies was February 
6th (2018) (with no limits applied for year of publication). The systematic 
review protocol was registered in the International Prospective Register of 
Systematic Reviews (PROSPERO, CRD42018088138). Studies were 
included based on the following eligibility criteria:  
a) The study was a randomized controlled trial (RCT) that was
compared to one of the following conditions: a waiting list control
condition, placebo, attention control condition, active control
condition (i.e. other treatment), and care as usual/treatment as
usual control condition.
b) The study was written in English.
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c) Participants were adults (18 years old and older).
d) Participants had at least a principal diagnosis of an anxiety disorder
or a score above a cutoff point on an anxiety self-report scale,
and/or a principal diagnosis of a depressive disorder or a score
above a cutoff point on a depression self-report scale.
e) The study evaluated a transdiagnostic treatment for
anxiety disorders and/or depression (i.e. unipolar mood disorders, 
anxiety disorders, posttraumatic stress disorder, and obsessive-
compulsive disorder). To be included in the systematic review, the 
intervention had to target at least two different anxiety disorders or 
an anxiety disorder in addition to a depressive disorder.  
Two assessors (AG-R and AD-G) conducted the review and 
selection of studies independently. The final selection of the included 
studies was supervised by a third expert evaluator (CB).  
The following variables were included: a) study (authors and year of 
publication); b) country; c) aims of the study; d) hypotheses (when 
available); e) setting (e.g. community, primary care) and delivery format 
(e.g. Internet, face-to-face, individual, group); f) inclusion criteria regarding 
the types of diagnoses or symptoms targeted (“or” when the participants 
had to have at least one of the disorders, and “+” when the participants 
had to have both disorders); g) groups (sample size); percentage of 
females; and i) the distribution of each type of diagnosis at baseline. In 
order to evaluate the data on comorbidity, three dichotomous variables 
(yes/no) were created and added to the table: a) whether a principal 
diagnostic or symptom complaint was reported (e.g. main complaint of 
generalized anxiety symptoms); b) whether comorbid disorders and/or 
symptoms were reported. To belong to this category, the study had to 
report at least the proportion of patients presenting comorbid disorders or 
symptoms (e.g. the number of patients with one comorbid disorder, two 
comorbid disorders, and so on); and c) whether treatment response on 
comorbid disorders/symptoms was evaluated, i.e. a diagnosis made using 
a diagnostic interview or the severity of the disorder or symptoms through 
scales. All the aforementioned variables were extracted and coded 
independently by AG-R and AD-G, and disagreements were solved by 
discussion with a third author (CB). 
Definition of emotional disorders included in the study 
ED were considered for this study following the criteria of the 
Diagnostic and Statistical Manual of mental disorders, 4th edition (DSM-IV-
TR) [54] and the definitions of these disorders adopted by previous 
authors (15), namely, unipolar mood disorders and anxiety disorders. 
Unipolar mood disorders included major depressive disorder (MDD), 
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dysthymic disorder (D), and depression not otherwise specified 
(Depression NOS), whereas anxiety disorders included generalized 
anxiety disorder (GAD), panic disorder with or without agoraphobia 
(PD/AG), social anxiety disorder (SAD), posttraumatic stress disorder 
(PTSD), obsessive-compulsive disorder (OCD), specific phobia (SP), and 
anxiety disorder not otherwise specified (Anxiety NOS). Although the 
classification of some of these disorders has changed with the publication 
of the DSM-5 [55] (i.e. PTSD and OCD are no longer considered anxiety 
disorders), the DSM-IV-TR was followed because most of the studies 
analyzed had recruited participants based on this diagnostic manual.  
Quality assessment 
The quality of the included studies was assessed using four items 
from the Cochrane Collaboration Risk of bias tool [56], which estimates 
potential bias in randomized controlled trials, including the following 
domains: random sequence generation, allocation concealment, blinding 
of outcome assessment (if applicable), and handling of incomplete 
outcome data. Each item on the tool was rated as low, high, or, in the case 
of insufficient information, unclear risk. This process was conducted by 
two independent researchers (AG-R and AD-G). Disagreements were 




Selection and inclusion of studies 
The study selection process is presented in the PRISMA flowchart 
(Figure 1). A total of 1881 studies were identified through database 
searches (Pubmed = 367; PsycINFO = 327; Embase = 510; Cochrane 
Library = 677), and 23 additional records were identified through other 
sources (i.e. meta-analyses about the efficacy of transdiagnostic 
treatments for anxiety and depression). After removing duplicates, 1103 
records were screened based on title and abstract. Of them, 128 full-
articles were assessed for eligibility, of which 52 were selected for final 




Figure 1. PRISMA flowchart 
 
 
Characteristics of included studies 
Relevant characteristics of the included studies are shown in Table 
1. All the studies were randomized controlled trials with a total of 7007 
participants. Most of the studies were conducted in the United States (n = 
19, 37%), Australia (n = 12, 23%), Sweden (n = 6, 12%), and the United 
Kingdom (n = 5, 10%). The most common setting was the community (37 
studies, 71%), followed by primary care (6 studies, 12%), specialized care 
(4 studies, 8%), community/primary care (3 studies, 6%) [57-59], and 
university students (2 studies, 4%) [60, 61]. Regarding the delivery format 
(i.e. face-to-face vs. web-based/computerized; individual vs. group), 24 
treatments were delivered face-to-face (46%), 23 were Internet-based 
(44%), 4 were computerized (8%) [25, 62-64], and 1 was delivered by 
telephone (2%) [58]. Of the 52 studies, 38 were delivered in an individual 
format (73%), whereas 13 were delivered in a group format (25%), and 
one combined individual and group formats (2%) [65]. Regarding the 
control conditions, 21 studies used an active control condition (of which 8 
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were disorder-specific treatments), 19 studies used a waiting list control, 8 
employed a care as usual/treatment as usual condition, 4 used an 
attention control condition [20, 64, 66, 67], and 1 employed a placebo 
control condition [50]. Finally, only 1 cost-effectiveness study was 
identified [67].  
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Table 1. Characteristics of included studies 
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survivors in a low-
resource setting. 
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condition to CBT 
focused only on 
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efficacy and 
acceptability when 





CBT and SD-CBT 
would improve 
symptoms of GAD. 
2. TD-CBT would 
improve symptoms of 
comorbid Dep, SAD 
and PD at each time 
point to a greater 














76 GAD (N = 
338) 
Yes Yes Yes 
Dear et al., 
2016 [35] 
AU To compare 
transdiagnostic CBT 
for SAD and comorbid 
symptoms to SD-CBT, 
in terms of efficacy 
and acceptability when 





CBT and SD-CBT 
would improve 
symptoms of SAD 
similarly.   
2. Transdiagnostic 
CBT would reduce 
symptoms of comorbid 
Dep, GAD and PD at 
each time point to a 


















Ejeby et al., 
2014 [70]  
SE To compare CBT and 
MMI to CAU alone for 




CBT and MMI would 
improve quality of life 
and psychological 
symptoms to a greater 
























80,8 Dep (N = 139) 
Anx disorders 
(N = 81) 
Somatoform 
disorders (N = 
10) 
Eating 
disorders (N = 
6) 
AUD (N = 2) 
 
No No No 
Erickson et 
al., 2007 [71] 
CA To compare CBT for 
different anxiety 
disorders to a WLC.  
 
1. CBT would improve 
anxiety symptoms to a 
greater degree than 
the WLC.  
2. CBT would improve 
within-group 
symptoms of anxiety 


















63,8 SAD (N = 46) 
PD/AG (N = 
36) 
GAD (N = 31) 
PSTD (N = 16) 
OCD (N = 16) 
SP (N = 7) 
 
Yes Yes No 
Farchione et 
al., 2012 [22] 
US To compare the UP for 
anxiety disorder to a 
WLC. 
 
1. The UP would be 
efficacious in 
improving the 
symptoms of patients 
with GAD, SAD, 
PD/AG, and OCD.  
2. The UP would 
reduce the severity of 
comorbid disorders at 
both post-treatment 















59,5 GAD (N = 7) 
SAD (N = 8) 
OCD (N = 8) 
Anx NOS (N = 
2) 
PDA (N = 8) 
PTSD (N = 1) 
SAD+Anx 




(N = 1) 
 
Yes Yes Yes 
54 
 
Fogliati et al., 
2016 [23] 
AU To compare 
transdiagnostic CBT 
for PD and comorbid 
symptoms to SD-CBT 
in terms of efficacy 
and acceptability when 





CBT and SD-CBT 
would improve 
symptoms of PD 
similarly.   
2. Transdiagnostic 
CBT would reduce 
symptoms of comorbid 
Dep, GAD, and SAD 
at each time point to a 















79 PD (N = 145) Yes Yes Yes 
Forman et al., 
2007 [51] 
US To compare ACT and 
CBT in the treatment 
of anxiety and 
depression.  
 
1. CBT would show 
stronger mediation 
effects for the ability to 
identify and report on 
internal experiences 
than ACT. 2. ACT 
would show stronger 



















80,2 Dep (N = 34) 
Anxiety 
disorder (N = 
32) 
AD (N = 10)  
No No No 
Hadjistavro- 
poulos et al., 
2017 [72] 
CA To compare CBT + 
standard support to 
CBT + optional 
support in the 
treatment of anxiety 
and depression.  
 
1. CBT + optional 
support would not be 
inferior to CBT + 
standard support.  
2. CBT + optional 
support and CBT+ 
standard support 
would be similar in 
terms of symptom 
improvement, 




















78,7 Dep (N = 97) 
GAD (N = 
100) 
PD (N = 80) 
SAD (N = 96) 
No Yes Yes 
55 
 




al., 2012 [73] 
SE To compare T-CBT for 
anxiety and comorbid 
symptoms to CBT, 
and to an active 
control group (Online 
DF focused on 
depression).  
1. T-CBT and CBT 
would produce 
improvements.  




3. An effect was 
expected on the online 
DF, but smaller than in 
















71,1 Dep (N = 121) Yes Yes No 
Johansson et 
al., 2013 [46] 
SE To compare PP and 
SC in patients with 
depression and 
anxiety disorders.  
1. PP would improve 
measures of 
depression and 
anxiety to a greater 
degree than SC.  
2. Larger effects were 
expected on measures 
of depression in 
patients with 
depression as their 
principal diagnosis 
compared to patients 
who did not have 
depression as their 
principal diagnosis. 
3. Larger effects were 
expected on measures 
of anxiety in patients 
with anxiety as their 
principal diagnosis 














82 Dep (N = 72) 
GAD (N = 49) 
SAD (N = 36) 
PD (N = 19) 
Anx/Dep NOS 
(N = 4) 
No Yes Yes 
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who did not have an 





al., 2011 [50] 
AU To compare Clinician-
guided CBT and 
Coach-guided CBT to 




1. The pooled 
Clinician-guided and 
Coach-guided groups 
would improve in 
general and on 
disorder-specific 
measures of anxiety, 
depression, and 
disability to a greater 
degree than the WLC.  
2. Participants in the 
CBT groups would 
rate the treatment as 
acceptable. 
 3. The pooled 
Clinician-guided and 
Coach-guided groups 
would show significant 
improvement on 
disorder-specific 
measures of anxiety 
over time. 
4. Participants in both 
CBT groups would 
show similar outcomes 























58,8 GAD (N = 59) 
SAD (N = 45) 
PD/AG (N = 
27) 
Yes Yes Yes 
Kim et al., 
2009 [43] 
KR To compare MBCT to 
a Psychoeducation 












37 GAD (N = 11) 
PD (N = 35) 
Yes No No 
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Lang et al., 
2017 [59] 
US To compare ACT and 
P-CT in veterans with 
anxiety or depressive 














34,2 (8) 20 Dep (N = 97) 
PTSD (N = 
131) 
PD/AG (N = 
124) 
SAD (N = 26) 
OCD (N = 21) 
GAD (N = 32) 
Anx NOS (N = 
6) 
 
No No No 
Marks et al., 
2004 [62]  
UK To compare Comp SE 
and face-to-face SE to 
a placebo group 
(relaxation) in patients 
with phobias or panic 
disorder.  
 
1. Comp-SE would 
show similar efficacy 
to face-to-face SE. 
2. Both SE groups 
would be more 


















38 (12) 69 PD+AG (N = 
24) 
AG (N = 3) 
SAD (N = 24) 
SP (N = 39) 
Yes Yes No 
Mullin et al., 
2015 [61] 
AU To compare CBT for 
university students 
with stress, anxiety, 
low mood, and 
depression to WLC, in 




1. CBT would reduce 
symptoms of anxiety 
and depression at 
post-treatment to a 
greater degree than 
the WLC. 
2. Participants with 
clinical levels 
symptoms would show 
improvements 
consistent with those 
found in prior studies 
















64,2 GAD (N = 40) 
PD (N = 12) 
SAD (N = 19) 
Dep (N = 18) 





be maintained at 3-
month follow-up.  
4. Participants would 
be satisfied with the 
treatment. 
 
Neacsiu et al., 
2014 [66] 
US To compare DBT-ST 
for emotion 
dysregulation to an 
activities-based 
support group in order 
to: 
1. Explore the effects 
of DBT-ST on anxiety 
and depression. 
2. Investigate the 
mediation effects of 
DBT skills use on 
differential changes. 
3. Explore whether 
confounding effects 
accounted for any 
significant outcomes. 
4. Explore the 
feasibility of DBT-ST 




compliance with the 
treatment protocol.  
 
1. DBT-ST would 
reduce emotion 
dysregulation to a 
greater degree than 
the activities-based 
support group. 2. The 
use of DBT skills 

















65,9 Dep (N = 34) 
PD (N = 6) 
AG (N = 3) 
GAD (N = 29) 
SAD (N = 16) 
SP (N = 8) 
OCD (N = 5) 
PTSD (N = 4) 
Anx NOS (N = 
4) 
SUD (N = 3) 
No Yes No 
Newby et al., 
2013 [52] 
AU To compare CBT for 
mixed GAD and MDD 
to a WLC. 
CBT would show 
greater improvements 












77,8 GAD/MDD (N 
= 47) 
GAD (N = 37) 
Yes Yes Yes 
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  (53) MDD (N= 15) 
 
Nordgren et 
al., 2014 [67] 
SE To compare CBT to an 
AC group in terms of 
cost-effectiveness on 
anxiety disorders.  
 
1. CBT would be 
moderately more 
effective than the AC 
group both at post-
treatment and at 1-
year follow-up. 
















63 GAD (N = 10) 
SAD (N = 32) 
PD/AG (N = 
31) 
AG (N = 8) 
Anx NOS (N = 
19) 
 
Yes Yes No 
Norton, 2012 
[28] 
US 1. To compare CBT to 
relaxation in terms of 
overall efficacy.  
2. To compare CBT to 
relaxation on 
treatment credibility 
and acceptability.  
3. To compare CBT 
effects across 
diagnoses to analyze 
differential efficacy by 
diagnosis.  
1. Participants in both 
groups would show 
significant 
improvements in 
anxiety over the 
course of treatment.  




3. Participants would 
not show differences 
in outcomes by 















62,1 SAD (N = 37) 
PD/AG (N = 
31) 
GAD (N = 15) 
Anx NOS (N = 
2) 
OCD (N = 1) 
SP (N = 1) 




US 1. To compare CBT to 





1. CBT would produce 
significant 
improvements on 
diagnostic indices.  
2. CBT would show 
significant reductions 
at post-treatment on 
measures of anxiety, 
whereas no 












60,9 SAD (N = 5) 
PD/AG (N = 4) 
GAD (N = 10) 
OCD (N = 3) 
PD (N = 1) 
PTSD (N = 1) 
Yes Yes No 
60 
 
observed in the WLC 
on these measures.  
3. CBT would improve 
measures of the 
common core 
psychopathology 
during the second 
phase of treatment, 
whereas no 
improvement would be 
observed in the WLC 





US To compare 
transdiangostic CBT to 
SD-CBT for PD, GAD, 
and SAD.  
 
 
Both conditions would 
significantly improve 
anxiety over the 
course of treatment, 
and these results in 
both conditions would 














50 SAD (N = 25) 
GAD (N = 10) 
PD (N = 11) 
Yes Yes No 
Proudfoot et 
al., 2003 [25] 
UK To compare CBT to 
TAU in patients with 
anxiety, depression, or 
mixed anxiety and 
depression.   
CBT would produce 
greater improvements 




















73,7 Mixed anx-dep 
(N = 80) 
Dep (N = 61) 
PD (N = 10) 
SP (N = 4) 
AG (N = 5) 
SP (N=5) 
 
Yes No No 
Proudfoot et 
al., 2004 [63] 
UK 1. To compare CBT to 
TAU in patients with 
anxiety, depression, or 
mixed anxiety and 
depression in terms of 
efficacy.  
2. To investigate 


















73,7 Mixed anx-dep 
(N = 142) 
Dep (N = 92) 
PD (N = 14) 
SP (N = 11) 
AG (N = 8) 
SP (N = 6) 
 







Riccardi et al., 
2017 [74] 
US To compare FSBET to 
a WLC.  
1. FSBET would 
improve overall 
outcome to a greater 
degree than the WLC.  






diagnosis symptoms.  
3. Improvements in 
the FSBET group 
would be maintained 
at 1-month follow-up.  
4. The relationship 
between pre- and 
post-treatment 
changes would be 
mediated by the 
















75 GAD (N = 9) 
PD (N = 8) 
SAD (N = 11) 
Yes Yes Yes 
Roy-Byrne et 
al., 2010 [47] 
US To compare CBT to 
CAU in patients with 
PD, GAD, SAD, or 
PTSD.   
CBT would reduce 
symptoms of anxiety, 
and improve 
measures of health-
related quality of life, 
functioning, and 
quality of care 
delivered to a greater 














71,1 PD (N = 475) 
GAD (N = 
756) 
SAD (N = 405) 
PTSD (N = 
181) 
Dep (N = 648) 
 
No Yes No 
62 
 
Schmidt et al., 
2012 [75] 
US To compare FSBET to 





 1. FSBET would 
improve in overall 
outcomes to a greater 
degree than the WLC.  
2. FSBET would show 
efficacy on each of the 
anxiety disorders 
evaluated. 
3. Improvements in 
the FSBET group 
would be maintained 















72 GAD (N = 26) 
PD (N = 36) 
SAD (N = 34) 
Yes Yes No 
Schmidt et al., 
2017 [64] 
US To compare CAST + 
CBM to PHET + sham 
CBM in patients with 
co-ocurring anxiety 
and suicidal ideation.  
 
 
1. CAST + CBM would 
improve overall 
anxiety sensitivy and 
the cognitive 
dimension of anxiety 
sensitivity to a greater 
degree than PHET + 
sham CBM. 
2. Reductions in 
anxiety sensitivity 
would be maintained 
at the 4-month follow-
up. 
3. Changes in anxiety 
sensitivity would affect 
symptoms of suicidal 
ideation at the follow-

























75,6 PD (N= 7) 
SAD (N = 10) 
OCD (N= 1) 
PTSD (N = 11) 
GAD (N = 2) 
Anx/Dep NOS 
(N = 2) 
Dep (N = 37) 
Yes No No 
Schneider et 
al., 2005 [76] 
UK To compare CBT to 
minimal CBT in the 
treatment of PD/AG, 
SAD, and SP.  
 
CBT would improve 
phobia/panic to a 
greater degree than 












39 (11) 74 PD+AG (N = 
25) 
AG (N = 2) 
SAD (N = 24) 
SP (N = 17) 
Yes Yes Yes 
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al., 2017 [77] 
DE 1. To compare CBT to 
CAU in individuals 
with panic and 
phobias.  
2. To explore 
differences in 
treatment effects by 

















72 PD (N = 91) 
AG (N = 119) 
PD+AG (N = 
73) 
SAD (N = 98) 
SP (N = 66) 
 
No No No 
Silfvernagel et 
al., 2012 [78] 
SE 
 
To compare T-CBT to 
a WLC in patients with 
panic symptoms with 
comorbid anxiety and 
depressive symptoms, 
in two age groups (18-
30 and 31-45 years 
old). 
 
1. T-CBT would 
produce decreases in 
measures of panic, 
anxiety, and 
depression.  
2. T-CBT would 
increase quality of life.  
3. The effects of T-
CBT would be 
maintained at 12-
month follow-up.  
4. No significant 
differences would be 
observed between the 














65 PD (N = 4) 
PD+AG (N = 
47) 
GAD (N = 11) 
SAD (N = 9) 
Anx NOS (N = 
1) 
Dep (N = 5) 
No Yes No 
Taylor et al., 
2017 [79] 
US To compare PAI to a 
WLC in individuals 


















60,7 MDD (N = 16) 
SAD (N = 16) 
GAD (N = 11) 
PTSD (N = 6) 
PD (N = 2) 
OCD (N = 1) 
Eating 
disorder (N = 
3) 
No Yes No 
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AUD (N = 2) 
SUD (N = 1) 
 
Titov et al., 
2010 [26] 
AU 1. To compare CBT to 
a WLC in individuals 
with PD/AG, GAD, 
and/or SAD.  
2. To analyze whether 
additional gains would 
be shown by the WLC 
after mofifying the 
treatment program 
with the feedback of 
the patients in the 
treatment group.  
 
1. CBT would improve 




disability to a greater 
degree than the WLC.  
2. Participants 
allocated to CBT 














67,9 GAD (N = 34) 
PD/AG (N = 
21) 
SAD (N = 23) 
Yes Yes Yes 
Titov et al., 
2011 [27] 
AU To compare CBT to a 
WLC in patients with 
GAD, SAD, and/or 
PD/AG.  
 
1. CBT would improve 
generic measures of 
depression and 
anxiety, neuroticism, 
and disability to a 
greater degree than 
the WLC 
2. Fewer patients 
would meet the 
diagnostic criteria for 
MDD, GAD, SAD, or 
PD/AG in the 
treatment group 
3. Participants 
allocated to CBT 
















73 Dep (N = 38) 
GAD (N = 21) 
PD/AG (N = 7) 
SAD (N = 8) 
Yes Yes Yes 
Titov et al., 
2013 [80] 
AU 1. To compare CBT + 
automated emails to 
1. CBT + automated 









73,5 Dep (N = 85) 
GAD (N = 84) 
Yes No No 
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CBT alone for 
symptoms of anxiety 
and depression in 
terms of clinical 
outcomes and 
adherence.  
2. To provide 




rates and reductions in 
clinical outcomes than 
CBT alone. 
2. CBT + automated 
emails would be more 
beneficial for more 
severe patients.  







PD (N = 34) 
SAD (N = 54) 
Titov et al., 
2015 [41] 
AU To compare 
transdiagnostic CBT 
for depression and 
comorbid symptoms 
toSD-CBT in terms of 
efficacy and 
acceptability when 





CBT and SD-CBT 
would improve 
symptoms of 
depression similarly.   
2. Transdiagnostic 
CBT would reduce 
symptoms of comorbid 
PD, GAD, and SAD at 
each time point to a 














72 Dep (N = 290) Yes Yes Yes 
Vøllestad et 
al., 2011 [45] 
NO To compare MBSR to 
a WLC in patients with 















67,1 PD/AG (N = 
38) 
SAD (N = 25) 
GAD (N = 13) 
 
Yes Yes No 
Wetherell et 
al., 2009 [44] 
US To compare MP to 
Enhanced community 
treatment in patients 
with GAD or Anxiety 
NOS.  
 
MP would improve 
anxiety, depression, 
and quality of life to a 





















1: 71 (7) 
2: 73,3 
(6,3) 
83,9 GAD (N = 27) 
Anx NOS (N = 
4) 






AU To compare CBT to a 
WLC in older patients 
with comorbid anxiety 
and depression.  
 
 
CBT would produce 
significant 
improvements on all 
symptom measures at 
post-treatment.  
Improvements would 
be maintained at the 













64,5 GAD (N = 21) 
SAD (N = 6) 
SP (N = 1) 
PTSD (N = 3) 
Dep (N = 29) 
Anx NOS (N = 
2) 
 
Yes Yes No 
Wuthrich et al. 
2016 [53] 
AU To compare CBT to a 
discussion group in 
older patients with 




Both conditions would 
improve diagnostic 
severity and symptom 
outcomes. 
CBT would improve 
anxiety and 
depression and 
diagnostic severity to 
a greater degree than 
the discussion group 
Improvements of 
participants allocated 
to CBT would be 
maintained at the 6-
















55,6 GAD (N = 44) 
Dep (N = 37) 
No No No 
Note. Ctry: Country; Comorb: Comorbidity; C: Community; F2F: Face-to-face; Indv: Individual; N/A: Not available; SP: Specialized care; PC: Primary care; T: Telephone; Univ stud: University 
students; Comp: Computerized; PD/AG: Panic disorder/agoraphobia; SAD: Social anxiety disorder; SP: Specific phobia; OCD: Obsessive-compulsive disorder; GAD: Generalized anxiety disorder; 
PTSD: Posttraumatic stress disorder; Anx NOS: Anxiety disorder not otherwise specified; MDD: Major depressive disorder; Dep NOS: Depressive disorder not otherwise specified; Dep: Depression 
(major depressive disorder, dysthymic disorder or dep NOS); M anx-dep: Mixed anxiety and depression; ACT: Acceptance and Commitment Therapy; CBT: Cognitive Behavioral Therapy; MBSR: 
Mindfulness-based Stress Reduction; UP: Unified Protocol; SD-CBT: Single-disorder Cognitive Behavioral Therapy; WLC: Waiting-list Control; SC: Supportive Counseling; T-CBT: Tailored Cognitive 
Behavioral Therapy; CAU: Care as Usual; MT: Mindfulness Treatment; CBT-T: Cognitive Behavioral Therapy delivered by Telephone; IO: Information-only; STPP: Short-term Psychodynamic 
Psychotherapy; TAU: Treatment as Usual; AC: Attention Control; MMI: Multimodal Intervention; PP: Psychodynamic Psychotherapy; MBCT: Mindfulness-based Cognitive Therapy; P-CT: Present-
centered Therapy; SE: Self-exposure; DBT: Dialectical Behavioral Therapy; FSBET: False Safety Behavior Elimination Therapy;  CAST: Cognitive Anxiety Sensitivity Treatment; CBM: Cognitive Bias 
Modification; PHET: Physical Health Education Training; PAI: Positive Activity Intervention; MP: Modular Psychotherapy; Hp: Hypochondriasis; SD: Somatoform disorder; AUD: Alcohol use disorder; 
AD: Adjustment disorder; SUD: Substance use disorder 
a
Data on diagnoses from Bolton et al. (2014) were not included in the analysis because patients with PTSD could not be distinguished from those with Dep (i.e. we could not determine whether 
patients had both PTSD and Dep, or how many patients had PTSD and how many had Dep)
 
b





Quality of the included studies 
The risk of bias assessment of the included trials is represented in 
Figure 2. In all, 38 of the 52 studies (73%) used an adequate random 
sequence generation method, whereas 14 studies did not report 
information about the randomization method. Allocation concealment was 
reached in 26 of the assessed trials (50%), but it was not clearly reported 
in the other half (50%). With regard to blinding the outcome assessment, 
23 trials (44%) reported using blinded raters, whereas 12 (23%) used only 
self-report measures. Almost all of the studies (92%) used an appropriate 
method for handling incomplete outcome data (i.e. intention-to-treat 
analyses). Sixteen studies (31%) met all the quality criteria, 30 studies 
(58%) met two or three criteria, and the six remaining trials met none or 
only one quality criterion. 
 
 
Figure 2. Risk of bias assessment 
Note. SR = Self-report 
 
Are comorbid disorders evaluated in transdiagnostic treatments for 
emotional disorders?  
We were also interested in the number of studies that reported and 
assessed comorbidity in their samples. Of the 52 studies analyzed, 39 
(75%) reported the presence of comorbid disorders (i.e. whether the 
sample presented comorbidity at baseline), and 13 (25%) did not. 
However, of the total number of studies, only 21 (40%) assessed the 
effects of the intervention on comorbid disorders (i.e. through scales or 
diagnostic interviews). 
What diagnoses are targeted in transdiagnostic treatments for 
emotional disorders?  
Figure 3 presents the number of studies that target each of the 
different diagnoses. In this figure, both specific diagnoses and broad 
diagnosis categories (i.e. anxiety, depression, and mixed anxiety-
0% 20% 40% 60% 80% 100% 
Incomplete outcome data 
Blinding of outcome assessment 
Allocation concealment 
Random sequence generation 




depression) are shown because we identified studies that targeted either 
specific diagnoses or broader categories of anxiety and depression. 
Of the 52 studies included in the review, the most commonly 
targeted diagnoses were PD/AG, (26 studies; 50%), GAD (24 studies; 
46%), and SAD (22 studies; 42%). In addition, SP was targeted in 6 
studies (12%) [31, 32, 62, 69, 76, 77], Anxiety NOS in 6 studies (12%) [20, 
44, 46, 57, 58, 68], PTSD in 4 studies (8%) [32, 42, 47, 71], and OCD in 4 
studies (8%) [18, 31, 32, 71]. Moreover, we identified 1 study targeting 
Depression NOS (2%) [46] and 1 study targeting somatoform disorders 
(2%) [70]. Finally, 22 studies targeted symptoms or diagnoses of 
depressive disorders (i.e. MDD or DD) (42%), 19 studies targeted 
symptoms or diagnoses of anxiety disorders (any type) (36.5%), 15 
targeted depression symptoms or diagnoses (any type) (29%), 3 targeted 
mixed anxiety and depression (6%) [25, 52, 63], and 2 targeted stress 
(4%) [60, 70]. 
 
 
Figure 3. Number of studies that target the different diagnoses 
Note. PD/AG: Panic disorder/agoraphobia; GAD: Generalized anxiety disorder; SAD: 
Social anxiety disorder; Dep: Depression; Anx: Anxiety; SP: Specific phobia; Anx NOS: 
Anxiety not otherwise specified; PTSD: Posttraumatic stress disorder; OCD: Obsessive-
compulsive disorder; M anx-dep: mixed anxiety and depression disorder; Dep NOS: 
Depression not otherwise specified; SD: somatoform disorder 
 
What is the real distribution of diagnoses at baseline in 
transdiagnostic treatments for emotional disorders? 
In order to obtain the distribution of each of the different diagnoses, 
we classified the studies into those that reported a principal diagnosis 
(subsample 1) and those that did not (subsample 2). Of the 52 studies 
included in the review, 36 established a principal diagnosis, and 4125 
patients with a principal diagnosis were identified in this subsample. The 
proportion of these patients for each of the different principal diagnoses 
























998; 24.1%), PD/AG (n = 935; 22.6%), SAD (n = 826; 20.0%), Dep (i.e. 
MDD or DD) (n = 789; 19.1%), and mixed anxiety and depression (n = 
222; 5.4%). Other much less frequent diagnoses were OCD (n = 95, 





Figure 4. Total number of principal diagnoses in subsample 1 
Note. GAD: Generalized anxiety disorder; PD/AG: Panic disorder and/or agoraphobia; 
SAD: Social anxiety disorder; Dep: Depression; M anx-dep: Mixed anxiety and 
depression; OCD: Obsessive-compulsive disorder; SP: Specific phobia; Anx NOS: 
Anxiety not otherwise specified; PTSD: Posttraumatic stress disorder. “Others” included 
GAD + MDD (n = 47), GAD + PD (n = 25), GAD + SAD (n = 1), SAD + Anxiety NOS (n = 
1), OCD + PD/AG (n = 1), and anxiety/depression NOS (n = 2). 
 
The proportion of different diagnoses in the studies that did not 
include information about a principal diagnosis (subsample 2) is shown in 
Figure 5. In this subsample, a total of 4926 diagnoses were identified 
(pertaining to 2882 patients), and the most common diagnoses were Dep 
(n = 1220; 24.8%), PD/AG (n = 1135; 23%), GAD (n = 1119; 22.7%), SAD 
(n = 855; 17.4%), and PTSD (n = 323; 6.6%). Other disorders in these 
studies included SP (n = 74; 1.5%), OCD (n = 28; 0.6%), and Anxiety NOS 




































Figure 5. Total number of diagnoses of each type in subsample 2 
Note. Dep: Depression; PD/AG: Panic disorder and/or agoraphobia; GAD: Generalized 
anxiety disorder; SAD: Social anxiety disorder; PTSD: Posttraumatic stress disorder; Anx 
dis: Anxiety disorders; SP: Specific phobia; OCD: Obsessive-compulsive disorder; Anx 
NOS: Anxiety not otherwise specified. “Others” included somatoform disorder (n = 10), 
adjustment disorder (n = 10), eating disorders (n = 9), alcohol use disorder (n = 4), 
substance use disorder (n = 4), and anxiety/depression NOS (n = 4). 
 
Discussion 
The aim of this systematic review was to analyze the following 
aspects about transdiagnostic treatments for ED: first, whether treatment 
response in the comorbid disorders is evaluated in transdiagnostic 
treatments for ED; second, what disorders are targeted in these studies; 
and third, what the real distribution of these disorders is at baseline in 
these studies. 
The first objective was to analyze how comorbidity is reported and 
whether the treatment change produced in comorbid disorders is 
assessed in transdiagnostic trials for ED. The results showed that the 
number of studies reporting comorbidity was quite high, with 39 out of 52 
reporting the presence of comorbid disorders in their samples at baseline. 
However, the number of studies assessing comorbidity was much lower, 
with only 21 (40.4%) studies assessing the comorbid conditions as well as 
the symptoms of the principal diagnosis, using either diagnostic interviews 
[18, 22] or self-report questionnaires [21, 40, 41]. From a transdiagnostic 
perspective that addresses the common maintenance vulnerabilities 
across disorders (e.g. neuroticism), it makes more sense to explore the 
extent to which these treatments are effective in improving both principal 
and comorbid disorders. In order to gain insight into how transdiagnostic 
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should be followed in future research on transdiagnostic treatments for 
ED. Furthermore, future meta-analyses of transdiagnostic treatments for 
ED would benefit from this strategy because they could analyze the impact 
of these treatments on comorbidities, in addition to their effects on broader 
measures of anxiety and depression. To date, some studies have included 
measures to assess treatment response in comorbidity in addition to the 
principal diagnosis [21-23]. However, as the results of this systematic 
review show, this is not the typical approach in RCTs on transdiagnostic 
treatments (i.e. only 40.4% of the trials analyzed in this review assessed 
the impact of the intervention on comorbidity).  As an example of this 
emphasis on comorbid diagnoses, a recent study tested the efficacy of a 
transdiagnostic treatment (the UP), compared to disorder-specific CBT 
with a specific focus on comorbid conditions, finding no differences in 
efficacy between the two treatment approaches [82]. These authors have 
also acknowledged the low number of treatments that, in general, evaluate 
treatment effects on comorbid disorders [82], whereas other authors have 
highlighted that transdiagnostic treatments should improve not only overall 
anxiety and depression, but also the disorder-specific comorbid 
psychopathology [38]. In this vein, most of the meta-analyses published to 
date have only analyzed the effects of transdiagnostic treatments using 
measures of overall anxiety and depression, except one recent meta-
analysis that also explored the impact of these interventions on 
comorbidities [38]. To do so, the authors compared the effects of 
transdiagnostic treatments for ED to control conditions on disorder-specific 
measures of generalized anxiety, panic, and social anxiety. However, only 
5 studies were included in this meta-analysis, which suggests the overall 
lack of attention paid to the evaluation of comorbidity in transdiagnostic 
treatments.  
It is important to note that some of the studies included in this 
review follow a treatment perspective that does not fall into the “shared 
mechanisms approach” described by Sauer-Zavala et al. [13]. Some of 
these approaches include tailoring the treatment to the specific disorders 
and comorbidities of each individual [19, 20, 73], changing the relationship 
of the patient with her or his own subjective experience (regardless of the 
specific disorder involved) through the delivery of “third wave” therapies 
(e.g. mindfulness, acceptance, and commitment therapy) [31, 32, 43, 51], 
or helping the patients to resolve their inner psychic conflicts using 
psychodynamic therapy [46, 69]. Regarding the usefulness of these 
transdiagnostic treatments for comorbid presentations, whereas tailored 
treatments aim to tailor the treatment according to the specific symptoms 
of the patient, third wave and psychodynamic therapies are considered 




different types of disorders. In sum, all of these approaches represent 
different strategies used to target comorbidity.  
Regarding the second objective, (i.e. what diagnoses are targeted 
in transdiagnostic treatments for emotional disorders?) PD/AG was 
targeted in half of the studies, followed by GAD, SAD, and Dep, which 
were also targeted in almost half of the studies (46, 42, and 42%, 
respectively). By contrast, Anxiety NOS and Depression NOS were only 
targeted in 12 and 2% of the studies, respectively. 
Finally, the third question tried to answer what the real distribution 
of the diagnoses is at baseline in transdiagnostic treatments for emotional 
disorders. Regarding this question, the findings show that, in patients with 
a principal diagnosis (subsample 1), GAD was the most frequent 
diagnosis, followed by PD/AG, SAD, and Dep. Taken together, these 
disorders represented 85.8% of subsample 1, with anxiety disorders being 
the most common disorders targeted in transdiagnostic treatments for ED. 
Other ED appeared much less frequently. These disorders included OCD, 
SP, Anxiety NOS, PTSD, and Depression NOS. In patients with 
unreported principal diagnoses (subsample 2), Dep was the most common 
diagnosis, followed by PD/AG, GAD, SAD, and PTSD. These disorders 
represented 94.5% of the total number of diagnoses, and anxiety 
disorders were again the most frequent disorders targeted in the 
transdiagnostic treatments. By contrast, Anxiety NOS and OCD only 
represented 1% of this subsample. Overall (both subsamples), the most 
common disorders targeted in transdiagnostic trials were GAD, PD/AG, 
SAD, and Dep. These results are consistent with the high prevalence rates 
observed for these disorders [8, 9, 54]. For instance, according to the 
DSM-IV-TR [54], lifetime prevalence is 5% for GAD, 10-25% (female) and 
5-12% (male) for major depression, 6% for dysthymic disorder, 1.5-3.5% 
for PD/AG, 2.5% for OCD, 3-13% for SAD, and 1-14% for PTSD. 
However, other ED, such as OCD, PTSD, Anxiety NOS, and SP, have 
received much less attention in the research on transdiagnostic treatments 
for ED, and they are usually not targeted in these protocols. On the one 
hand, it is worth noting that there is a low proportion of patients with OCD 
as the principal diagnosis included in the transdiagnostic interventions, 
even though this disorder can be appropriately treated from a 
transdiagnostic perspective, based on common maintenance 
vulnerabilities across ED [15, 17, 22]. In the case of PTSD, earlier studies 
with transdiagnostic protocols like the UP [83], which originally targeted 
this diagnosis, do not include this category in later studies [18, 22], in spite 
of the fact that this disorder might be an appropriate treatment target from 
a mechanistically transdiagnostic approach (i.e. a treatment approach that 
addresses the common underlying mechanisms across a range of 
disorders) [18, 84]. On the other hand, transdiagnostic treatments have 
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the potential to target diagnoses that do not fit any specific category (e.g. 
Anxiety NOS) [12,15]. Although there are data indicating that there is a 
high proportion of these presentations [85, 86], the number of diagnoses 
with Anxiety NOS analyzed in this study represented less than 1% of all 
the patients. In this regard, one somewhat surprising result is that the 
overall number of patients with a diagnosis of SP is larger than the number 
of patients with Depression or Anxiety NOS, even though one of the 
advantages of the transdiagnostic perspective is the possibility of treating 
NOS diagnoses, clinical presentations for which there is a lack of 
evidence-based treatments.  
Regarding the control conditions, both the waitlist control and the 
active control conditions were the most frequent among the analyzed 
studies. Of the studies that used active control conditions, only 8 were 
disorder-specific treatments. In order to accumulate evidence about the 
efficacy of transdiagnostic treatments, more studies should compare these 
protocols to disorder-specific treatments [21, 23]. Thus, although there is 
some evidence showing that a transdiagnostic approach may benefit 
depressive symptomatology more than disorder-specific protocols [36], 
overall the literature suggests that these two treatment approaches have 
equivalent effects [18, 39-41]. However, the number of studies comparing 
these two approaches is still low, and so more research is warranted to 
more firmly establish their relative efficacy. Likewise, research comparing 
the cost-effectiveness of transdiagnostic treatments and disorder-specific 
protocols is of paramount importance, for a number of reasons. First and 
foremost, by using a transdiagnostic treatment, less training of clinicians is 
required because a single protocol is used to address multiple disorders, 
which is likely to facilitate its implementation in real-world settings (e.g. 
primary care and mental health services). Second, these treatments may 
be more useful for clinicians that have to address comorbid presentations, 
either by targeting the underlying common processes, by tailoring the 
treatment to the symptoms and needs of each patient [20], or by 
addressing how the patients relate to their own cognitive, behavioral, and 
emotional experiences [31, 32]. Although the aforementioned reasons are 
true for most transdiagnostic treatments, there are other reasons specific 
to the protocols that fall in the category of the “shared mechanisms 
approach”. For instance, transdiagnostic treatments are designed to 
address the underlying common vulnerabilities across ED that are 
hypothesized to account for the onset and maintenance of these disorders 
[15]. Thus, by focusing on treating these processes rather than disorder-
specific variations, larger and more lasting effects on clinical outcomes 
would be expected [13]. These results would lead to a lower prevalence of 
ED, and therefore to a decreased need for treatments in the short and 




more research on the cost-effectiveness of transdiagnostic treatments is 
needed, especially in comparison with disorder-specific protocols, as 
evidenced by the scarcity of studies of this kind found in this review (e.g. 
the study by Nordgren et al.) [67]. Given the substantial burden of ED and 
the lack of resources to tackle these disorders, especially in public 
services, research on how to enhance the cost-effectiveness of 
psychological interventions should be a research priority. A characteristic 
example of a treatment strategy to further increase the efficiency of 
transdiagnostic protocols entails personalizing the treatment to a specific 
presentation, i.e. by selecting the treatment components that best fit the 
specific set of symptoms or “weaknesses” shown by each patient [87], 
thereby lowering the number of sessions required to successfully treat an 
individual’s symptoms. 
Regarding the settings, 71% of the studies were conducted in 
community samples, whereas 20% were carried out in primary or 
specialized care, and only 4% with university students. Thus, community 
samples continue to be the setting of choice when conducting 
transdiagnostic trials for ED. Regarding the way these treatments were 
delivered, approximately half of the studies were face-to-face, whereas the 
other half were delivered through Information and Communication 
Technologies (web-based and computerized), and only one study was 
delivered by telephone. These results are not surprising because research 
on Internet interventions has increased enormously in recent years, and 
these interventions have been applied to different problems using a variety 
of treatment approaches [88]. As the field of Internet interventions 
advances, researchers are more likely to select this delivery format to 
explore new interventions. Finally, transdiagnostic treatments were mostly 
individual, with 68% of the studies conducted in an individual format and 
the rest in groups. These results are not surprising because most 
transdiagnostic treatments were originally developed to be applied 
individually, with some exceptions [89]. However, the potential of 
transdiagnostic treatments for improving the dissemination of empirically 
supported treatments (i.e. only one protocol is needed to address a range 
of psychological disorders) may be enhanced by modifying the way the 
treatments are delivered [90]. For example, Internet or group formats can 
be used to reach a larger number of people in need of psychological help 
[92 ,93], especially in ecological settings where resources are generally 
scarcer, such as primary care or public mental health units [91, 93]. 
Finally, regarding the risk of bias assessment, the overall quality of 
the trials included was acceptable, especially regarding the handling of 
incomplete outcome data, with almost all the studies using an appropriate 
approach. However, it is worth noting that a large percentage of the 
studies did not properly report specific methodological aspects, such as 
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the sequence random generation method and whether it was performed 
by an independent party, which led us to rate it as unclear. In order to 
improve the methodological quality of trials and reduce the different 
sources of bias, we encourage authors to follow guidelines for conducting 
and reporting on clinical trials, such as the CONSORT statement 
(Consolidated Standards of Reporting Trials) [94, 95] or the SPIRIT 
guidelines (Standard Protocol Items: Recommendations for Interventional 
Trials) [96, 97].  
Limitations 
This systematic review has several limitations that should be 
mentioned. First, although a comprehensive search was conducted (4 
different databases were used), some important studies might have not 
been identified. Moreover, studies written in languages other than English 
were excluded, which might have affected the representativity of the 
findings in this study. Second, the generalizability of the results is also 
limited by the fact that most of the studies included in this review were 
conducted in Western countries. Third, although aspects of the 
methodology were unreported or not clear in some studies, we did not 
contact the authors of these studies to obtain information that might have 
clarified these details. Thus, aspects of the study methods that were not 
clear were rated as unclear. However, based on our experience in 
conducting prior systematic reviews, we have observed that contacting the 
authors of these studies is often very difficult and, therefore, impractical. 
Fourth, as in any systematic review, this study is vulnerable to publication 
bias, and so some relevant unpublished studies might have been missed. 
Conclusions 
In conclusion, this systematic review found that, although most of 
the studies reported the presence of comorbid disorders in their samples 
at baseline, less than half of them evaluated the effects of the intervention 
on the comorbid disorders. Patients with comorbid disorders normally 
exhibit greater rates of severity, disability, and chronicity. One main reason 
for using a transdiagnostic approach to the treatment of ED is better 
management of comorbidity. Therefore, efforts should be made to assess 
the impact of the intervention on the comorbid disorders, in addition to the 
principal diagnoses targeted in these studies. On the other hand, as the 
results showed, the most commonly targeted diagnoses in transdiagnostic 
treatments were PD/AG, GAD, SAD, and Dep. More research is needed 
with other diagnoses much less targeted in transdiagnostic treatments, 
such as PTSD, OCD, and anxiety/depression NOS, to further explore the 





ED: Emotional disorders; CBT: Cognitive behavioral therapy; RCT: 
Randomized controlled trial; DSM-IV-TR: Diagnostic and Statistical 
Manual of mental disorders, 4th edition-text revision; MDD: Major 
depressive disorder; DD; Dysthymic disorder; NOS: Not otherwise 
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Abstract 
Background: Emotional disorders (depression and anxiety disorders) are 
highly prevalent mental health problems. Although evidence showing the 
effectiveness of disorder-specific treatments exists, high comorbidity rates 
among emotional disorders limit the utility of these protocols. This has led 
some researchers to focus their interest on transdiagnostic interventions, a 
treatment perspective that might be more widely effective across these 
disorders. Also, the current way of delivering treatments makes it difficult 
provide assistance to all of the population in need. The use of the Internet 
in the delivery of evidence-based treatments may help to disseminate 
treatments among the population. In this study, we aim to test the 
effectiveness of EmotionRegulation, a new transdiagnostic Internet-based 
protocol for unipolar mood disorders, five anxiety disorders (panic 
disorder, agoraphobia, social anxiety disorder, generalized anxiety 
disorder and anxiety disorder not otherwise specified), and obsessive-
compulsive disorder in comparison to treatment as usual as provided in 
Spanish public specialized mental health care. We will also study its 
potential impact on basic temperament dimensions 
(neuroticism/behavioral inhibition and extraversion/behavioral activation). 
Expectations and opinions of patients about this protocol will also be 
studied. 
Methods/Design: The study is a randomized controlled trial. 200 
participants recruited in specialized care will be allocated to one of two 




Primary outcome measures will be the BAI and the BDI-II. Secondary 
outcomes will include a specific measure of the principal disorder, and 
measures of neuroticism/behavioral inhibition and extraversion/behavioral 
activation. Patients will be assessed at baseline, pos post-treatment, and 
3- and 12-month follow-ups. Intention to treat and per protocol analyses 
will be performed. 
Discussion: Although the effectiveness of face-to-face transdiagnostic 
protocols has been investigated in previous studies, the number of 
published transdiagnostic Internet-based programs is still quite low. To our 
knowledge, this is the first randomized controlled trial studying the 
effectiveness of a transdiagnostic Internet-based treatment for several 
emotional disorders in public specialized care. Combining both a 
transdiagnostic approach with an Internet-based therapy format may help 
to decrease the burden of mental disorders, reducing the difficulties 
associated with disorder-specific treatments and facilitating access to 
people in need of treatment. Strengths and limitations are discussed. 
 
Trial registration: ClinicalTrials.gov NCT02345668. Registered 27 July 
2015. 
 
Keywords: Transdiagnostic, Internet, Randomized controlled trial, 
Emotional disorders, Depression, Anxiety, Computer-delivered 





Emotional disorders (ED) (anxiety and mood disorders) are among 
the most prevalent mental disorders, with a life prevalence of 29 % and 
comorbidity rates ranging between 40 and 80 % [1, 2]. If the person 
experiencing the disorder is not adequately treated, the course often 
becomes chronic and can significantly affect important functioning areas 
such as work and social relationships [3, 4]. Moreover, the medical care 
costs and production losses associated with these mental health problems 
in Europe are huge [2]. These data strongly suggest that efficacious and 
efficient treatments are needed to address this important health problem 
[5–8]. Nevertheless, despite these alarming data, evidence exists 
indicating that most people with depression and anxiety disorders (less 
than 50 %) do not receive treatment. [9]. To reduce the burden of mental 
illness, some authors have emphasized the need for an approach that 
goes beyond the dominant face-to-face treatment approach in order to 
provide help to people in need of evidence-based treatments, and this 
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approach includes the use of the media, self-help interventions, the use of 
special settings and information and communication technologies (ICT) 
[10]. 
Efficacious psychological treatments for ED currently exist, and a 
number of evidence-based cognitivebehavioral treatments (CBT) targeting 
specific disorders have been developed in the past 20 years [11–17]. 
However, disorder-specific treatment protocols have some problems. First, 
the high comorbidity rates among ED. Epidemiological studies have 
shown that at least 55 % of people suffering from depression and an 
anxiety disorder suffer from another anxiety disorder at the time of the 
assessment, and this prevalence rate increases to 76 % when different 
lifespan diagnoses are taken into account [18]. Consequently, clinicians 
often have to decide on which is the most adequate disorderspecific 
protocol in these cases, and because these treatments focus on disorder-
specific symptomatology, other comorbid diagnoses do not receive 
sufficient attention [19]. Second, disorder-specific protocols frequently do 
not target subthreshold symptoms that did not meet diagnostic thresholds 
for one disorder or another but that may be important to address in the 
treatment [20]. Third, the high rate in which “not otherwise specified” 
diagnoses of clinical significance are assigned as current and lifetime 
conditions for which there are not specific interventions [18]. Finally, the 
fact that each manualized specific-disorder treatment requires the use of 
separate handbooks, workbooks and protocols may be an obstacle in the 
dissemination of evidence-treatments due to its costs and the important 
amount of training to become adequately familiar with each of the different 
treatments [20]. 
Transdiagnostic approach 
In recent years, there has been great interest in treatment 
strategies (referred to as transdiagnostic treatments) that might be more 
widely effective across these diverse mental health disorders. Unlike 
disorder-specific treatment protocols, transdiagnostic treatments generally 
include treatments aimed at addressing different disorders (for example, 
different anxiety disorders) with a single protocol [21]. A growing body of 
research showing the efficacy of transdiagnostic treatments for anxiety 
disorders [22–27], and for comorbid depression and anxiety disorders [28–
30] has emerged in the past years. Moreover, the efficacy and 
effectiveness of transdiagnostic treatment protocols for ED have been 
shown in two recent meta-analyses [31, 32]. 
An important line of research within the transdiagnostic approach is 
that initiated by D. H. Barlow [20, 33–36]. Barlow’s theory of triple 
vulnerability emphasizes the underlying vulnerabilities that are common to 




diverse conditions [20, 33]. From this theoretical framework, ED are 
regarded as minor variations in the manifestation of a broader syndrome 
(that is, “ general neurotic syndrome”) such that the development of 
treatments directly targeting this underlying syndrome rather than 
symptom-specific variations would result in a more parsimonious, easier to 
disseminate treatment approach [20]. It would also result in a more 
inclusive approach, as it lays on the existence of biological and 
psychological vulnerabilities that are hypothesized to be common among 
anxiety disorders, unipolar mood disorders, and other disorders such as 
somatoform and dissociative disorders [20, 37]. Based on this perspective, 
Barlow’s team designed the Unified Protocol (UP) [37–41], a 
transdiagnostic treatment protocol that emphasizes the role of emotion 
regulation in understanding and treating ED. Due to difficulties in emotion 
regulation, people with ED often react negatively to their own emotions, 
and they are more likely to use maladaptive emotion regulation strategies 
that, in turn, increase the frequency and intensity of negative emotions 
[37]. To enhance adaptive emotion regulation strategies, the UP focuses 
on four essential aspects: increasing present-focused emotional 
awareness, addressing emotional avoidance, promoting cognitive 
flexibility, and facilitating exposure to avoided situations and sensations. 
The results obtained using this protocol in a traditional face-to-face format 
demonstrate its effectiveness and are encouraging [30, 38, 42].  
The core of all emotion regulation difficulties has been pointed out 
to be neuroticism/behavioral inhibition (N/BI) [34, 43, 44]. Previous 
research supports the role of N/BI in accounting for the onset, overlap, and 
maintenance of ED [33, 44–46]. Literature has also highlighted the role of 
extraversion/behavioral activation (E/BA) in ED. For instance, structural 
models have indicated that low E/BA is associated with unipolar 
depression [47], social anxiety [48] and agoraphobia [49]. Also, a recent 
meta-analysis indicated that most individuals with anxiety and mood 
disorders show low levels of E/BA [50]. The effect of the UP on these two 
temperament dimensions has been demonstrated recently [51]. 
Literature about Dialectical Behavior Therapy (DBT) has also 
highlighted the role of emotion dysregulation in psychological disorders 
[52, 53]. A primary goal in DBT is training patients in adaptive emotion 
regulation strategies, as emotion dysregulation is assumed to be a key 
factor in the development and maintenance of these problems [52]. 
Emotion regulation difficulties have also been shown to be a 
transdiagnostic factor across a number of psychological disorders, 
including anxiety and depression [54–58]. A treatment protocol derived 
from DBT emotion regulation skills training has been tested in a recent 
study, suggesting that training patients in emotion regulation strategies (for 
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example increasing emotional awareness) may help to reduce anxious 
and depressive symptoms among distinct ED [59]. 
Internet-based treatment protocols 
ICT such as the Internet may facilitate access by people for whom 
traditional therapy is not available [10]. Internet-based treatments have 
proven to be a very promising tool for solving several mental health 
problems and enhancing the dissemination of evidence-based treatments 
[60–63]. Several advantages regarding the recruitment of patients, 
assessment, diagnosis and case management in Internet-based treatment 
protocols have been indicated in a recent article [64]. A number of 
systematic reviews have shown that Internet-based treatments are 
efficacious [65–69]. Moreover, meta-analyses reveal that these protocols 
produce higher effect sizes compared to control groups [60, 65, 70] and 
that they are as efficacious as face-to-face traditional treatments [66, 70– 
72]. In sum, there is extensive evidence showing the efficacy of these 
treatments. However, the evidence available about Internet-based 
treatments is almost exclusively limited to disorder-specific protocols. 
Indeed, very few studies combining both a transdiagnostic approach and 
an Internet-based delivery format have been tested through randomized 
controlled trials (RCT) [25, 26, 29, 73]. Moreover, studies analyzing the 
efficacy of transdiagnostic Internet-based treatments, address the 
treatment of anxiety disorders only [25, 26, 73] or have used open-trial 
designs [28, 74]. Among those focused on anxiety and depression the 
existing protocols do not contemplate either the treatment of “ not 
otherwise specified”  diagnoses or obsessive-compulsive disorder [29], or 
target a small range of ED [29]. Moreover, to our knowledge, no RCT have 
been carried out on the effectiveness of a transdiagnostic Internet-based 




Our research group has developed a traditional transdiagnostic 
treatment that is partly based on the UP [37]. Taking into account the 
importance of emotion regulation in the treatment of ED, it also includes 
components of emotion regulation from DBT [52]. Based on the traditional 
treatment protocol, we developed EmotionRegulation, an adaptation of 
this treatment that can be applied online over the Internet.  
In this study, we aim to present EmotionRegulation, and test its 
effectiveness for the treatment of ED in an RCT with a sample made up of 
participants from specialized care in the Spanish public mental health 




depression disorder (MDD), dysthymic disorder (DD), panic disorder (PD), 
agoraphobia (A), social anxiety disorder (SAD), generalized anxiety 
disorder (GAD), and obsessive-compulsive disorder (OCD). Anxiety 
disorder not otherwise specified (ADNOS) and (unipolar) mood disorder 
not otherwise specified (MDNOS) will also be targeted. Secondary 
objectives will include the following: a) study of the effects of 
EmotionRegulation on two dimensions of temperament (that is, N/BI and 
E/BA) and b) study of the acceptability (expectations and opinions) of the 




A two-armed simple-blinded randomized controlled trial will be 
conducted. Participants will be randomly allocated to one of two 
conditions: a) EmotionRegulation and b) TAU. Randomization will be 
stratified by primary diagnosis. Block randomization will be performed 
within each strata in order to ensure all primary diagnoses are equally 
represented across conditions. The study will be conducted following the 
CONSORT statement (Consolidated Standards of Reporting Trials, 
http://www.consort-statement.org) [75, 76] and CONSORT-EHEALTH 
guidelines [77]. Participants will be assessed at pre- and post-treatment, 





Figure 6. Study flowchart 
EmotionRegulation, transdiagnostic Internet-based protocol; TAU, treatment as usual 
 
Study population 
The clinical trial will be conducted in the Mental Health Department 
of the Provincial Consorcio Hospitalario in Castellon and the University 
Hospital La Ribera in Valencia (Spain). Participants will be adult 
outpatients from specialized care who attend mental health units to seek 
psychological and/or psychiatric treatment. Participants will be recruited by 




required sample is complete. In order to facilitate the selection of 
participants in the study, both clinical psychologists and psychiatrists will 
be given a sheet containing the eligibility criteria. 
Ethics 
This trial will be conducted in compliance with the study protocol, 
the Declaration of Helsinki and good clinical practice. Data 
security/confidentially will be guaranteed; all relevant EU legislation and 
international texts on privacy will be observed and respected. Access to 
the Internet platform is through a unique usernamepassword combination 
and will be available on a 24/7 basis. All transferred data will be secured 
via AES-256 encryption. 
The study has been approved by the Ethics Committee of 
University Jaume I (Castellon, Spain) and the Clinical Research Ethics 
Committee from two hospitals (Consorcio Hospitalario Provincial de 
Castellon, and Hospital Universitario de la Ribera). The trial was 
registered at clinicalstrials.gov as NCT02345668. For ethical reasons, 
patients allocated to TAU will be offered free access to EmotionRegulation 
after the study has been completed. 
Eligibility criteria 
Inclusion criteria will include the following: a) be 18 years or older; 
b) ability to understand and read Spanish; c) access to Internet at home 
and having an email address; d) meeting the DSM-IV diagnostic criteria 
[78] for ED (MDD, DD, MDNOS, PD, A, SAD, GAD, ADNOS, OCD); and e) 
providing written, informed consent. Exclusion criteria include the 
following: a) suffering from a severe mental disorder (schizophrenia, 
bipolar disorder, and alcohol and/or substance dependence disorder); b) 
the presence of a high risk of suicide; c) medical disease/condition that 
prevents the participant from carrying out the psychological treatment; or 
d) receiving another psychological treatment during the study in the 
experimental group. Receiving pharmacological treatment is not an 
exclusion criterion during the study period, but patients having an increase 
and/or change in the medication 2 months prior to enrollment will not be 
considered for the trial. Also, the increase and/or change in the medication 
during the study period in the experimental group will imply the 
participant’s exclusion from subsequent analyses (a decrease in 
pharmacological treatment is accepted). 
Recruitment 
When the psychiatrist or clinical psychologist identifies a potential 
participant, he or she will describe the study characteristics to him/her. 
Those candidates interested in participating will sign an informed consent, 
and the professional will fill out a document describing the participant’s 
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sociodemographic and clinical characteristics, and give him/her a patient 
information sheet and a handout describing the study. After confirming that 
the participant has signed the informed consent and understands the 
study and the treatment options, the researcher will administer 
assessment instruments related to the inclusion criteria. If the patient 
fulfills all the study criteria, the researcher will contact an independent 
researcher to implement randomization. Participants who meet all the 
inclusion criteria will then be randomized to either EmotionRegulation or 
TAU and complete the remaining assessment instruments. Participants 
will be free at any time to withdraw from the treatment or the study without 
giving any explanation. 
Randomization and blinding 
Patients will be randomly allocated in a 1:1 ratio to either of the two 
groups (EmotionRegulation or TAU) using a computer-generated random 
number sequence. The Epidat 4.1 program will be used to generate this 
sequence. The allocation will be carried out by an independent researcher 
who will be unaware of the characteristics of the study. The sequence will 
be concealed until interventions are assigned. Patients will agree to 
participate before the random allocation and without knowing to which 
treatment they will be allocated. Study researchers conducting 
psychological assessments (that is, diagnostic interviews) throughout the 
entire study will be masked to the participants' treatment conditions and 
unaware of the treatment group to which the patient belongs. For ethical 
and practical reasons, participants will not be blind to the treatment 
conditions. 
Interventions 
Transdiagnostic Internet-based protocol (EmotionRegulation)  
Our research group developed a transdiagnostic protocol made up 
of 12 modules designed for the treatment of the following mental 
disorders: MDD, DD, MDNOS, PD, A, SAD, GAD, ADNOS and OCD. This 
protocol is partly based on the UP by David H. Barlow [37] and partly on 
the emotion regulation skills from DBT by Marsha Linehan [52]. The 
intervention aims to enhance present-focused emotional awareness, 
facilitate cognitive flexibility, identify and modify behavioral and emotional 
avoidance patterns, and promote interoceptive and situational exposure. 
Each module includes several tasks to practice the different techniques 
and skills.  
We have adapted this protocol for its application on the Internet 
(EmotionRegulation). EmotionRegulation is an internet-delivered, 
multimedia, interactive, selfadministered program for ED that allows the 




from a transdiagnostic perspective. EmotionRegulation will be delivered 
through a web platform (https://www.psicologiaytecnologia.com/) designed 
by our research group. This web platform has four main sections (shown 
in Table 2). 
EmotionRegulation includes a Welcome module that provides the 
participant with general information about the protocol and its objectives, 
as well as recommendations for benefiting from it, and the following 12 
treatment modules: 
M1. Emotional disorders and emotion regulation. This module provides 
information about the role of emotion regulation in emotional disorders. A 
brief description of the program modules is also presented, as well as 
videos with examples of people suffering from different ED. 
M2. Motivation for change. The aims are to analyze the advantages and 
disadvantages of changing, emphasize the importance of being motivated, 
and highlight the importance of establishing significant life goals. 
M3. Understanding the role of emotions. This module provides information 
about the adaptive roles and functions of emotions and the three-
component model of emotions. 
M4. The acceptance of emotional experiences. This module aims to teach 
the patient the acceptance of emotional experiences and its importance in 
the treatment. 
M5. Practicing acceptance. The objective is to continue to learn about the 
acceptance of emotional experiences and increase awareness of physical 
sensations, thoughts, emotions and daily activities. 
M6. Learning to be flexible. It focuses on the importance of maladaptive 
ways of thinking in the maintenance of emotional disorders, and on 
learning how to identify them. 
M7. Practicing cognitive flexibility. This module aims to teach the patients 
the ways maladaptive ways of thinking can be modified. It also provides 
information about intrusive thoughts and how to deal with them. 
M8. Emotional avoidance. This module aims to teach the patients the 




Table 2. Main sections of the web platform 
a) “Home”: This section is the start point from which participants can access the other 
sections. It also displays a progress bar (0 to 100 %) that shows the progress through 
the treatment. 
 
b) “Calendar”: This section shows pending tasks as well as the days in which the 
participant has accessed the program and has done the module tasks. 
 
c) “Review”: This section allows participants to review the treatment modules already 




d) “How am I?”: This section allows participants to monitor their progress through several 
graphs as they advance in the program. 
 
M9. Emotion Driven Behaviors (EDBs). The aim is to learn the concept of 
EDBs, and replace their own maladaptive EDBs with other more adaptive 
behaviors. 
M10. Accepting and facing physical sensations. The objectives are to 
teach the patients the role of physical sensations in the emotional 
response and train them in interoceptive exposure, in order to increase 
tolerance and promote habituation to physical sensations. 
M11. Facing emotions in the contexts in which they occur. The purpose is 
the construction of exposure hierarchies to help the patients to begin to 
face the avoided situations that contribute to the maintenance of the 
problem. 
M12. Relapse prevention. This module aims to review the strategies 
learned throughout the program and teach the patient how to identify and 
cope with future high-risk situations. 
 
These modules are sequential, in order to move through the 
program step by step. The program duration can vary among the users, 
and it is estimated that for most participants the duration will be 18 weeks. 
During the study, EmotionRegulation will be accessible only to participants 
in the online intervention group. Participants will be allowed to use the 
program at any time they want during the trial period. See Table 3 for 
other functionalities in EmotionRegulation. 
Participants in the EmotionRegulation condition will be allowed to 
maintain medication if there are not changes and/or increases but will not 
be allowed to receive another psychological treatment during the study 
period. Failure to fulfill these criteria will result in the participant’s data 
being excluded from data analysis. 
 
Table 3. Other functionalities in EmotionRegulation  
a) Assessments: The program allows the pre-, post- and follow-up instruments to be 
completed online. 
 
b) Module self-assessments: Each module ends with a short list of multiple-choice 
questions that allow participants to assess their understanding of the module and help 
them to decide whether they need to review its contents. 
 
c) Automatic e-mails with reminders when participants have not accessed the program in 
the past 15 days. 
 
d) Suicide risk alarms: Therapists receive warnings of participants with high risk of 






e) Post-module questionnaires: Each module includes three brief questionnaires 
(OASIS, ODSIS and PANAS) to evaluate anxiety, depression and positive/negative 
affect after each treatment module. Participants are able to monitor these scores in the 
feedback section through the ‘How am I?’ button. 
 
f) Printable documents: Each module contains several printable documents (PDF) with 
summaries and self-monitoring sheets that participants are encouraged to use to 
practice the skills and strategies. 
 
Treatment as usual 
Treatment as usual (TAU) is treatment as delivered in current daily 
practice by psychiatrists and clinical psychologists in the mental health 
centers in Spain. TAU may refer to psychiatric treatment, which typically 
includes prescription and monitoring of antidepressant and/or anxiolytic 
medication, psychological treatment (this may include case management, 
group psychotherapy, empathic listening and/or supportive counselling), or 
a combination of both. Patients in the TAU condition already receiving any 
of the aforementioned treatments are informed they will continue to 
receive as usual the services received before enrollment in the study. 
Support 
Meta-analyses have shown that attrition rates are higher when no 
support of any kind is provided to patients in self-administered Internet-
based programs [60, 68]. Therefore, we will provide human support and 
ICT support to all participants in EmotionRegulation.  
Human support will be provided by trained predoctoral students in 
our group and will include the following: a) an initial face-to-face session to 
explain the participant the characteristics of the study and to administer 
the diagnostic interview to confirm him/her to fulfill the eligibility criteria, b) 
an initial phone call encouraging participants to start the intervention once 
baseline assessments have been completed, and c) one weekly brief 
phone call (maximum of 10 minutes) during the treatment period. The 
objective of these weekly phone calls will be as follows: 1) to ask the 
participants about any difficulties or doubts they might have found in the 
use of the online protocol and help them to solve those problems, 2) to 
remind them to review the treatment contents as many times as 
necessary, 3) to emphasize the importance of doing the homework tasks, 
4) to encourage participants to keep using the protocol and reinforce them 
for engaging in the treatment, and 5) to recommend that they complete 
one module per week. Finally, d) a final phone call will be made after the 
18-week treatment period to remind participants that they will be allowed 
to use the program at any time they want during the trial period and that 
they will be contacted for follow-up assessments.  
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ICT support will consist of two weekly mobile phone text messages 
with reminders about the importance of doing the homework tasks and 
encouraging participants to review the modules. A commercial platform 
(www.trendoo.es) will be used to send these messages. 
Instruments 
Patients will be assessed at baseline, post-treatment (18 weeks 
after baseline), and at 3- and 12-month follow-ups. Scores on anxiety, 
depression and negative and positive affect will also be obtained after 
each module has been completed. The study variables and assessment 
times are summarized in Table 4. 
Diagnosis interview 
Mini International Neuropsychiatric Interview Version 5.0.0 (MINI) 
[79]. It is a short structured diagnostic psychiatric interview that yields key 
DSM-IV and ICD-10 diagnoses. The MINI can be administered in a short 
period of time, and clinical interviewers need only brief training. The MINI 
has been translated into Spanish and validated [80]. 
 
Table 4. Study variables and assessment points 
Instrument Assessment area Time of assessment 
MINI Neuropsychiatric 
Interview 
Psychiatric diagnosis Baseline, Post-T and 
follow-ups 
BAI Severity of anxiety Baseline, Post-T and 
follow-ups 
BDI-II Severity of depression Baseline, Post-T and 
follow-ups 
Sociodemographic data Gender, age, marital status, 
education, occupation, economic level 
Baseline 
OASIS Severity of anxiety Post-module 
ODSIS Severity of depression Post-module 
SIAS Severity of SAD symptoms Baseline, Post-T and 
follow-ups 
PDSS-SR Severity of PD and A symptoms Baseline, Post-T and 
follow-ups 
PSWQ Severity of GAD symptoms Baseline, Post-T and 
follow-ups 
OCI-R Severity of OCD symptoms Baseline, Post-T and 
follow-ups 
EQ-5D Health-related quality of life Baseline, Post-T and 
follow-ups 
PANAS Positive and negative affect Post-module 
BIS-BAS Behavioral inhibition/activation Baseline, Post-T and 
follow-ups 
ETS Expectation of treatment Baseline 
OTS Opinion of treatment Post-T 
Post-T, post-treatment (18 weeks after baseline); follow-ups, 3- and 12-month follow-ups. 
BAI, Beck Anxiety Inventory; BDI-II, Beck Depression Inventory-II; OASIS, Overall 




Impairment Scale; SIAS, Social Interaction Anxiety Scale; PDSS-SR, Self-Reported 
Panic Disorder Severity Scale; PSWQ, Penn State Worry Questionnaire; OCI-R, 
Obsessive-Compulsive Inventory-Revised; EQ-5D, EuroQoL-5D questionnaire PANAS, 
Positive and Negative Affect Scale; BIS-BAS, Behavioral Inhibition and Behavioral 





Beck Anxiety Inventory (BAI) [81]. The BAI is a 21-item self-report 
measure designed to assess anxiety, with a maximum of 63 points. Each 
item has a four-point severity scale (for example, not at all, mildly, 
moderately, and severely) that addresses symptoms experienced during 
the past week. The internal consistency of the BAI has been found to 
range from .85 to .94, and it has shown adequate convergent and 
divergent validity. The Spanish version of the BAI has shown high internal 
consistency (α = .93) [82]. 
Beck Depression Inventory (BDI-II) [83]. It is one of the most widely 
used questionnaires to evaluate depression severity in pharmacological 
and psychotherapy trials. It consists of 21 items about the different 
symptoms characterizing major depression disorder, added together to 
obtain the total score, which can be a máximum of 63 points. The 
instrument has good internal consistency (α = 0.76 to 0.95). The Spanish 
version of this instrument has also shown a high internal consistency (α = 
0.87) for both the general and clinical populations (α  = .89) [84]. 
 
Secondary outcomes 
Sociodemographic variables   
The following sociodemographic variables will be collected: gender, 
age, marital status (single, married/relationship, separated/divorced, and 
widowed), education (years of education), and work status. 
Diagnosis-specific measures   
In order to evaluate the specific anxiety disorder shown by each 
participant, four different instruments will be implemented. One of the four 
following questionnaires will be selected and included at pre, post-
treatment, and 3- and 12-month follow-up assessments, depending on the 
main diagnosis given to each participant. 
SAD: Social Interaction Anxiety Scale (SIAS) [85]. This scale is 
made up of twenty items rated from 0 to 4 that assess the anxiety 
experienced by the patient in social interaction situations. The scale has 
good internal consistency (α = .88 to .94), good test-retest and 
discriminant reliability, and appropriate construct validity. The Spanish 
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validation showed adequate internal consistency and good construct 
validity [86]. 
PD/A: Self-Reported Panic Disorder Severity Scale (PDSS-SR) 
[87]. The scale evaluates the severity of the PD symptomatology through 
measures of panic attack frequency, distress during panic attacks, 
anticipatory anxiety, fear and agoraphobic avoidance, fear and avoidance 
of physical sensations, and work and social impairment. Scale reliability (α 
= .917) and test-retest reliability (ICC = .81) were shown to be excellent. 
The psychometric analysis of the Spanish version showed excellent 
internal consistency (α = .85), good test-retest reliability, and adequate 
convergent validity [88]. 
GAD: Penn State Worry Questionnaire (PSWQ) [89], which 
evaluates worry as an uncontrollable, generalized and excessive 
experience. The PSWQ has good psychometric properties, with an 
internal consistency ranging from .91 to .95, and good validity and test-
retest reliability. The Spanish version of the scale showed an internal 
consistency of .90 and a test-retest reliability of .82, as well as adequate 
convergent and discriminant validity [90]. 
OCD: Obsessive-Compulsive Inventory-Revised (OCI-R) [91]. The 
OCI-R is a scale made up of 18 items rated from 1 to 4 and organized in 
six dimensions (washing, verification, order, obsession, hoarding and 
mental neutralization) that assess obsessive-compulsive behaviors. The 
OCI-R has showed good internal consistency (α = .81 to .93), good to 
excellent test-retest reliability (α = .57 to .91) and good convergent validity. 
The internal consistency of the Spanish version of the OCI-R has been 
found to be good (α = .86) [92]. 
N/BI and E/BA   
Behavioral Inhibition and Behavioral Activation Scales (BIS/BAS) 
[93]. These scales were designed to assess two temperaments identified 
in Gray’ s biobehavioral theory of emotion [94], namely, behavioral 
inhibition and behavioral activation. The scale is made up of 20 items 
rated from 1 to 4, with seven BIS subscale items that evaluate individuals’  
emotional responses to impending negative events and 13 BAS items that 
assess individuals’  behavioral and emotional responses to potentially 
positive events. The BIS/BAS have demonstrated good reliability in a large 
sample of individuals with emotional disorders (α = .73 to .92), and 
stronger associations with other measures of temperament (that is, 
neuroticism/negative affect and extraversion/positive affect, respectively) 
than with measures of anxiety or depressive disorder constructs, 
suggesting that they have good convergent and discriminant validity as 
indicators of temperament [95]. The internal consistency of the Spanish 




Post-module measures   
Overall Anxiety Severity and Impairment Scale (OASIS) [97]. The 
OASIS consists of a 5-item questionnaire, rated from 0 to 4, that assesses 
the frequency and severity of the anxiety symptoms. The instrument also 
provides measures of avoidance, as well as work, academic, social and 
everyday life impairment related to anxiety symptoms. A psychometric 
analysis of the OASIS scale found good internal consistency (α  = .80), 
test-retest reliability (k = .82) and convergent validity for this instrument. 
Overall Depression Severity and Impairment Scale (ODSIS) [98]. 
The ODSIS is a self-report measure with five items that evaluate 
experiences related to depression. The ODSIS measures the frequency 
and severity of depression, as well as the level of avoidance, work/ 
school/home interference, and social interference associated with 
depression. The internal consistency of the scale has been shown to be 
excellent, with a Cronbach's alpha between .91 and .94 and good 
convergent and discriminant validity. The Spanish psychometric properties 
of both the OASIS and the ODSIS are being studied by members of our 
research team at the time of the publication of this paper. 
Positive and Negative Affect Scale (PANAS) [99]. The PANAS 
consists of 20 items that evaluate two independent dimensions: positive 
affect (PA) and negative affect (NA). The range for each scale (10 items 
on each) is from 10 to 50. The Spanish version has demonstrated high 
internal consistency (α  = 0.89 and 0.91 for PA and NA in women, 
respectively, and α  = 0.87 and 0.89 for PA and NA in men, respectively) 
in college students [100]. 
Quality of life   
EuroQoL-5D questionnaire (EQ-5D) [101]. It is a generic instrument 
that measures healthrelated quality of life and consists of two parts: Part 1 
assesses self-reported problems in each of five domains: mobility, self-
care, daily activities, pain/discomfort and anxiety/depression. Each domain 
is divided into three levels of severity corresponding to no problems, some 
problems, and extreme problems, yielding a population-based preference 
score or societal index (SI). A total of 243 theoretically possible health 
states can be obtained, and the SI is calculated on the basis of these 
health states. Values range from 1 (best health state) to 0 (death). 
However, this index may also provide negative values that correspond to 
health states perceived as worse than death. Utility scores for these health 
states were assigned using readily available Spanish population tariffs 
[102]. Part 2 records the subject's self-assessed health on a visual 
analogical scale (VAS), a 10 cm vertical line on which the best and worst 




Treatment expectations and treatment opinion   
Expectation of Treatment Scale (ETS) and Opinion of Treatment 
Scale (OTS). These questionnaires are adapted from Borkovec and Nau 
[103]. The content of the six items, rated on a scale from 0 to 10, cover 
how logical the treatment seemed, to what extent it could satisfy the 
patient, whether it could be used to treat other psychological problems, its 
usefulness for the patient’ s specific problem, and to what extent the 
treatment could be aversive. The expectation scale is applied once the 
treatment rationale has been explained, at the end of the welcome 
module. Its aim is to measure subjective patient expectations about this 
treatment. The opinion scale is administered when the patient has 
completed the treatment, and its aim is to assess satisfaction with this 
treatment. Our group has used this questionnaire in several research 
studies [104, 105]. 
Sample size 
The data from an RCT using the UP yielded betweengroup effect 
sizes of 0.56 for anxiety and 1.11 for depression, as measured with the 
BAI and BDI-II, respectively [30]. As we aim to compare the intervention 
with a TAU group, the results of a meta-analysis comparing CBT 
transdiagnostic treatments versus TAU have also been considered in the 
estimation of the expected sample size [106]. This meta-analysis reported 
a medium post-treatment effect size of 0.44 for depression and of 0.34 for 
anxiety between transdiagnostic treatment protocols vs. TAU conditions. 
The type of support we provide in this intervention (contact with 
researchers before, during and after the treatment period) has also been 
taking into account when estimating the expected sample size, as defined 
in a previous meta-analysis focused on Internet-based psychological 
treatments for depression [107]. Based on a power of .80 in a one-tailed 
test, an alpha of .05, and an estimated drop-out rate of around 30 % [65, 
108] we need a sample size of 100 per condition to detect a post-
treatment effect size of 0.40 (Cohen’ s d) between both groups. Therefore, 
the total sample size was determined at 200. 
Analysis 
Intention-to-treat analyses and per protocol analyses will be 
performed. Reporting of the results will follow CONSORT 
recommendations [75, 76]. First, the two groups will be compared in order 
to verify that there are no significant differences between them at baseline 
using samples t-tests for continuous distributed variables and chi-squares 





The intention-to-treat principle will be used when analyzing primary 
and secondary post-treatment data and data collected at the 3- and 12-
month follow-ups using mixed effect models with full information maximum 
likelihood estimation. This method has been recommended for its flexibility 
over repeated-measures ANOVAs to handle missing date more 
appropriately [109]. 
Within and between-group changes will be computed calculating 
standardized effect sizes (Cohen’s d). Cohen’s d is calculated by dividing 
the differences between means by the pooled standard deviation [110]. An 
effect size of 0.20 is considered to be small, of 0.50 to be moderate, and 
0.80 and above to be large [110]. 
Per protocol analyses (compliers only analysis) will also be 
conducted. Despite this procedure suffers from selection bias, it can help 
to draw conclusions about the maximum treatment efficacy in patients who 
comply fully with the treatment [111]. 
As the trial is still in execution, the state of the art regarding analytic 
methodology for RCT will be reviewed before analyzing the data, thus 




This study has several aims. The first is to provide data from a RCT 
about the effectiveness of a transdiagnostic Internet-based protocol for the 
treatment of ED in a sample of participants from specialized care in the 
Spanish public mental health system, compared to TAU. Second, whether 
the treatment may temper the psychological vulnerability by analyzing its 
effect on psychological higher-order dimensions (neuroticism/behavioral 
inhibition and positive affect/behavioral activation) will be studied. The 
third aim is to study the acceptability of this online program by patients in 
an ecological setting (public specialized care in Spain). 
The advantages of a transdiagnostic Internet-based protocol are 
two-fold. First, a wide range of ED can be treated with a single protocol, 
reducing the costs associated with disorder-specific protocols and 
contributing to solving the problem of comorbidity and NOS diagnoses, as 
the protocol focuses more on the common pathological processes than on 
any specific disorder and/or symptomatology. Second, Internet-based 
protocols can help to disseminate CBT evidence-based treatments, so that 
more people can benefit from them. This study will provide additional data 
about the transdiagnostic perspective proposed by Barlow [20], as well as 




In addition, this study has various strengths. First, this is the first 
RCT of transdiagnostic Internet-based psychotherapy in specialized care 
in our country. Positive results achieved with this protocol may have an 
important impact, since protocols of this type could help to decrease the 
saturation of the public mental health system, reducing costs and 
contributing to a general improvement in the public mental health services 
in our country (for example, reductions in waiting lists, hours of clinical 
assistance and hours of face-to-face treatment; a higher number of 
patients who receive psychological treatment; etcetera). Second, the 
online protocol combines the transdiagnostic cognitive-behavioral 
principles (psychoeducation about emotions, enhancement of cognitive 
flexibility, interoceptive and situation-based emotion exposure) with 
components of acceptance and emotion regulation for the treatment of 
ED. The data obtained with this protocol can help us to understand the 
psychopathology of these mental disorders. And third, even though 
transdiagnostic Internet-based protocols are thought to treat different ED, 
most of the existing studies exclusively target anxiety disorders [25, 26, 
73], and others have used open-trial designs [28, 74] and do not 
contemplate either the diagnosis of obsessive-compulsive disorder or 
NOS diagnoses [29] or they focus on a smaller number of ED [29]. We 
consider that this study broadens the current literature about 
transdiagnostic Internet-based protocols as it is designed for a wide range 
of anxiety and depressive disorders. Combining the advantages of both a 
more inclusive transdiagnostic intervention and an Internet-based delivery 
format may broaden the scope of evidence-based treatments among the 
population in need. Moreover, the population in which the study is being 
conducted, that is, patients who attend a variety of public specialized care 
settings across Spain, can help to draw conclusions about the external 
validity of the intervention. 
Finally, a number of potential limitations should be indicated. First, 
dropout rates are expected to be high (around 30 %) [67, 110]. Efforts to 
maintain these dropout rates below this percentage will be made by 
providing human support (before, during, and after the intervention) and 
ICT-support (for example, emails and mobile phone text messages). 
Second, negative attitudes towards Internet interventions by both 
clinicians and patients may affect recruitment as well as dropout rates. To 
minimize the effect of negative attitudes, the nature and characteristics of 
the intervention will be explained to clinicians involved in the trial. 
Moreover, for this purpose they will be given a handbook with relevant 
information about the study (for example objectives of the study, study 
design, and characteristics of the intervention). In order to increase 
participant’s credibility, prior to enrollment they will be given a sheet with 




study, and other issues related to ethics, voluntary participation and 
confidentiality of the data. Finally, other difficulties could be problems with 
recruitment, as many people who attend public mental health units do not 
have access to the Internet at home. 
 
Trial status 
The trial is active and recruiting. 
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Abstract 
The Overall Anxiety Severity and Impairment Scale (OASIS) is a 
self-report questionnaire designed to evaluate the severity and functional 
impairment associated with anxiety. Given its transdiagnostic nature, it can 
be used indistinctly across anxiety and depressive disorders. In this study, 
the psychometric properties of the online version of the OASIS were 
evaluated in a Spanish clinical sample with emotional disorders. Patients 
(n = 583) with anxiety (n = 250) and depression (n = 333) with a mean age 
of 37.21 (SD = 12.22), underwent a diagnostic interview and 
questionnaires assessing anxiety, depression, positive and negative 
affectivity, and quality of life. Factorial structure, internal consistency, 
convergent and discriminant validity, cutoff scores, and sensitivity to 
change were analyzed. Confirmatory Factor Analysis yielded a 
unidimensional factor structure, consistent with previous validations of the 
instrument. The analyses showed good internal consistency and adequate 
convergent and discriminant validity, as well as sensitivity to change. A 
cutoff score of 7.5 was found to meet the criteria used in this study to 
select the optimal cutoff point. Overall, in this study, the psychometric 
properties of the online version of the OASIS were found to be 
appropriate. The brevity and ease of use of the OASIS support its 
adequacy as a valid measure of anxiety severity and impairment in 





Anxiety and depressive disorders, also known as emotional 
disorders (ED), are prevalent [1, 2] and costly [3, 4] and an important 
cause of suffering and disability worldwide [5, 6]. Moreover, the literature 
has shown the high comorbidity rates among anxiety disorders, and 
between anxiety and depressive disorders [7]. 
Along with depression, anxiety disorders are one the most prevalent 
disorders, with a 12-month prevalence of 18.1% [8], and a lifetime 
prevalence of 28.8% [1]. In Spain, the 12-month prevalence of an anxiety 
disorder has been estimated at 6.2%, and the lifetime prevalence at 9.3% 
[9]. Anxiety disorders are associated with important impairments [10], 
significantly poorer quality of life [11], and high rates of comorbidity with 
other anxiety disorders and with depression [2, 7]. Therefore, the 
development of treatments for anxiety is a key aspect in addressing this 
important health problem. Moreover, the impact of these interventions 
cannot be ascertained without the use of appropriate assessment 
instruments. In this vein, despite the importance of evidence-based 
assessment (i.e. the use of research and theory to guide the selection of 
the most appropriate instrument for the assessment of a specific 
construct) [12], the attention paid to assessment is more recent than the 
importance given to evidence-based treatments, first described in a book 
published ten years earlier [13]. Therefore, the development and validation 
of rigorous assessment tools is an important task for researchers and 
clinicians involved in the assessment and treatment of anxiety disorders. 
In this vein, the need for digital versions of pen and paper scales has 
increased exponentially due to the proliferation of web-based interventions 
[14, 15]. Nevertheless, the literature highlights that paper and online 
versions of the same instrument show strong correlations but may differ in 
psychometric properties [14]. Therefore, as research on web-based 
treatments advances, it becomes crucial to develop and validate 
assessment instruments that can be applied online [16]. 
Currently, there are a number of measurement tools to assess 
overall anxiety, such as the Beck Anxiety Inventory [17] or the State-Trait 
Anxiety Inventory [18]. These scales have been translated into Spanish 
and validated in previous research [19–21]. Additionally, several 
instruments have been developed and validated for the assessment of the 
symptoms associated with each of the different anxiety disorders (i.e. 
disorder-specific symptoms), such as the Penn State Worry Questionnaire 
[22] for generalized anxiety disorder, the Panic Disorder Severity Scale 
[23]  for panic disorder and/or agoraphobia, and the Social Interaction 
Anxiety Scale [24] for social anxiety disorder. However, all these 
instruments focus on the assessment of individual anxiety symptoms (i.e. 
the occurrence of cognitive, emotional, and physiological symptoms), but 
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they do not provide a measure of the global severity and impairment 
associated with these problems.   
The Overall Anxiety Severity and Impairment Scale (OASIS) is a 
short scale made up of 5 items developed to assess the severity and 
impairment associated with anxiety disorders and/or symptoms [25–27]. 
Two advantages of the OASIS include its brevity and ease of use and its 
transdiagnostic nature. Regarding brevity, the need for short scales (i.e. 
less than 10 items) has been highlighted in the literature [25]. Several 
advantages have been indicated in this regard, such as the fact that it is 
an easier way to obtain relevant data in clinical settings such as primary 
care (where resources are normally limited) (Laura Campbell-Sills et al., 
2009; Ziegler, Kemper, & Kruyen, 2014) or that symptoms can be more 
easily monitored throughout a treatment [12]. For instance, this latter 
aspect might be particularly useful when it is necessary to evaluate anxiety 
symptoms repeatedly throughout a treatment (i.e. after each treatment 
module or session). Finally, in a more general way, even though brevity 
might compromise a scale’s validity [29], compared to longer scales, the 
use of shorter scales provides a more efficient way to collect data and 
maximize the representativeness of the sample [28]. In addition, from a 
transdiagnostic perspective, it is logical to develop and validate measures 
that capture the severity and impairment of anxiety disorders, regardless 
of the specific anxiety disorder suffered by the patients [25, 30] . Following 
the DSM-IV-TR guidelines to establish the severity and associated 
impairment caused by anxiety, the five items on the OASIS were 
developed in an attempt to capture the most important domains of anxiety 
that are common to all anxiety disorders, namely, severity (i.e. frequency 
and intensity), behavioral avoidance, and functional impairment (i.e. work 
and social interference) [26]. Because the OASIS focuses on the severity 
and functional consequences of anxiety, rather than the occurrence of 
specific anxiety symptoms (which might vary depending on the specific 
presentation of each patient), the scale can be used in a transdiagnostic 
manner across different anxiety disorders. Given the theoretical and 
empirical association between anxiety and depression [2] and the high 
comorbidity rates between these disorders, the scale can also be used to 
assess the severity and impairment of anxiety in individuals with 
depression. 
Previous versions of the OASIS have been validated in both clinical 
[25, 31–33]  and non-clinical samples [26, 27]. In sum, the OASIS has 
shown sound psychometric properties in the existing literature. 
Nevertheless, to our knowledge, the OASIS has not yet been validated in 
Spanish clinical samples with anxiety and depressive disorders. 
Furthermore, most of the previous work in clinical populations has focused 




exceptions [31, 32] that also included patients with a principal diagnosis of 
depression. However, in these studies, the proportion of patients with 
depression was low, compared to patients with anxiety [31]. Regarding the 
online validation of the OASIS, to our knowledge, only one study in the 
literature has used online surveys [32]. However, even though this study 
showed good psychometric properties, it relied on patients’ self-reports to 
establish a formal diagnosis, rather than well-validated measures such as 
diagnostic interviews or self-report questionnaires. 
Current study  
In this study, we aimed to contribute to filling this gap by analyzing 
the psychometric properties of the OASIS in two clinical subsamples of 
individuals with emotional disorders: a subsample with a principal 
diagnosis of anxiety (n = 250) and a subsample with a principal diagnosis 
of depression (n = 333). Specific objectives were: a) to examine how the 
scale performs in patients with anxiety disorders vs. depressive disorders; 
b) to examine the scale’s factorial structure, reliability, and validity; c) to 
obtain cutoff scores; and d) to analyze sensitivity to change. To the best of 
our knowledge, this is the first study to evaluate the psychometric 
properties of the online version of the OASIS in a sample of adults with 
anxiety and depressive disorders in the Spanish population. 
 
Methods 
Spanish Translation of the OASIS 
First, a native Spanish-speaker who was aware of the purpose of 
the study translated the OASIS items from English to Spanish. Second, a 
Spanish-English bilingual speaker who was not familiar with the 
questionnaire performed a back-translation from Spanish to English. The 
person involved in the translation process is a native English speaker who 
has been living in Spain for many years and is fluent in both languages. 
The two English versions were compared, and the Spanish version of the 
OASIS was judged to be an accurate translation of the original English 
version. 
Procedure 
The sample was recruited from patients attending the Emotional 
Disorders Clinic at Jaume I University (Castellon, Spain), whose principal 
focus is the treatment of ED using Information and Communication 
Technologies such as web-based interventions. Individuals who were 
waiting to receive an online treatment were invited to participate in the 
study, and those who agreed to participate provided written, informed 
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consent. Only participants with a principal diagnosis of an emotional 
disorder (i.e. anxiety and depressive disorders) were considered for the 
study. All participants were assessed with a structured diagnostic 
interview, and a battery of questionnaires. All these measurement tools 
are described in detail in the Instruments section. The study was approved 
by the Ethics Committee of Universitat Jaume I. 
Participants 
A total of 583 individuals with a mean age of 37.21 years (SD = 
12.22; range: 18-68 years old) took part in the study. Most participants 
were female (n= 421; 72.21%), married or living with a partner (n = 273; 
46.83%), and had completed higher education studies (n = 371; 56.3%). 
All of the participants were Caucasian. Regarding their diagnoses, 333 
patients had a principal diagnosis of a mood disorder (i.e. major 
depressive disorder, dysthymic disorder, mood disorder not otherwise 
specified), and 250 had a principal diagnosis of an anxiety disorder. In all, 
more than half the sample had at least one comorbid anxiety or 
depressive disorder (53.5%). Diagnostic assessments were performed by 
pre-doctoral students who had been previously trained in the use of the 
diagnostic interview. A full description of the patients’ sociodemographic 
and clinical data is displayed in Table 5. 
Table 5. Sociodemographic and clinical characteristics of the sample (n = 583) 
Age in years, Mean (SD) 37.21 (12.22) 





















Principal diagnosis, n (%) 
Major depressive disorder 
Generalized anxiety disorder 













Anxiety disorder NOS 
Specific phobia 
Postraumatic stress disorder 
Mood disorder NOS 




































OASIS = Overall Anxiety Severity and Impairment Scale; BAI = Beck Anxiety Inventory; 
BDI-II = Beck Depression Inventory-II; ODSIS = Overall Depression Severity and 
Impairment Scale; PANAS-P = Positive and Negative Affect Schedule-Positive Affect; 
PANAS-N = Positive and Negative Affect Schedule-Negative Affect; QLI = 
Multidimensional Quality of Life Questionnaire 
Instruments 
Diagnostic Interview 
Mini-International Neuropsychiatric Interview [34]. The MINI is a 
short, structured clinical interview designed to perform diagnoses 
according to the DSM-IV and ICD-10 criteria. It has shown excellent test-
retest and interrater reliability, as well as high predictive validity rates. The 
Spanish validation was used in this study [35].  
 
Self-reported questionnaires 
Overall Anxiety Severity and Impairment Scale (OASIS) [25]. 
The OASIS is a 5-item self-report scale that evaluates the frequency and 
severity of anxiety symptoms, the functional impairment related to these 
symptoms (i.e. school, work, home, or social impairment), and behavioral 
avoidance. Each item instructs respondents to endorse one of five 
responses that best describes their experiences over the past week. 
Response items are coded from 0 to 4, added together to obtain a total 
score ranging from 0 to 20. Previous studies have shown high internal 
consistency (α=0.80), test-retest reliability, and convergent and 
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discriminant validity [25–27]. In the current study, Cronbach’s alpha 
coefficient for the five items on the OASIS was good (0.86). 
Beck Anxiety Inventory (BAI) [17]. This is a 21-item self-report 
questionnaire for the measurement of anxiety symptoms experienced 
during the past week. Each item is rated from 0 to 3 (i.e. not at all, mildly, 
moderately, severely), added together to obtain a maximum score of 63. 
The BAI has demonstrated good to excellent internal consistency in prior 
validations of the scale (.85-.94), as well as adequate convergent and 
divergent validity [20]. Cronbach’s alpha for the BAI in the present study 
was excellent (.91). 
Beck Depression Inventory (BDI-II) [36]. The BDI-II is a 21-item 
self-report scale designed to assess depressive symptoms experienced 
during the past week. Items are rated on a Likert scale rated from 0 to 3, 
and the total score ranges from 0 to 63. The BDI-II has shown optimal 
validity and reliability in both clinical and nonclinical samples [36-38]. 
Cronbach’s alpha for the BDI-II in the present study was excellent (0.91). 
Overall Depression Severity and Impairment Scale (ODSIS) 
[39]. The ODSIS consists of five items that measure the severity and 
impairment related to depression, as well as its interference with school, 
work, and social life. The measure has shown excellent internal 
consistency (α=0.94 in an outpatient sample, 0.92 in a community sample, 
and 0.91 in a student sample) [39] and good convergent and discriminant 
validity. In the present study, the ODSIS showed excellent internal 
consistency (0.93). 
Positive and Negative Affect Schedule (PANAS) [40]. The 
PANAS is a self-report measure that evaluates two dimensions on two 
independent scales: positive (PANAS-P) and negative affect (PANAS-N). 
Each scale is composed of 10 items coded in a range from 10 to 50 
points. The PANAS has shown excellent convergent and divergent 
validity, as well as high internal consistency [40-42]. In the current study, 
Cronbach’s alpha was excellent for the PANAS-P (0.93) and good for the 
PANAS-N (0.88). 
Multidimensional Quality of Life Questionnaire (QLI) [43]. The 
QLI is a self-report questionnaire that consists of 10 items aimed at 
assessing quality of life in ten areas: psychological well-being, physical 
well-being, emotional and social support, interpersonal functioning, self-
care and independent functioning, community and service support, 
occupational functioning, self-realization, spiritual satisfaction, and an 
overall assessment of quality of life. The Spanish version of the QLI has 
shown good internal consistency and test-retest reliability in previous 




First, descriptive statistics (mean, standard deviation, skewness, 
and kurtosis) for the anxiety and depression subsamples were calculated 
for all the measures. Next, one-way ANOVAs were calculated to analyze 
whether there were significant differences in the scores on the OASIS 
based on gender, marital status, studies, and diagnosis. Furthermore, 
correlations between age and the OASIS score were calculated in order to 
study whether there were any associations between these variables. In 
addition, reliability was analyzed by calculating internal consistency 
indexes (Cronbach’s alpha) for the five items on the OASIS.  
To analyze the factor structure of the OASIS, we performed 
Confirmatory Factor Analysis (CFA), a procedure based on Classical Test 
Theory (CTT) [45]. CFA models were estimated with maximum likelihood 
and robust corrections (MLR), given the scale’s non-normality and five-
point response scale. Full Information Maximum Likelihood was employed 
to handle missing data. Following Norman et al. [27], a single latent factor 
with correlated error variances between items 1 and 2 was tested as the 
basis for the CFA model. Model fit was evaluated using several criteria, 
specifically, the chi-square test (χ2), comparative fitness index (CFI), 
Tucker-Lewis index (TLI), standardized root mean residuals (SRMR), and 
root mean square error of approximation (RMSEA). The following cutoff 
scores were used to determine good fit: CFI and TLI above .90 (better if 
above .95) and RMSEA below .08 [46]. Following recommendations by 
McNeish, An, & Hancock [47], factor loadings with their corresponding p 
values and the correlations between the error variances of the items were 
reported to evaluate the validity of the factor model. A correlation between 
the error variance of items 1 and 2 was expected because a response of 0 
to item 1 (frequency of anxiety) would entail a response of 0 to item 2 
(intensity of anxiety) [25]. 
Construct validity was examined through correlations with 
measures of anxiety (BAI), depression (BDI-II), positive and negative 
affect (PANAS-P and PANAS-N), and quality of life (QLI). Cohen’s [48] 
benchmarks for the interpretation of the correlation values were used, 
where effect sizes between .10 and .30 are considered small, those 
between .30 and .50 are considered medium, and those of .50 or above 
are considered large.   
To assess the sensitivity and specificity of the OASIS scores in 
detecting anxiety symptoms, cutoff scores of the BAI scores were used to 
classify participants between those without anxiety (BAI score < 10) and 
with anxiety (BAI score ≥10) [49]. The cutoff point on the BAI to assess the 
sensitivity and specificity of the OASIS scores was 10, so that BAI scores 
≥10 were considered to reflect anxiety symptoms. To examine the 
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precision of the OASIS scores in detecting cases with and without anxiety 
symptoms, the receiver operating characteristic (ROC) curve was 
calculated, as well as the area under the curve (AUC). The AUC is a 
quantitative index that combines sensitivity and specificity in order to 
provide information about the precision of a test score as a proportion, so 
that the larger the proportion, the greater the precision of the test. The 
sensitivity of test scores is the proportion of positive cases (i.e., 
participants with anxiety, assessed with the BAI) that are correctly 
identified by the OASIS scores. The specificity of test scores is the 
proportion of negative cases (i.e., participants without anxiety, assessed 
by the BAI) correctly identified by the OASIS scores as the best result. 
AUC values under .5 will reflect lack of precision, whereas AUC values 
above .9 indicate excellent precision, values between .7 and .9 indicate 
moderate precision, and values between .5 and .7 indicate mild precision. 
The AUC represents the probability that a participant randomly selected 
from the group with anxiety will obtain a higher score on the OASIS than 
another participant, also randomly selected, from the group of people 
without anxiety. A 95% confidence interval around the AUC and its 
statistical significance were also calculated [50]. Sensitivity and specificity 
were calculated for each cutoff point, as well as Positive Predictive Values 
(PPV), Negative Predictive Values (NPV), and their corresponding 95% 
confidence intervals. PPV represents the proportion of cases correctly 
identified by the OASIS as positive with regard to all the positive cases, 
whereas NPV represents the proportion of cases correctly identified as 
negative by the OASIS with regard to all the negative cases. In order to 
identify the optimum cutoff point for the OASIS, four methods were applied 
to each cutoff score [51]: the Youden index (J), Index of Union (IU), 
Closest to (0, 1) Criteria (ER), and Concordance Probability Method (CZ). 
The Youden index is defined as J = max(Sensitivity + Specificity -1), so 
that the OASIS cutoff point that correspond to the maximum J value is 
considered the optimal cutoff point. The Index of Union (IU) was calculated 
as IU = min(|Sensitivity – AUC| + |Specificity - AUC|). The IU is calculated 
to guarantee that the sensitivity and specificity obtained at this cutoff point 
is simultaneously close to the AUC value, and the difference between the 
sensitivity and specificity obtained at this cutoff point should be minimal. 
The Closest to (0, 1) Criteria is calculated as 
   , and the optimal cutoff point 
according to this index is defined as the point closest to the point (0, 1) on 
the ROC curve. Finally, the Concordance Probability Method defines the 
optimal cutoff point as the point that maximizes the product of sensitivity 
and specificity. CZ is calculated as CZ = Sensitivity*Specificity. The OASIS 
score that met the four criteria, or most of them, was selected as the 
optimal cutoff point. 
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Finally, in order to analyze sensitivity of OASIS scores to change, 
means and standard deviations for the pretest and posttest were 
calculated with the OASIS scores from two studies about the efficacy of 
Internet CBT in patients with emotional disorders. Part of the total sample 
completed the OASIS before and immediately after receiving an Internet-
based treatment. Thus, 24 patients received Smiling is Fun [52] 
(hereinafter subsample 1), and 68 patients received Emotion Regulation 
[53, 54] (hereinafter subsample 2). Smiling is Fun is an 8-module Internet-
based treatment for depression that includes components of evidence-
based treatments. The protocol stresses the importance and benefits of 
being active and staying involved in life, values, and goals. It allows the 
individual to learn and practice adaptive ways to cope with depressive 
symptoms and confront daily problems. Specifically, some components of 
Barlow’s Unified Protocol (UP) have been adapted, namely, motivation, 
psychoeducation, cognitive therapy, and relapse prevention [55]. 
Furthermore, the program incorporates a Behavioral Activation component 
[56] and a Positive Psychology component, which includes strategies to 
promote and enhance personal strengths, positive feelings, positive 
cognitions, and positive behavior [57, 58]. Emotion Regulation is a 12-
module transdiagnostic Internet-based treatment for anxiety and 
depressive disorders. The treatment protocol is delivered through a 
multimedia web platform https://www.psicologiaytecnologia.com/) (with 
videos, images, printable documents, etc.), which allows participants easy 
and optimal use on a PC or tablet. The content of the protocol is adapted 
from the Unified Protocol [59] and from Marsha Linehan’s protocol [60], 
with four core components: present-focused emotional awareness, 
cognitive flexibility, behavioral and emotional avoidance patterns, and 
interoceptive and situational exposure. The protocol also includes 
traditional therapeutic components of evidence-based treatments, such as 
psychoeducation, motivation for change, and relapse prevention.  
Minimum and maximum OASIS scores were also obtained from the 
pretest to check potential floor or ceiling effects. Evidence of floor or 
ceiling effects is present when more than 17% of the participants obtained 
the lowest or highest possible score on the test, respectively [in our case, 
0 and 20). In addition, t-tests were applied to test the statistical 
significance of the pretest-posttest mean differences. To quantify the 
OASIS scores’ sensitivity to change, the standardized mean change index 
was used as the effect size, defined as the difference between the pretest 
and the posttest means divided by the standard deviation of the change 
scores. The positive bias of the d index for small sample sizes was 
corrected with the c(m) correction factor [61]: 
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with  and  being the pretest and posttest means, and c(m) being: 
In addition, 95% confidence intervals for the d indices were 
calculated by means of d ± 1.96xSE(d), with 1.96 being the 97.5 percentile 
of the standard normal distribution, and SE(d) being the standard error of 
the d index [61]: 
All of these calculations were applied separately for subsamples 1 
and 2. To offer a contextualized interpretation of the d indices obtained in 
subsamples 1 and 2, we used the results of a systematic review of meta-
analyses carried out on the efficacy of psychological treatments that 
applied the standardized mean change index as the effect size [62]. In this 
review, percentiles 25, 50, and 75 of the d indices’ distribution were 0.64, 
0.75, and 1.26. Therefore, a reasonable interpretation of these three 
values is to consider them as reflecting low, moderate, and large 
magnitudes of the effect. 
CFA was calculated using the EQS program, version 6.1. 
Sensitivity, specificity, PPV, and NPV were calculated using a web 
application (http://vassarstats.net/clin1.html). The software SPSS Statistics 
version 22.0 was used for the remaining analyses.  
Results 
Preliminary analyses 
The mean OASIS score was 8.69 (SD= 4.21) in the total sample (n 
= 583), 8.92 (SD= 4.28) for females (n= 421), and 8.15 (SD= 3.96) for the 
male participants (n= 162). Table 6 and Table 7 show descriptive statistics 
for each item and the total score on the OASIS, and for the remaining 
instruments, for both the depressive and anxiety disorder samples, 
respectively.  
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Table 6. Descriptive statistics for each item and the total score on the OASIS in 
depressive and anxiety disorder samples 
Anxiety sample 
(n = 250) 
Depression sample 
(n = 333) 
M SD λ1 λ2 M SD λ1 λ2 
Item 1 1.96 1.06 .108 -.466 2.05 1.04 -.145 -.881 
Item 2 1.80 .88 -.157 -.911 1.79 .86 -.285 -.124 
Item 3 1.56 1.16 .330 -.049 1.65 1.13 .246 -.684 
Item 4 1.61 1.08 .229 -.723 1.70 1.05 -.087 -.925 
Item 5 1.53 1.11 .371 -.808 1.70 1.06 -.045 -.697 
Total score 8.37 4.29 .230 -.624 8.96 4.17 -.190 -.420 
M = Mean; SD = Standard deviation; λ1 = skewness; λ2 = kurtosis 
Table 7. Descriptive statistics for convergent and discriminant validity measures in 
depressive and anxiety disorder samples 
Anxiety sample Depression sample 
M SD λ1 λ2 M SD λ1 λ2 
BAI 20.41 11.94 .451 -.588 19.13 11.39 -.690 -.008 
BDI-II 21.74 11.45 .284 -.339 24.70 10.70 .409 .331 
ODSIS 6.41 4.93 .384 -.899 8.64 4.68 -.107 -.778 
PANAS-P 23.45 8.13 .695 .073 19.64 6.53 .828 .317 
PANAS-N 27.24 7.81 .110 -.574 25.32 7.98 .286 -.282 
QLI 4.94 1.66 .041 -.473 4.51 1.71 .275 -.407 
M = Mean; SD = Standard deviation; λ1 = skewness; λ2 = kurtosis; BAI = Beck Anxiety 
Inventory; BDI-II = Beck Depression Inventory-II; ODSIS = Overall Depression Severity 
and Impairment Scale; PANAS-P = Positive and Negative Affect Schedule-Positive 
Affect; PANAS-N = Positive and Negative Affect Schedule-Negative Affect; QLI = 
Multidimensional Quality of Life Questionnaire 
Significant differences were found in the OASIS scores based on 
the number of comorbid disorders (F= 6.91; p < .001), with higher anxiety 
levels found the participants with a larger number of comorbid disorders. 
There were no significant differences based on sex, civil status, education 
level, or principal diagnosis. In addition, no statistical relationships were 
observed between the participants’ age and OASIS scores.  
Factor Structure 
A single-factor model resulted in an adequate model fit: χ24 = 
11.693, p > .01; SRMR= .027; RMSEA= .058, 90% CI [.015, .104]; CFI= 
.995. Factor loadings showed that all the items were strongly related to 
this factor, with values ranging from .65 to .82 All these values reached 
significance at p < .05 (see Figure 7). 
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Figure 7. Confirmatory factor analysis (CFA) model 
Rectangles are measured variables, the large circle is the latent construct, and small 
circles are residual variances. Factor loadings are standardized. All values are significant 
at p < .05. The solution specified correlated error variance between items 1 and 2. 
Internal Consistency 
Cronbach’s alpha for the five items on the OASIS was .86.  Table 8 
shows the results for Cronbach’s alpha when omitting items, corrected 
correlations between each item and the total score, and correlations 
between the five items of the OASIS. The results obtained indicate good 
internal consistency of the OASIS that would not be increased by 
excluding any item.  
Table 8. Cronbach’s alpha if item is deleted, corrected item-total score correlation, 








Correlations between items 
I1 I2 I3 I4 I5 
I1 .842 .658 1 
I2 .838 .692 .689* 1 
I3 .849 .640 .422* .464* 1 
I4 .825 .726 .560* .585* .587* 1 
I5 .824 .729 .543* .543* .643* .628* 1 





Table 9 shows the correlation between the OASIS and the 
convergent validity measures. A large positive correlation was expected 
between the OASIS and the BAI. A positive but medium correlation was 
expected between the OASIS and the BDI-II. Given the theoretical and 
empirical associations between the dimensions of positive and negative 
affect and anxiety [2], we anticipated a positive but medium correlation 
between the OASIS and the PANAS-N, and a negative and medium 
correlation with the PANAS-P. Finally, we anticipated a negative and 
medium correlation between the OASIS and QLI (quality of life).  All these 
results were interpreted as evidence for convergent validity.  
The OASIS correlated significantly with all the measures. As 
predicted, positive and large correlations were found between the OASIS 
and the BAI (r = .61, p < .01). In addition, large and positive correlations 
were found between the OASIS and the BDI-II (r = .60, p < .01), and 
between the OASIS and the ODSIS (r = .65, p < .01). The OASIS 
correlated largely with the PANAS-N (r = .60, p < .01). Finally, the 
analyses yielded a negative medium correlation between the OASIS and 
the PANAS-P (r = -.40, p < .01), and a negative large correlation between 
the OASIS and the QLI (r = -.58, p < .01). 
 
Table 9. Correlations of the OASIS with convergent validity measures 
  OASIS BAI ODSIS BDI-II PANAS-P PANAS-N QLI 
OASIS - .61* .65* .60* -.40* .60* -.58* 
BAI  - .35* .47* -.25* .53* -.41* 
ODSIS    - .67* -.57* .49* -.69* 
BDI-II      - -.56* .57* -.76* 
PANAS-P        - -.32* .71* 
PANAS-N          - -.48* 
QLI            - 
*Correlation was statistically significant at p < .01 (2-tailed); OASIS = Overall Anxiety 
Severity and Impairment Scale, BAI = Beck Anxiety Inventory, ODSIS = Overall 
Depression Severity and Impairment Scale, BDI-II = Beck Depression Inventory-II, 
PANAS-P = Positive and Negative Affect Schedule-Positive Affect, PANAS-N = Positive 





Receiver Operating Characteristic (ROC) 
A ROC curve was calculated in the sample when a cutoff point ≥ 10 
was applied to the BAI scores. The AUC obtained was .817 (95%CI: .731 
and .903) and reached statistical significance (p < .001). This AUC can be 
interpreted as indicating that there was a .817 probability of randomly 
selecting a participant from the anxiety group (i.e., with a BAI score ≥ 10) 
with an OASIS score higher than that of any other participant, also 
randomly selected, from the group without anxiety (i.e., with BAI score < 
10). An AUC = .817 can also be interpreted as reflecting moderate 
precision from a clinical point of view. Therefore, the precision of the 
OASIS scores in detecting any type of anxiety (mild, moderate, or severe) 
can be considered to have a moderate magnitude. Table 10 presents the 
sensitivity, specificity, PPV, and NPV obtained with the OASIS scores for 
the cutoff point ≥ 10 on the BAI. The table also shows the results of the 
four methods used to select the optimal cutoff score for the OASIS 
(Youden index, J, Index of Union, IU, the Closest to (0, 1) Criteria, ER, and 
the Concordance Probability Method, CZ). The OASIS score = 7.5 met 
three of the four criteria (IU, ER, and CZ criteria); regarding the Youden 
index, this score obtained the second best value (.498), very close to the 
maximum value obtained with this method (.503). Therefore, 7.5 was 
selected as the optimal cutoff point to detect anxiety symptoms (i.e., 
OASIS scores over 7 indicate anxiety symptoms). For this cutoff point, 
sensitivity was .727 (95% CI: .650; .792), and specificity was .771 (95% 
CI: .594; .889). PPV was .936 (95% CI: .874; .970), and NPV was .380 
(95% CI: .270; .504). 
 



















0.5 .994 .171 .846 .857 .165 .823 .829 .170 
1.5 .994 .200 .851 .875 .194 .794 .800 .199 
2.5 .975 .314 .867 .733 .289 .661 .686 .306 
3.5 .969 .457 .891 .762 .426 .512 .544 .443 
4.5 .932 .571 .909 .645 .503 .361 .434 .532 
5.5 .876 .600 .910 .512 .476 .276 .419 .526 
6.5 .814 .657 .916 .434 .471 .163 .390 .535 
7.5 .727 .771 .936 .380 .498 .136 .356 .561 
8.5 .627 .800 .935 .318 .427 .207 .423 .502 
9.5 .528 .857 .944 .283 .385 .329 .493 .452 
10.5 .435 .914 .959 .260 .349 .479 .572 .398 
11.5 .354 .914 .950 .235 .268 .560 .652 .324 
12.5 .242 .914 .928 .208 .156 .672 .763 .221 
13.5 .161 .971 .963 .201 .132 .810 .840 .156 




15.5 .093 1 1 .193 .093 .907 .907 .093 
16.5 .043 1 1 .185 .043 .957 .957 .043 
17.5 .019 1 1 .181 .019 .981 .981 .019 
18.5 .006 1 1 .179 .006 .994 .994 .006 
20 0 1 NA NA 0 1 1 0 
Se = Sensitivity; Sp = Specificity; PPV = Positive Predictive Value; NPV = Negative 
Predictive Value; J = Youden index; IU = Index of Union; ER = Closest to (0, 1) Criteria; 
CZ = Concordance Probability Method; NA = Not applicable.  
 
Analysis of sensitivity to change 
Two subsamples were used for the analysis of sensitivity to change. 
Subsample 1 consisted of 24 patients who completed an Internet-based 
treatment for depression [52], and subsample 2 was made up of 68 
patients who underwent a transdiagnostic Internet-based treatment for 
anxiety and depressive disorders [53, 54]. To examine potential floor and 
ceiling effects for the OASIS scores, the frequency and percentage of 
minimum (0) and maximum (20) scores was tabulated for subsamples 1 
and 2 on the pretest. The results showed that only 2 patients out of 24 
(12%) in subsample 1, and 3 out of 68 in subsample 2 obtained a score of 
0 (minimum). In addition, no patient in any of the subsamples obtained a 
score of 20 (maximum). Therefore, evidence of floor and ceiling effects 
can be ruled out, as the percentage was lower than 17% in all cases.  
To examine the sensitivity to change of the OASIS scores, means 
and standard deviations were calculated for each subsample, both on the 
pretest and the posttest. The statistical significance of the pretest-posttest 
change scores was assessed by applying t-tests, which, as Table 11 
reveals, were statistically significant for both studies. The clinical 
significance was assessed by means of the effect size index ‘standardized 
mean change index’ (d). Following  Rubio-Aparicio et al. results [62], 
subsamples 1 and 2 obtained d indices that can be interpreted as 
reflecting moderate (d = 0.72) and moderate-to-large (d = 0.90) clinical 
relevance, respectively.  
 
Table 11. Descriptive and inferential results from the two subsamples for the 
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0.72 [0.26, 1.18] 
0.90 [0.61, 1.19] 
***p < .001; N = sample size; SD = standard deviation; t = t statistic for testing the pretest-





The aim of this study was to analyze the psychometric properties of 
the online version of the OASIS in a Spanish sample of patients with 
emotional disorders. This study evaluated the reliability, construct validity, 
and latent structure of the OASIS. In addition, cutoff scores were obtained, 
and sensitivity to change was examined.  
First, preliminary analyses showed that patients with more comorbid 
disorders were significantly more anxious than patients with fewer 
comorbid disorders, a finding that was somewhat expected given the 
strong association observed between comorbidity and severity [63]. By 
contrast, no statistically significant differences were found based on sex, 
education level, marital status, or principal diagnosis (i.e. anxiety disorder 
vs. depressive disorder), which, taken together, suggests that the Spanish 
version of the OASIS can be used indistinctly across patients with different 
sociodemographic and clinical characteristics. In this vein, it is important to 
note that a large proportion of patients in this study (53.5%) presented at 
least with one anxiety or depressive disorder. Second, regarding reliability, 
the five items on the OASIS demonstrated good internal consistency 
(alpha = .86). Third, as in previous validations of the instrument [25–27], 
confirmatory factor analysis revealed a unidimensional factor structure. 
Moreover, as expected, the model showed correlated error variance 
between items 1 and 2. 
Regarding the ROC analysis, a cutoff point of 7.5 was found to 
meet three of the four criteria used to select the optimal cutoff point (i.e. 
Index of Union, Closest to (0, 1) Criteria, and Concordance Probability 
Method). These findings suggest that this score (i.e. scores above 7 at the 
OASIS) can be used as a cutoff point to discriminate between patients 
with anxiety symptoms of clinical consideration vs. anxiety symptoms of no 
clinical consideration. This information might be useful, for instance, for 
screening and selecting patients with anxiety symptoms for clinical trials. 
The results obtained in this study using ROC curves are consistent with 
prior validations of the instrument in clinical populations, which showed 
that cutoff scores of around 8 differentiate anxious patients from non-
anxious patients [25, 27]. 
This study also examined sensitivity to change by analyzing the 
significance of the improvements from pre- to post-treatment on the 
OASIS scores. The analyses showed moderate to large effect sizes 
(Cohen’s d between .72 and .90), which suggests that the scale can not 
only be used for screening purposes (i.e. by using the cut-off point), but 
also that it is able to detect changes in anxiety and therefore it can be 




Regarding construct validity, positive and large correlations were 
found between the OASIS and the BAI, as anticipated, which is interpreted 
in this study as evidence of adequate convergent validity with one of the 
most widely used questionnaires for the assessment of anxiety. The fact 
that the OASIS also correlated significantly with measures of positive and 
negative affectivity, but less than with measures of anxiety (i.e. BAI), was 
interpreted as evidence for the discriminant validity of the instrument. 
Finally, although we predicted medium correlations between the OASIS 
and the depression measures (i.e. ODSIS and BDI-II), the results showed 
large correlations between these measures. In this regard, it is important 
to note that a large proportion of the patients (53.5%) had comorbid 
depressive or anxiety disorders, which might account for the large 
correlations between anxiety and depression obtained in this study. 
Overall, the results obtained in this study were interpreted as evidence for 
construct validity.  
Overall, the results of this study are consistent with those obtained 
in prior validations of the scale [25, 31, 32], and they support the adequacy 
of the OASIS as a valid measure for the online assessment of the anxiety 
severity and impairment associated with anxiety symptoms.  
This study has several strengths. First, to the best of our 
knowledge, this is the first study to evaluate the psychometric properties of 
the OASIS in a Spanish clinical sample of individuals with anxiety and 
depressive disorders. Brief instruments to assess the severity and 
impairment related to anxiety are lacking in Spain, and so this study 
contributes to filling the gap in this particular field. Second, although the 
OASIS has already been validated in transdiagnostic samples with 
emotional disorders [31], the sample size of patients with principal 
diagnoses of a depressive disorder was larger in this study. Unlike the 
study by Bragdon et al. [31], in which most patients had a principal 
diagnosis of an anxiety disorder (85.6%), we used a sample with a more 
balanced number of patients with a principal diagnosis of anxiety (55.2%) 
versus depression (44.8%). Given the burden and prevalence of 
depression, as well as its transdiagnostic nature and high comorbidity 
rates with anxiety disorders [2], the findings obtained in this study 
contribute to the literature on the OASIS by providing data about how the 
scale performs in patients with a principal diagnosis of depression. Third, 
the large sample size used in this study (n = 583), and its high diagnostic 
heterogeneity (i.e. individuals with a variety of anxiety and depressive 
disorders), helps to increase the generalizability of the results obtained in 
the study. Fourth, although various validations of the OASIS have been 
performed in clinical samples [25, 31, 33, 64], none of them have analyzed 
how the scale performs as a treatment outcome measure. Following 
previous recommendations [31, 64], in this study we intended to contribute 
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to filling this gap by analyzing sensitivity to change in two subsamples of 
patients who received Internet treatments. Fifth, all the patients in the 
study completed the OASIS through online surveys. Therefore, the results 
obtained in this study suggest that the online version of the OASIS is an 
adequate instrument for the online assessment of anxiety (e.g. in trials 
examining Internet treatments, where both the assessment and the 
treatment are delivered through an online platform). Given the proliferation 
of Internet-based treatments in the past decade, the need for validated 
online assessment instruments is greater than ever before.  
Limitations 
This study has some limitations that should be acknowledged. First, 
test-retest reliability was not evaluated in this study. Because all the 
participants in this study were derived from clinical samples that were 
receiving treatment, we were not able to analyze this aspect. Second, we 
were not able to analyze sensitivity to change with the entire sample 
because scores from pre- to post-treatment were not available for all 
participants in this study. Moreover, we were not able to examine the 
sensitivity to change of the OASIS compared to other scales for the 
assessment of anxiety, such as the BAI. Third, it might have been useful 
to include additional measures of anxiety in this study to further evaluate 
the convergent validity of the OASIS. However, it is important to note that 
the inclusion of instruments in this study was determined by the fact that 
all the patients were derived from trials where the selection of instruments 
was already pre-specified. For this reason, only two measures for the 
assessment of anxiety were used in this study (OASIS and BAI). Fourth, 
even though the BAI is a well-established measure and one of the more 
widely used scales for the assessment of anxiety [65-67], we did not follow 
the optimum approach for the calculation of the ROC curve because the 
classification of subjects was based on a cutoff from a scale (BAI) rather 
than a group of healthy control individuals. Hence, the cutoff score 
obtained in this study should be considered with caution. Finally, the 
proportion of females and males in this study was not balanced, which 
might affect the representativity of the results. However, the proportion of 
females versus males in this study is likely to have been affected by the 
higher prevalence rates of anxiety and depressive disorders in females 
compared to males [68]. 
Conclusions 
In conclusion, the results obtained in this study support the 
adequacy of the online version of the OASIS in clinical samples of Spanish 
patients with anxiety and depressive disorders. The brevity and ease of 
use of the OASIS makes this scale an adequate tool for the quick 




validations of the OASIS should analyze its sensitivity to change in 
comparison with other measures of anxiety, in order to draw firmer 
conclusions about this aspect. 
The psychometric properties of the online version of the OASIS 
were analyzed in this study. Similarly to evidence-based online treatments, 
the validation of online scales can have a direct impact in the 
dissemination of evidence-based methods for the assessment of 
behavioral, cognitive and psychopathological processes.  
 
Supporting Information 
S1 Appendix. OASIS (Spanish version). 
DOCX 




1. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters 
EE. Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV 
Disorders in the National Comorbidity Survey Replication. Arch Gen 
Psychiatry. 2005;62(6): 593–602.  
2. Brown T, Barlow D. A proposal for a dimensional classification 
system based on the shared features of the DSM-IV anxiety and mood 
disorders: Implications for assessment. Psychol Assess. 2009;21(3): 256–
71.  
3. Parés-Badell O, Barbaglia G, Jerinic P, Gustavsson A, Salvador-
Carulla L, Alonso J. Cost of Disorders of the Brain in Spain. Foffani G, 
editor. PLoS One. 2014;9(8): e105471.  
4. Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, 
Jönsson B, et al. The size and burden of mental disorders and other 
disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 
2011;21(9):655–79.  
5. Kazdin  AE, Blase SL. Rebooting Psychotherapy Research and 
Practice to Reduce the Burden of Mental Illness. Perspect Psychol Sci. 
2011;6(1):21–37.  
6. McLean CP, Asnaani A, Litz BT, Hofmann SG. Gender differences 
in anxiety disorders: prevalence, course of illness, comorbidity and burden 
of illness. J Psychiatr Res. 2011;45(8): 1027–35.  
143 
 
7. Brown TA, Campbell LA, Lehman CL, Grisham JR, Mancill RB. 
Current and lifetime comorbidity of the DSM-IV anxiety and mood 
disorders in a large clinical sample. J Abnorm Psychol. 2001;110(4): 585–
99.  
8. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. 
Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in 
the National Comorbidity Survey Replication. Arch Gen Psychiatry. 
2005;62(6): 617–27.  
9. Haro J, Palacín C, Vilagut G, Bernal M, Luque I, Codony M, et al. 
Prevalencia de los trastornos mentales y factores asociados: resultados 
del estudio ESEMeD-España. Med Clin. 2006;126(12): 445–51.  
10. Kroenke K, Spitzer RL, Williams JBW, Monahan PO, Löwe B. 
Anxiety Disorders in Primary Care: Prevalence, Impairment, Comorbidity, 
and Detection. Ann Intern Med. 2007;146(5): 317-25. 
11. Olatunji BO, Cisler JM, Tolin DF. Quality of life in the anxiety 
disorders: A meta-analytic review. Clin Psychol Rev. 2007;27(5): 572–81.  
12. Hunsley J, Mash EJ. Developing Criteria for Evidence-Based 
Assessment. In: Hunsley J, Mash EJ. Oxford series in clinical psychology. 
A guide to assessments that work . New York: Oxford University Press; 
2008. pp. 3–14.  
13. Nathan PE, Gorman JM. A Guide to Treatments That Work. New 
York: Oxford University Press; 1998. 
14. Alfonsson S, Pernilla M, Timo H. Interformat reliability of digital 
psychiatric self-report questionnaires: a systematic review." J Med Internet 
Res. 2014;16(12): e268. 
15. Andersson G. Internet-delivered psychological treatments. Annu 
Rev Clin Psycho. 2016;12: 157–79. 
16. Van Ballegooijen W, Riper H, Cuijpers P, van Oppen P, Smit JH. 
Validation of online psychometric instruments for common mental health 
disorders: a systematic review. BMC Psychiatry; 2016;16: 45. 
17. Beck AT, Steer RA. Manual for the Beck Anxiety Inventory. San 
Antonio, TX: The Psychological Corporation; 1993. 
18. Spielberger CD. Manual for the State-Trait Anxiety Inventory 
(STAI). Palo Alto, CA: Consulting Psychologists Press; 1983. 
19. Guillén-Riquelme A, Buela-Casal G. Actualización psicométrica y 
funcionamiento diferencial de los items en el State Trait Anxiety Inventory 
(STAI). Psychometric revision and differential item functioning in the State 




20. Magán I, Sanz J, García-Vera MP. Psychometric properties of a 
Spanish version of the Beck Anxiety Inventory (BAI) in general population. 
Span J Psychol. 2008; 11(2): 626–40.  
21. Spielberger CD, Gorsuch RL, Lushene R. Manual del Cuestionario 
de Ansiedad Estado/Rasgo (STAI). Madrid: TEA Ediciones; 1982. 
22. Meyer TJ, Miller ML, Metzger RL, Borkovec TD. Development and 
validation of the penn state worry questionnaire. Behav Res Ther. 
1990;28(6): 487–95.  
23. Houck PR, Spiegel DA, Shear MK, Rucci P. Reliability of the self-
report version of the panic disorder severity scale. Depress Anxiety. 
2002;15(4): 183–5.  
24. Mattick RP, Clarke JC. Development and validation of measures of 
social phobia scrutiny fear and social interaction anxiety. Behav Res Ther. 
1998;36(4): 455–70.  
25. Campbell-Sills L, Norman SB, Craske MG, Sullivan G, Lang AJ, 
Chavira DA, et al. Validation of a brief measure of anxiety-related severity 
and impairment: the Overall Anxiety Severity and Impairment Scale 
(OASIS). J Affect Disord. 2009;112(1–3): 92–101.  
26. Norman SB, Hami Cissell S, Means-Christensen AJ, Stein MB. 
Development and validation of an Overall Anxiety Severity And 
Impairment Scale (OASIS). Depress Anxiety. 2006;23(4): 245–9.  
27. Norman SB, Campbell-Sills L, Hitchcock CA, Sullivan S, Rochlin A, 
Wilkins KC, et al. Psychometrics of a brief measure of anxiety to detect 
severity and impairment: the Overall Anxiety Severity and Impairment 
Scale (OASIS). J Psychiatr Res. 2011;45(2): 262–8.  
28. Ziegler M, Kemper CJ, Kruyen P. Short Scales – Five 
Misunderstandings and Ways to Overcome Them. J Individ Differ. 
2014;35(4): 185–9.  
29. Haynes SN, Richard D, Kubany ES. Content validity in 
psychological assessment: a functional approach to concepts and 
methods. Psychol Assess. 1995;7(3): 238–47. 
30. Barlow DH, Allen LB, Choate ML. Toward a unified treatment for 
emotional disorders. Behav Ther. 2004;35(2): 205–30.  
31. Bragdon LB, Diefenbach GJ, Hannan S, Tolin DF. Psychometric 
properties of the Overall Anxiety Severity and Impairment Scale (OASIS) 
among psychiatric outpatients. J Affect Disord. 2016;201: 112–5.  
32. Ito M, Oe Y, Kato N, Nakajima S, Fujisato H, Miyamae M, et al. 
Validity and clinical interpretability of Overall Anxiety Severity And 
Impairment Scale (OASIS). J Affect Disord. 2015;170: 217–24.  
145 
 
33. Moore SA, Welch SS, Michonski J, Poquiz J, Osborne TL, Sayrs J, 
et al. Psychometric evaluation of the Overall Anxiety Severity And 
Impairment Scale (OASIS) in individuals seeking outpatient specialty 
treatment for anxiety-related disorders. J Affect Disord. 2015;175: 463–70.  
34. Sheehan D V, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, 
Weiller E, et al. The Mini-International Neuropsychiatric Interview 
(M.I.N.I.): the development and validation of a structured diagnostic 
psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998; 59 
Suppl 20: 22-33. 
35. Ferrando L, Franco-Alfonso L, Soto M, Bobes J, Soto O, Franco L, 
et al. M.I.N.I. Mini International Neuropsychiatric interview. Spanish 
version 5.0.0. DSM-IV. Madrid: Instituto IAP; 1998. 
36. Beck AT, Steer RA, Brown GK. Beck Depression Inventory. San 
Antonio: The Psychological Corporation; 1996. 
37. Sanz J, García-Vera MP, Espinosa R, Fortún M, Vázquez C. 
Adaptación española del Inventario para la Depresión de Beck-II (BDI-II): 
3. Propiedades psicométricas en pacientes con trastornos psicológicos. 
Clínica y Salud. 2005;16(2): 121–42. 
38. Storch EA, Roberti JW, Roth DA. Factor structure, concurrent 
validity, and internal consistency of the beck depression inventory? –
second edition in a sample of college students. Depress Anxiety. 
2004;19(3): 187–9.  
39. Bentley KH, Gallagher MW, Carl JR, Barlow DH. Development and 
validation of the Overall Depression Severity and Impairment Scale. 
Psychol Assess. 2014;26(3): 815–30.  
40. Watson D, Clark LA, Tellegen A. Development and validation of 
brief measures of positive and negative affect: the PANAS scales. J Pers 
Soc Psychol. 1988;54(6): 1063–70.  
41. Crawford JR, Henry JD. The Positive and Negative Affect Schedule 
(PANAS): Construct validity, measurement properties and normative data 
in a large non-clinical sample. Br J Clin Psychol. 2004;43(3): 245–65.  
42. Sandín B, Chorot P, Lostao L, Joiner TE, Santed MA, Valiente RM. 
Escalas PANAS de afecto positivo y negativo: Validacion factorial y 
convergencia transcultural. Psicothema. 1999;11(1): 37–51.  
43. Mezzich JE, Cohen NL, Ruiperez MA, Banzato CEM, Zapata-Vega 
MI. The Multicultural Quality of Life Index: presentation and validation. J 
Eval Clin Pract. 2011;17(2): 357–64.  
44. Mezzich JE, Ruipérez MA, Pérez C, Yoon G, Liu J, Mahmud S. The 
Spanish version of the quality of life index: presentation and validation. J 




45. DeVellis RF. Classical Test Theory. Med Care. 2006;44(Suppl 3): 
S50–9.  
46. Marsh HW, Hau KT, Wen Z. In Search of Golden Rule : Comment 
on Hypothesis Testing Approaches to Setting Cutoff Value for Fit Indexes 
and Danger in Overgeneralizing Hu and Bentler’s (1999) Findings. Struct 
Equ Modeling. 2004; 11(3): 320–41. 
47. McNeish D, An J, Hancock GR. The thorny relation between 
measurement quality and fit index cutoffs in latent variable models. J Pers 
Assess. 2018;100(1): 43–52. 
48. Cohen J. Statistical power analysis for the behavioral sciences. 2nd 
ed. Hillsdale: Erlbaum; 1988. 
49. Beck AT, Epstein N, Brown G, Steer RA. An inventory for 
measuring clinical anxiety. J Consult Clin Psych. 1988;56(6): 893–97. 
50. Argimon JM, Jiménez J. Métodos de investigación clínica 
epidemiológica (4th ed.). Barcelona: Elsevier España; 2013. 
51. Unal I. Defining an optimal cut-point value in ROC analysis: An 
alternative approach. Comput Math Methods Med. 2017. doi: 
10.1155/2017/3762651 
52. Mira A, Bretón-López J, García-Palacios A, Quero S, Baños RM, 
Botella C. An internet-based program for depressive symptoms using 
human and automated support: A randomized controlled trial. 
Neuropsychiatr Dis Treat. 2017;13: 987–1006.  
53. Gonzalez-Robles A, Garcia-Palacios A, Banos R, Riera A, Llorca G, 
Traver F, et al. Effectiveness of a transdiagnostic internet-based protocol 
for the treatment of emotional disorders versus treatment as usual in 
specialized care: study protocol for a randomized controlled trial. Trials. 
2015;16: 488.  
54. Díaz-García A, González-Robles A, Fernández-Álvarez J, García-
Palacios A, Baños RM, Botella C. Efficacy of a Transdiagnostic internet-
based treatment for emotional disorders with a specific component to 
address positive affect: Study protocol for a randomized controlled trial. 
BMC Psychiatry. BMC Psychiatry; 2017;17(1): 145. 
55. Barlow DH, Ellard KK, Fairholme CP, Farchione TJ, Boisseau CL, 
Allen LB, Ehrenreich-May J. The unified protocol for transdiagnostic 
treatment of emotional disorders: Client workbook. New York: Oxford 
University Press; 2011. 
56. Lejuez CW, Hopko DR, Hopko SD. A brief behavioral activation 




57. Seligman ME, Steen TA, Park N, Peterson C. Positive psychology 
progress: Empirical validation of interventions. Am Psychol. 2005; 60: 
410–21. 
58. Sin NL, Lyubomirsky S. Enhancing well-being and alleviating 
depressive symptoms with positive psychology interventions: A practice-
friendly metaanalysis. J Clin Psychol. 2009;65: 467–87. 
59. Barlow DH, Farchione TJ, Fairholme CP, Ellard KK, Boisseau CL, 
Allen LB, Ehrenreich-May J. The unified protocol for transdiagnostic 
treatment of emotional disorders: therapist guide. New York: Oxford 
University Press; 2011. 
60. Linehan MM. Skills training manual for treating borderline 
personality disorder. Diagnosis and treatment of mental disorders. New 
York: Guilford Press; 1993. 
61. Morris SB, DeShon RP. Combining effect size estimates in meta-
analysis with repeated measures and independent-groups designs. 
Psychol Methods. 2002;7(1): 105–25.  
62. Rubio-Aparicio M, Marín-Martínez F, Sánchez-Meca J, López-
López JA. A methodological review of meta-analyses of the effectiveness 
of clinical psychology treatments. Behav Res Methods. 2017: 1–17. 
63. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. 
Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in 
the National Comorbidity Survey Replication. Arch Gen Psychiatry. 
2005;62(6): 617–27.  
64. Hermans M, Korrelboom K, Visser S. A Dutch version of the Overall 
Anxiety Severity and Impairment Scale (OASIS): Psychometric properties 
and validation. J Affect Disord. 2015;172: 127–32.  
65. Julian LJ. Measures of anxiety: State-Trait Anxiety Inventory (STAI), 
Beck Anxiety Inventory (BAI), and Hospital Anxiety and Depression Scale 
Anxiety (HADS-A). Arthrit Care Res.  2011;63(S11): S467–S72. 
66. Piotrowski C. The status of the Beck inventories (BDI, BAI) in 
psychology training and practice: A major shift in clinical acceptance. J 
Appl Biobehav Res. 2017: e12112. 
67. Piotrowski C, Gallant N. Research Use of Clinical Measures for 
Anxiety in the Recent Psychological Literature. J Instruct Psychol. 
2009;36(1): 84–6. 
68. American Psychiatric Association. Diagnostic and statistical manual 









Overall Anxiety Severity and Impairment Scale (OASIS) 
 
Los siguientes ítems preguntan sobre ansiedad y miedo. Para cada ítem, 
selecciona el número que mejor describe tu experiencia durante la última 
semana. 
 
1. Durante la última semana, ¿con qué frecuencia te has sentido 
ansioso? 
0 = No me sentí ansioso durante la última semana. 
1 = Ansiedad infrecuente. Me sentí ansioso en algunos momentos. 
2 = Ansiedad ocasional. La mitad del tiempo me sentí ansioso y la otra 
mitad no. Me costó relajarme. 
3 = Ansiedad frecuente. Me sentí ansioso la mayor parte del tiempo. Me 
resultó muy difícil relajarme. 
4 = Ansiedad constante. Me sentí ansioso todo el tiempo y nunca llegué a 
relajarme. 
 
2. Durante la última semana, cuando te sentiste ansioso, ¿en qué 
medida tu ansiedad fue intensa o severa? 
0 = Poco o nada. La ansiedad estuvo ausente o casi no la noté.  
1 = Leve. La ansiedad fue de baja intensidad. Pude relajarme cuando lo 
intenté. Los síntomas físicos fueron sólo un poco molestos. 
2 = Moderada. La ansiedad me generó malestar en algunos momentos. 
Me resultó difícil relajarme o concentrarme, pero pude hacerlo cuando lo 
intenté. Los síntomas físicos fueron molestos. 
3 = Severa. La ansiedad fue intensa la mayor parte del tiempo. Me resultó 
muy difícil relajarme o concentrarme en cualquier otra cosa. Los síntomas 
físicos fueron enormemente molestos. 
4 = Extrema. La ansiedad me sobrepasó. Me fue totalmente imposible 
relajarme. Los síntomas físicos fueron insoportables. 
 
3. Durante la última semana, ¿con qué frecuencia evitaste 
situaciones, lugares, objetos o actividades debido a tu ansiedad o 
miedo? 
0 = Ninguna. No evité lugares, situaciones, actividades o cosas por miedo. 
1 = Infrecuente. Evité algunas cosas de vez en cuando, pero por lo 
general me enfrenté a las situaciones u objetos. Mi estilo de vida no se vio 
afectado. 
2 = Ocasional. Tuve algo de miedo a ciertas situaciones, lugares u 
objetos, pero todavía pudo manejarlos. Mi estilo de vida sufrió pocos 
cambios. Siempre o casi siempre evité las cosas que me dan miedo si 
estaba solo, pero las pude manejar si alguien venía conmigo. 
3 = Frecuente. Tuve bastante miedo y realmente intenté evitar las cosas 
que me asustan. He hecho cambios significativos en mi estilo de vida para 
evitar objetos, situaciones, actividades o lugares. 
4 = Todo el tiempo. Evitar objetos, situaciones, actividades o lugares ha 
ocupado gran parte de mi vida. Mi estilo de vida se ha visto enormemente 






4. Durante la última semana, ¿en qué medida ha interferido la 
ansiedad en tu capacidad para hacer las cosas que tenías que hacer 
respecto al trabajo, el colegio o tu hogar? 
0 = Nada. La ansiedad no interfirió en mi trabajo/hogar/colegio. 
1 = Leve. La ansiedad me causó algo de interferencia en mi 
trabajo/hogar/colegio. Las cosas eran más difíciles, pero pude realizar 
todo lo que necesitaba hacer. 
2 = Moderada. La ansiedad definitivamente interfirió en mis tareas. He 
podido realizar la mayoría de las cosas, pero sólo algunas las he hecho 
tan bien como en el pasado. 
3 = Severa. La ansiedad verdaderamente ha cambiado mi capacidad para 
hacer las cosas. Algunas cosas las he podido realizar, pero otras no. Mi 
rendimiento se ha visto definitivamente afectado. 
4 = Extrema. La ansiedad ha llegado a ser incapacitante. He sido incapaz 
de completar mis tareas y he tenido que irme del colegio, he dejado o me 
han despedido de mi trabajo o he sido incapaz de completar las tareas del 
hogar y he sufrido consecuencias como desalojos, cobradores, etc. 
 
5. Durante la última semana, ¿en qué medida ha interferido la 
ansiedad en tu vida social y en tus relaciones? 
0 = Nada. La ansiedad no interfirió en mis relaciones. 
1 = Leve. La ansiedad apenas interfirió en mis relaciones. Algunas de mis 
amistades y otras relaciones se han visto afectadas, pero en conjunto mi 
vida social sigue siendo satisfactoria. 
2 = Moderada. La ansiedad interfirió algo en mi vida social, pero sigo 
teniendo algunas relaciones cercanas. No paso tanto tiempo con otros 
como en el pasado, pero sigo teniendo relaciones sociales algunas veces. 
 3 = Severa. Mis amistades y otras relaciones se han visto muy afectadas 
a causa de mi ansiedad. No disfruto de las actividades sociales. Tengo 
muy pocas relaciones sociales. 
4 = Extrema. La ansiedad ha alterado completamente mis actividades 
sociales. Todas mis relaciones se han visto afectadas o han finalizado. Mi 






Overall Anxiety Severity and Impairment Scale (OASIS) 
 
The following items ask about anxiety and fear. For each item, select the 
number for the answer that best describes your experience over the past 
week. 
 
1. In the past week, how often have you felt anxious? 
0 = No anxiety in the past week. 
1 = Infrequent anxiety. Felt anxious a few times. 
2 = Occasional anxiety. Felt anxious as much of the time as not. It was 
hard to relax. 
3 = Frequent anxiety. Felt anxious most of the time. It was very difficult to 
relax. 
4 = Constant anxiety. Felt anxious all of the time and never really relaxed. 
 
2. In the past week, when you have felt anxious, how intense or 
severe was your anxiety? 
0 = Little or None: Anxiety was absent or barely noticeable. 
1 = Mild: Anxiety was at a low level. It was possible to relax when I tried. 
Physical symptoms were only slightly uncomfortable. 
2 = Moderate: Anxiety was distressing at times. It was hard to relax or 
concentrate, but I could do it if I tried. Physical symptoms were 
uncomfortable. 
3 = Severe: Anxiety was intense much of the time. It was very difficult to 
relax or focus on anything else. Physical symptoms were extremely 
uncomfortable. 
4 = Extreme: Anxiety was overwhelming. It was impossible to relax at all. 
Physical symptoms were unbearable. 
 
3. In the past week, how often did you avoid situations, places, 
objects, or activities because of anxiety or fear? 
0 = None: I do not avoid places, situations, activities, or things because of 
fear. 
1 = Infrequent: I avoid something once in a while, but will usually face the 
situation or confront the object. My lifestyle is not affected. 
2 = Occasional: I have some fear of certain situations, places, or objects, 
but it is still manageable. My lifestyle has only changed in minor ways. I 
always or almost always avoid the things I fear when I’m alone, but can 
handle them if someone comes with me. 
3 = Frequent: I have considerable fear and really try to avoid the things 
that frighten me. I have made signifi cant changes in my lifestyle to avoid 
the object, situation, activity, or place. 
4 = All the Time: Avoiding objects, situations, activities, or places has 
taken over my life. My lifestyle has been extensively affected and I no 
longer do things that I used to enjoy. 
 
4. In the past week, how much did your anxiety interfere with your 
ability to do the things you needed to do at work, at school, or at 
home? 




1 = Mild: My anxiety has caused some interference at work/home/school. 
Things are more difficult, but everything that needs to be done is still 
getting done. 
2 = Moderate: My anxiety definitely interferes with tasks. Most things are 
still getting done, but few things are being done as well as in the past. 
3 = Severe: My anxiety has really changed my ability to get things done. 
Some tasks are still being done, but many things are not. My performance 
has definitely suffered. 
4 = Extreme: My anxiety has become incapacitating. I am unable to 
complete tasks and have had to leave school, have quit or been fired from 
my job, or have been unable to complete tasks at home and have faced 
consequences like bill collectors, eviction, etc. 
 
5. In the past week, how much has anxiety interfered with your social 
life and relationships? 
0 = None: My anxiety doesn’t affect my relationships. 
1 = Mild: My anxiety slightly interferes with my relationships. Some of my 
friendships and other relationships have suffered, but, overall, my social 
life is still fulfilling. 
2 = Moderate: I have experienced some interference with my social life, 
but I still have a few close relationships. I don’t spend as much time with 
others as in the past, but I still socialize sometimes. 
3 = Severe: My friendships and other relationships have suffered a lot 
because of anxiety. I do not enjoy social activities. I socialize very little. 
4 = Extreme: My anxiety has completely disrupted my social activities. All 
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Abstract 
Transdiagnostic cognitive-behavioral therapy for emotional disorders (ED) 
has proven to be effective. However, current transdiagnostic treatment 
protocols address only the regulation of negative affectivity, and they do 
not include treatment components to more directly target the regulation of 
positive affectivity. In this study, we propose to evaluate the preliminary 
efficacy and acceptability of a transdiagnostic treatment protocol for ED 
that includes, as an innovative feature, a specific treatment component to 
directly upregulate positive affectivity based on positive psychology 
interventions. A total of 24 participants were randomized to either a 
transdiagnostic treatment protocol (n  = 12) or a transdiagnostic treatment 
protocol with an additional component designed to regulate positive 
affectivity (n = 12). Participants completed measures of anxiety, 
depression, positive and negative affectivity, and quality of life, as well as 
treatment acceptability at pre- and posttreatment and at the 3-month 
follow-up. Both interventions led to improvements in all measures at 
posttreatment, and these outcomes were maintained at the 3-month 
follow-up, with large effect sizes for all measures. The effect sizes for 
positive affect were larger in the condition that included the component to 
upregulate positive affectivity. Attrition rate was low, and both treatment 
protocols were well accepted by participants. The results obtained in this 
study indicate the feasibility of testing the treatment protocol in a larger, 
randomized, controlled trial, and they suggest the potential of including 
treatment components for directly upregulating positive affectivity in future 
research on transdiagnostic treatment protocols for ED.  
 
Keywords: Positive affectivity, transdiagnostic, cognitive-behavioral 





Emotional disorders (ED; depression and anxiety disorders) are 
highly prevalent mental disorders (Kessler et al., 2005; Wittchen et al., 
2010) and one of the main causes of disability worldwide (Kazdin & Blase, 
2011; McLean, Asnaani, Litz, & Hofmann, 2011). Currently, there is 
extensive evidence showing the efficacy and effectiveness of disorder-
specific cognitive-behavioral therapy (CBT) for several ED, including major 
depression disorder (MDD; Cuijpers, Smit, Bohlmeijer, Hollon, & 
Andersson, 2010; Hollon & Ponniah, 2010), obsessive-compulsive 
disorder (OCD; McKay et al., 2015), and different anxiety disorders, such 
as generalized anxiety disorder (GAD), panic disorder (PD), agoraphobia 
(AG), and social anxiety disorder (SAD; Antony & Stein, 2009; Barlow, 
2002; Nathan & Gorman, 2007; Olatunji, Cisler, & Deacon, 2010). 
However, high comorbidity rates among ED (Kessler et al., 2005) have led 
some researchers to shift the focus to treatment strategies (referred to as 
transdiagnostic treatments) that might be more widely effective across 
these diverse mental health problems (D. A. Clark & Taylor, 2009).  
To date, there is evidence showing the efficacy of transdiagnostic 
treatments for anxiety disorders (Reinholt & Krogh, 2014), and for mixed 
depression and anxiety disorders (Newby, McKinnon, Kuyken, Gilbody, & 
Dalgleish, 2015; Păsărelu, Andersson, Nordgren, Dobrean, 2016). An 
important line of research within the transdiagnostic treatment of ED was 
initiated by D. H. Barlow (Barlow, Allen, & Choate, 2004). Barlow’s theory 
of triple vulnerability emphasizes the common underlying vulnerabilities in 
ED and helps to explain the comorbidity among these diverse conditions 
(Brown & Barlow, 2009). A central aspect within this theoretical 
perspective is the role of emotion regulation in ED (Barlow et al., 2004). 
Emotion regulation has been defined as the attempt to influence the types 
of emotions people experience, when they experience these emotions, 
and how these emotions are expressed and experienced (Gross, 1998), 
with regard to either negative or positive emotions. Moreover, people can 
use emotion regulation to upregulate (increase and/or maintain) or 
downregulate (decrease) emotions (Gross, 1998). Difficulties in the 
regulation of both negative and positive emotions have emerged in 
research as a common feature in depression and anxiety disorders (Carl, 
Soskin, Kerns, & Barlow, 2013; Hofmann, Sawyer, Fang, & Asnaani, 
2012). The core of these emotion regulation difficulties has been identified 
as neuroticism or negative affect (N/NA; Barlow, Sauer-Zavala, Carl, 
Bullis, & Ellard, 2013; Brown & Barlow, 2009). However, these déficits 
have also been associated with low extraversion/positive affect (E/PA). 
For instance, the association between low PA and several ED, such as 
unipolar depression (L. A. Clark & Watson, 1991), SAD (Brown, Chorpita, 
& Barlow, 1998), and AG (Rosellini, Lawrence, Meyer, & Brown, 2010), 
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has been shown in previous research. In addition, there is evidence 
indicating that most individuals with anxiety and mood disorders show low 
levels of PA (Kotov, G.mez, Schmidt, & Watson, 2010). Regarding 
depression, literatura has suggested that there is a link between the 
maladaptive strategies used by depressed patients to regulate PA and 
depression symptoms (Gilbert, 2012; Gilbert, Nolen-Noeksema, & Gruber, 
2013; Werner-Seidler, Banks, Dunn, & Moulds, 2013), and that deficits in 
PA regulation are associated with a worse depression prognosis 
(Shankman, Nelson, Harrow, & Faull, 2011). Finally, a review focused on 
PA regulation in ED concluded that there are transdiagnostic disturbances 
in the strategies used to regulate positive emotions that may account for 
low levels of PA in depression and several anxiety disorders such as GAD, 
AG, PD, SAD, and OCD (Carl et al., 2013).  
The regulation of negative emotions in transdiagnostic models for 
ED such as the unified protocol (UP) has received a great deal of attention 
in research (Barlow, Sauer-Zavala, Carl, Bullis, & Ellard, 2013; Ellard, 
Fairholme, Boisseau, Farchione, & Barlow, 2010). This protocol focuses 
on four essential aspects that have the general purpose of downregulating 
NA: increasing present-focused emotional awareness, addressing 
maladaptive emotional avoidance behavior patterns, promoting cognitive 
flexibility, and facilitating interoceptive and situational exposure. However, 
although Barlow highlighted the role of low PA in the onset and 
maintenance of ED (Barlow et al., 2004; Brown & Barlow, 2009), the main 
objective of the treatment components in the UP is to train patients in NA 
regulation, and less attention is paid to the inclusion of treatment 
components to directly target PA regulation. This is also the case in other 
empirically evaluated transdiagnostic treatments for anxiety disorders 
(e.g., Norton, 2012; Titov, Andrews, Johnston, Robinson, & Spence, 2010) 
and mixed anxiety and depression (e.g., Berger, Boettcher, & Caspar, 
2013; Titov et al., 2011).  
PA regulation may have important implications in treatment 
because high PA is associated with better physical and psychological 
health, healthier lifestyles, and better general functioning (S. Cohen & 
Pressman, 2006; Fredrickson, 2001; Livingstone & Srivastava, 2012; 
Pressman & Cohen, 2005; Quoidbach, Berry, Hansenne, & Mikolajczak, 
2010; Tugade & Fredrickson, 2007). Moreover, the importance of fostering 
PA, in addition to reducing NA, to improve treatment outcomes in 
depression and anxiety disorders has been highlighted in the literature 
(Carl et al., 2013) because high PA seems to promote general well-being, 
prevent relapses, and produce resilience (Dunn, 2012; Tugade & 
Fredrickson, 2007; Wood & Joseph, 2010).  
Positive psychology interventions (PPIs) mainly focus on enhancing 




Parks, 2014). Schueller and Parks (2014) distinguished five categories 
under the umbrella of PPIs: (a) savoring experiences and sensations, (b) 
cultivating and expressing gratitude, (c) engaging in kind actions, (d) 
promoting positive relationship processes, and (e) pursuing hope and 
meaning. Meta-analyses have shown that these interventions are effective 
for enhancing well-being and reducing depressive symptoms in both the 
general population and in individuals with a variety of psychosocial 
problems (Bolier et al., 2013; Schueller & Parks, 2014; Sin & Lyubomirsky, 
2009; Weiss, Westerhof, & Bohlmeijer, 2016). The addition of PPIs to 
existing CBT interventions (e.g., transdiagnostic interventions) could help 
to strengthen their effect on PA, leading to greater and more lasting effects 
on positive emotional functioning and wellbeing. Taylor, Lyubomirsky, and 
Stein (2017) recently studied the efficacy of a transdiagnostic intervention 
based on PPIs for mixed anxiety and depression, reporting significant 
gains in PA and secondary gains in NA, depression, and anxiety 
symptoms. However, this study differs from ours in that it does not include 
strategies for downregulating NA. In regard to this point, the literature has 
mainly focused on studying the impact of PPIs on depressive symptoms 
rather than anxiety (see Bolier et al., 2013; Sin & Lyubomirsky, 2009; 
Weiss et al., 2016). However, research suggests that anxiety disorders 
may be also appropriate targets for treatments based on PPIs. For 
instance, AG or SAD has been shown to be characterized by low levels of 
PA (Brown et al., 1998; Rosellini et al., 2010). Another reason why anxiety 
disorders may benefit from PPIs is that anxious individuals often engage in 
strategies that lead to the avoidance of positive experiences and 
emotions, as outlined in the review by Carl et al. (2013). Accordingly, well-
being may be increased in these patients by training them in strategies to 
upregulate PA. 
Another intervention for depression that can help to promote well-
being is behavioral activation (Lejuez, Hopko, & Hopko, 2001; Lewinsohn, 
1974). From the approach of behavioral activation, depressive symptoms 
are deemed as the result of decreased levels of activity that lead to a loss 
of positive reinforcement (Lewinsohn, 1974). The efficacy of behavioral 
activation in improving well-being has been shown in previous research in 
both depressed (Mazzucchelli, Kane, & Rees, 2009) and nondepressed 
populations (Mazzucchelli, Kane, & Rees, 2010). Thus, the ability to 
increase well-being and positive emotional functioning may be 
strengthened by including behavioral activation procedures in 
interventions, at least for individuals with depression. 
Taking all this into consideration, an important treatment goal from 




We developed a transdiagnostic protocol (TP) for ED based on the 
UP (Barlow et al., 2011) and another version of this protocol that also 
includes a specific component mainly based on PPIs to directly address 
PA regulation (TP + PA).  
Both protocols were tested using a two-armed randomized pilot 
study. The aim was to assess the differential effect of both interventions 
on measures of depression, anxiety, and quality of life, and on PA and NA. 
Another goal was to evaluate treatment retention and the acceptability of 
both interventions by participants. It was hypothesized that (a) both 
interventions would result in significant improvements on all clinical 
measures at posttreatment, and these results would be maintained in the 
short term (3-month follow-up); (b) the TP + PA would significantly 
outperform the TP group on PA measures; (c) acceptability would be high 
in both conditions, with no statistical differences between conditions. 
Method 
Procedure 
Participants were recruited from individuals seeking treatment at the 
Emotional Disorders Clinic (Castellon, Spain). After an initial screening 
assessment that included the administration of a diagnostic interview, 
participants who met the inclusion criteria were asked to sign a consent 
form and then randomly assigned to either the TP group or the TP + PA 
group. Block randomization in blocks of four was performed using a 
computer-generated random number sequence. Once participants had 
been assigned to one of the conditions, they completed pretreatment 
primary and secondary outcome measures (self-reported questionnaires). 
In both groups, the interventions started immediately after pretreatment 
assessment. After each treatment session, participants were given a 
patient treatment handbook and asked to do homework tasks to review the 
specific contents and practice the proposed strategies and skills learned in 
each session. After completing the treatment protocols, a diagnostic 
interview and primary and secondary outcome measures were 
administered to obtain posttreatment data. The assessment instruments 
were also applied at the 3-month follow-up. All assessments (i.e., 
diagnostic interviews) were conducted by independent assessors who 
were blind to the participants’ allocation.  
The study was registered in Clinicaltrials.gov 
(https://clinicaltrials.gov/) as NCT02790398 and approved by the Ethics 
Committee of Universitat Jaume I (Castellon, Spain). 
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Participants 
In total, 26 participants met the inclusion criteria. In the TP + PA 
group, one participant dropped out after 11 treatment sessions, stating 
that she had no time to dedicate to the therapy. In the TP group, one 
participant dropped out after Session 5 because she had to move to 
another city. These participants were excluded from the analyses; 
therefore, the final sample included 24 participants (see flow of 
participants in Figure 12). 
The baseline characteristics of the sample are described in Table 
12. Inclusion criteria were as follows: (a) being 18 years old or older; (b)
meeting the Diagnostic and Statistical Manual of Mental Disorders  (4th 
ed., text rev.; DSM-IV-TR; American Psychiatric Association [APA], 2000) 
diagnostic criteria for ED, which included MDD, dysthymic disorder (DD), 
GAD, SAD, PD, AG, anxiety disorder not otherwise specified (ADNOS), 
(unipolar) mood disorder not otherwise specified (MDNOS), and OCD; and 
(c) ability to understand and read Spanish. Exclusion criteria included (a) 
schizophrenia, bipolar disorder, or alcohol and/or substance dependence 
disorder; (b) high risk of suicide; (c) receiving another psychological 
treatment during the study; and (d) in the case of receiving 
pharmacological treatment, an increase and/or change in this treatment 
during the study period (a decrease in pharmacological treatment was 
accepted).  
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Note. ED = Emotional disorders; TP = Transdiagnostic Protocol; PA = Positive affect 
Figure 8. Flowchart of participants 
166 
Table 22. Description of participants at baseline 
TP+PA TP 
Gender, n (%) 
  Female 
  Male 
Age; M (SD), range 
Education, n (%) 
  Basic studies 
  Medium studies 
  Superior studies 
Marital status, n (%) 
  Married/partnered 
  Single 
  Divorced/Widowed 
Principal diagnostic, n (%) 
  Generalized anxiety disorder 
  Major depressive disorder 
  Agoraphobia 
  Panic disorder 
  Social anxiety disorder 
  Dysthymic disorder 
Number of comorbid diagnoses, n (%) 
  0 
  1 







































Note. TP + PA = Transdiagnostic protocol + positive affect regulation component; TP = 
Transdiagnostic protocol 
In the TP group, four participants were taking pharmacological 
treatment at the time of enrollment. All of them were taking 
benzodiazepines. In the TP + PA group, three participants were receiving 
pharmacological treatment at the time of enrollment. Two of them were 
taking benzodiazepines, and one was taking antidepressants in addition to 
benzodiazepines. All participants in both conditions decreased the dosage 
or stopped taking medication during the study. At posttreatment and at the 
3-month follow-up, none of the participants were receiving 
pharmacological treatment.  
Measures 
Diagnostic measure 
Mini International Neuropsychiatric Interview, Version 5.0.0 (MINI). 
This is a short, structured, diagnostic psychiatric interview that yields key 
Diagnostic and Statistical Manual of Mental Disorders (4th ed.; DSM-IV; 
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APA, 1994) and International Statistical Classification of Diseases and 
Related Health Problems, 10th Revision (ICD-10) diagnoses (Sheehan et 
al., 1998). The MINI can be administered in a short period of time, and 
clinical interviewers only need brief training. The MINI has been translated 
into Spanish and validated (Ferrando, Bobes, Gibert, & Lecrubier, 1997).  
Self-administered questionnaires 
Overall Anxiety Severity and Impairment Scale (OASIS). This is 
a five-item scale, rated from 0 to 4, that evaluates the frequency, severity, 
and work, social, academic, and everyday life impairment caused by 
anxiety symptoms in the past week (Norman et al., 2011). The internal 
consistency of the OASIS has been found to be good (α = .80). The scale 
has also shown good test–retest reliability (k = .82) and convergent 
validity. We used the Spanish version of the instrument, which also 
showed adequate psychometric properties (Mira et al., 2015). In the 
present study, the Cronbach’s alpha for the OASIS was α = .81.  
Beck Depression Inventory–II (BDI-II). It is one of the most widely 
used questionnaires to evaluate depression severity in pharmacological 
and psychotherapy trials (Beck, Steer, & Brown, 1990). It consists of 21 
items about the different symptoms characterizing MDD, added together to 
obtain the total score, which can yield a maximum of 63 points. The 
instrument has shown good internal consistency (α = .76-.95). The 
Spanish version of this instrument has also shown high internal 
consistency (α = .87) in both general and clinical populations (α = .89) 
(Sanz, Navarro, & Vázquez, 2003). In the present study, the Cronbach’s 
alpha for the BDI-II was α = .92.  
Positive and Negative Affect Schedule (PANAS). The PANAS 
consists of 20 items that evaluate two independent dimensions: PA and 
NA (Watson, Clark, & Tellegen, 1988). It contains 10 descriptors 
evaluating PA (e.g., “enthusiastic,” “inspired,” “proud”) and 10 others 
assessing NA (e.g., “scared,” “irritable,” “guilty”). The range for each scale 
(10 items on each) is from 10 to 50, and the patient has to answer how he 
or she usually feels regarding each of these emotions. The scale showed 
excellent internal consistency (α between .84 and .90) and convergent and 
discriminant validity. The Spanish version has demonstrated high internal 
consistency (α = .89 and .91 for PA and NA in women, respectively, and α 
= .87 and .89 for PA and NA in men, respectively) in college students 
(Sand.n et al., 1999). In the present study, the Cronbach’s alpha for the 
PANAS PA was α = .94, and for the PANAS NA, α = .88. 
The Quality of Life Inventory (QLI). This is a brief self-report 
questionnaire that assesses perceived quality of life in different life-related 
areas (Mezzich, Cohen, & Ruiperez, 1996). The questionnaire includes 10 
items, rated on a scale from one to 10, that assess physical well-being, 
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psychological well-being, self-care and independent functioning, 
occupational functioning, interpersonal functioning, social emotional 
support, community and services support, personal fulfillment, spiritual 
fulfillment, and overall quality of life. The QLI has shown excellent internal 
consistency (between .90 and .92), test–retest reliability (.87), and 
discriminant validity. The Spanish validation of the QLI (Mezzich et al., 
2000) has also demonstrated good test–retest reliability (α = .89) and 
discriminant validity. In the present study, the Cronbach’s alpha for the QLI 
was α = .87. 
Acceptability of treatment 
Expectations and Opinion of Treatment Scales.  These 
questionnaires are adapted from Borkovec and Nau (1972). Each scale is 
made up of five items, rated on a scale from 0 (nothing at all ) to 10 
(completely ), that cover how logical the treatment seems to be (“How 
logical do you think this treatment is?”), to what extent it could satisfy the 
patient (“How satisfied are you with the treatment?”), whether it could be 
recommended to a person with the same problem (“To what extent do you 
feel confident recommending this treatment to a friend who has the same 
problems?”), whether it could be used to treat other psychological 
problems (“To what extent do you think this treatment could be useful in 
treating other psychological problems?”), and its usefulness for the 
patient’s problem (“To what extent do you think this treatment will be/was 
helpful to you?”). The expectation scale is applied once the treatment 
rationale has been explained. Its aim is to measure subjective patient 
expectations about this treatment. The opinion scale is administered when 
the patient has completed the treatment, and its aim is to assess 
satisfaction with this treatment. Our group has used this questionnaire in 
several research studies (Botella et al., 2009, 2007). 
Interventions 
Transdiagnostic Protocol (TP) 
We developed a TP for the treatment of ED, adapted from the UP 
(Barlow et al., 2011) and some of the strategies for emotion regulation 
from dialectical behavior therapy (DBT; Linehan, 1993). All the strategies 
and techniques from the original protocols (UP) have been translated into 
Spanish, and the contents (e.g., clinical examples) adjusted for cultural 
differences. The addition of some strategies from DBT (i.e., mindfulness 
“what” and “how” skills) was considered important because emotion 
regulation difficulties have been shown to be a key transdiagnostic factor 
across distinct ED (Campbell-Sills, Barlow, Brown, & Hofmann, 2006; 
Cisler, Olatunji, Feldner, & Forsyth, 2010) and an important treatment 
target (Neacsiu, Eberle, Kramer, Wiesmann, & Linehan, 2014). The main 
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differences between the UP and the protocol developed for the present 
study (TP) are shown in Table 13.  
The TP is a manualized, structured treatment protocol made up of 
12 treatment modules with the general aim of regulating NA (Botella, 
GarcÍa- Palacios, Baños, 2012). These modules are usually administered 
in 12 to 15 weekly face-to-face sessions (maximum of 18) lasting 60 min. 
Modules 1 to 11 contain strategies for the regulation of NA with the 
following main therapeutic components from the UP: (a) present-focused 
emotional awareness, (b) cognitive flexibility, (c) emotion avoidance and 
emotion-driven behaviors (EDB), (d) awareness and tolerance of physical 
sensations, and (e) interoceptive and situation-based emotion exposure. 
Modules 1 to 11 are preceded by three modules (Module 1 is an 
introduction to treatment, Module 2 is focused on motivation 
enhancement, and Module 3 provides psychoeducation about emotions) 
and followed by a relapse prevention module (Module 12). The treatment 
protocol includes one patient handbook and one therapist handbook for 
each treatment session. In this condition, participants completed a mean 
of 13.25 sessions (SD = 0.75; range = 12-14). Modules 1 to 12 are 
described below: 
Module 1. Introduction to treatment: Provides a framework about the role 
of emotion regulation in ED. A brief description of the program modules is 
also presented, as well as videos with examples of people suffering from 
different ED. 
Module 2. Motivation for change and goal-setting: The aims are to 
analyze the advantages and disadvantages of changing, emphasize the 
importance of being motivated, and highlight the importance of 
establishing significant life goals. 
Module 3. Understanding the role of emotions: Provides psychoeducation 
about the adaptive roles and functions of emotions and trains the patient in 
tracking of emotional experiences using the three-component model of 
emotions. 
Module 4. Nonjudgmental emotional awareness and acceptance of 
emotional experiences: This module aims to train the patient in 
nonjudgmental emotional awareness (i.e., mindfulness “what” and “how” 
skills) and in the acceptance of emotional experiences and its importance 
in the treatment. 
Module 5. Practicing present-focused awareness: The objective is to 
continue to learn about the acceptance of emotional experiences and 
increase awareness of physical sensations, thoughts, emotions, and daily 
activities. 
Module 6. Learning to be flexible: It focuses on the importance of 
maladaptive ways of thinking (i.e., thinking traps) in the maintenance of 
ED, and on learning how to identify them. 
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Module 7. Practicing cognitive flexibility: This module aims to teach the 
patients how maladaptive ways of thinking can be modified (i.e., cognitive 
reappraisal). It also provides information about intrusive thoughts and how 
to deal with them. 
Module 8. Emotional avoidance: This module aims to teach the patients to 
identify the emotion avoidance strategies that contribute to the 
maintenance of ED. 
Module 9. EDB: The aim is for patients to learn the concept of EDB and 
replace their own maladaptive EDB with other more adaptive behaviors. 
Module 10. Accepting and facing physical sensations: The objectives are 
to teach the patients the role of physical sensations in their emotional 
response and train them in interoceptive exposure, to increase tolerance 
and promote habituation to physical sensations. 
Module 11. Facing emotions in the contexts in which they occur: The 
purpose is the construction of exposure hierarchies to help the patients 
begin to face the avoided situations that contribute to the maintenance of 
the problem. 
Module 12. Relapse prevention: This module aims to review the strategies 
learned throughout the program, schedule the future practice of the 
learned strategies, and teach the patient how to identify and cope with 
future high-risk situations. 
Table 23. Differences between the TP and the UP 
TP UP (Barlow et al., 2011) 
M1. Introduction to treatment 
M2. Motivation for change and goal setting 
M3. Understanding the role of emotions 
(psychoeducation about emotions and goal 
setting) 
M0. Introduction to treatment 
M1. Motivation engagement for treatment 
enhancement 
M2. Psychoeducation and tracking of 
emotional experiences 
Component 1: Present-focused 
emotional awareness 
M4. Non-judgmental emotional awareness 
and acceptance of emotional experiences  
M5. Practicing present-focused awareness: 
physical sensations, thoughts, emotions 
and daily activities  
Component 1: Present-focused 
emotional awareness 
M3. Emotion awareness training 
Component 2: Cognitive Flexibility 
M6. Learning to be flexible (identification of 
thinking traps) 
M7. Practicing cognitive flexibility (cognitive 
reappraisal and evaluation of intrusive 
thoughts) 
Component 2: Cognitive Flexibility 
M4. Cognitive Appraisal and Reappraisal 
Component 3: Emotion avoidance and 
emotion-driven behaviors 
M8. Emotional avoidance 
M9. Emotion-driven behaviors 
Component 3: Emotion avoidance and 
emotion-driven behaviors 
M5. Emotion avoidance and emotion-driven 
behaviors 
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Components 4 and 5:  
Awareness and tolerance of physical 
sensations  
Interoceptive and situation-based 
emotion exposure 
M10. Accepting and facing physical 
sensations 
M11. Facing emotions in the contexts in 
which they occur 
Components 4 and 5:  
Awareness and tolerance of physical 
sensations  
Interoceptive and situation-based 
emotion exposure 
M6. Awareness and tolerance of physical 
sensations  
M7. Interoceptive and situation-based 
emotion exposures 
M12. Relapse prevention 
Number of sessions: 12-18 
Session duration: 60 minutes 
M8. Relapse prevention 
Number of sessions: maximum of 18 
Session duration: 50-60 minutes 
Note: A full description of UP modules can be found in Barlow et al. (2011) 
Transdiagnostic protocol + positive affectivity regulation component (TP + 
PA). 
This intervention comprises 16 modules generally delivered in 16 to 
19 treatment sessions (maximum of 22). As in the TP, this protocol also 
includes one patient handbook and one therapist handbook for each 
module. The structure of this protocol is as follows: (a) Modules 1 to 11 
are the same modules as in the TP; (b) Modules 12 to 15 constitute a 
treatment component aimed at the regulation of PA (i.e., enhancement 
and maintenance of PA); (c) Module 16 is focused on relapse prevention. 
In this condition, participants completed a mean of 17.42 sessions (SD  = 
1.08; range = 16-19). Modules 12 to 15 (PA regulation component) are 
depicted below: 
Module 12. Learning to move on. This module is focused on the role of 
behavioral activation, teaching the patient the importance of “moving on.” 
Behavioral activation is trained using a diary of daily activities. To 
complete this diary, the patient is provided with monitoring sheets with a 
scale ranging from 0 to 10 to score both the level of satisfaction with the 
activities the patient is involved in during the day and to what extent they 
are linked to his or her personal goals and values. The practice of this 
exercise is intended to help the patient realize the positive relationship 
between meaningful activities and mood to promote behavioral activation 
(Lejuez et al., 2001). 
Module 13. Learning to enjoy. This module consists of psychoeducation 
about the role of positive emotions in life and how to generate and 
maintain them (e.g., using savoring strategies; Bryant & Veroff, 2007). The 
strategies included in this module are consistent with Fredrickson’s 
Broaden-and-Build Theory (Fredrickson, 2001), which highlights the effect 
of positive emotions in broadening intellectual, social, and physical 
resources. The module contains the following techniques: 
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 The importance of smiling. The week is divided into days when the
patient has to smile as much as possible when interacting with
other people and days when the patient has to act normally. The
effects of “smiling days”/normal “no-smiling days” are discussed
with the therapist in the following session.
 Savoring. The patient is asked to engage in everyday activities that
he or she normally does fast and without paying attention in a
slower and more mindful manner (e.g., eating, taking a shower,
walking, or driving to work). The patient is then asked to think about
how the slow, mindful way of doing these activities makes him or
her feel compared with engaging in activities fast and unmindfully.
 Daily time of enjoyment. The patient is encouraged to engage in
some pleasant activity on a daily basis (e.g., drinking a cup of
coffee or tea, doing sports, listening to music, going for a walk,
having a conversation). The patient is also asked to think about
how he or she felt during the activity and whether he or she would
repeat it again, change it, or add something new to it.
Module 14. Learning to live. This module is divided into two sections. The 
first section is focused on the importance of identifying the individual’s own 
psychological strengths. The patients are shown the list of strengths 
proposed by Peterson and Seligman (2004)—for example, curiosity, 
creativity, kindness, self-control, honesty, enthusiasm, equity, respect, 
gratitude—and asked to choose some of them and think about the ways to 
promote these strengths. The second section addresses the dimensions of 
well-being identified by Ryff (1995, 2014)—for example, purpose in life, 
autonomy, and personal growth. This section includes an exercise to help 
the patient select and perform meaningful activities linked to personal 
values (e.g., for the value “being a thoughtful friend”: “calling my friends 
once a week”/“catch up with a friend who I have not seen in a while”). 
Module 15. Living and learning. One objective is to practice some 
exercises to promote emotions linked to well-being, such as gratitude 
(e.g., visit of gratitude, expressing gratitude; Seligman, Steen, Park, & 
Peterson, 2005), hope (using an exercise based on the best possible self; 
Sheldon & Lyubomirsky, 2006), and curiosity (encouraging the patient’s 
interest in different topics or activities). Another aim is to teach the patient 
to identify episodes of well-being and maintain them, using the strategy 
proposed by Fava (1999) in Well-Being Therapy, which consists of 
identifying thoughts and beliefs leading to the premature interruption of 
well-being. The patient is then asked to think about a more realistic way to 
interpret the situation to prolong the feelings of well-being as long as 
possible. 
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Therapists and Treatment Fidelity 
The treatment protocols were administered by five different 
therapists working at the Emotional Disorders Clinic at Universitat Jaume 
I. All therapists but one delivered both protocols (TP and TP + PA). All of 
them were PhDs or PhD students with 3 to 5 years of experience in the 
diagnosis, psychological assessment, and application of CBT for several 
ED. To ensure treatment fidelity, both therapists and patients were 
provided with detailed manualized treatment protocols for each of the 
modules. In addition, therapists had been previously trained in the 
application of the treatment manuals, and they were supervised on a 
weekly basis by expert clinical psychologists, members of our research 
team who had been involved in the design and development of the 
treatment protocol. 
Statistical Methods 
All analyses were performed using the software SPSS Version 
22.0. Descriptive statistics (means and standard deviations) were 
calculated for all measures. Two-way repeated-measures ANOVAs (time, 
treatment, Treatment x Time) were performed to explore the statistical 
significance of the differences within and between subjects on all 
measures. The magnitude of the intervention was expressed as Hedges’s 
g , a variation of Cohen’s d  (J. Cohen, 1988) that corrects for biases due 
to small sample sizes (Hedges & Olkin, 1985) and a recommended effect 
size estimator when sample sizes are lower than 20 (Hunter & Schmidt, 
2004). To interpret effect sizes, Cohen’s d  convention (J. Cohen, 1988) 
was used, according to which an effect size of 0.20 is considered small, 
0.50 is considered moderate, and 0.80 and above is considered large. 
Confidence intervals were also calculated for each of the effect sizes.  
Because the number of participants who dropped out from both 
groups is low (1 participant in each condition), only completer analyses 
were performed. 
Results 
Within- and Between-Group Changes in Primary and Secondary 
Outcomes 
Means and standard deviations for both groups before and after the 
intervention and at the 3-month follow-up are displayed in Table 14.  
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Table 24. Descriptive statistics for all measures 
Within- and between-group effect sizes (Hedges’s g), as well as 
confidence intervals, are displayed in 
TP+PA TP 



































































Note. Pre-T: Pre-treatment; Post-T: Post-treatment; F/U: 3-month follow-up. TP+PA: 
Transdiagnostic Protocol + Positive Affect regulation component; TP: Transdiagnostic 
Protocol; OASIS: Overall Anxiety Severity and Impairment Scale; BDI-II: Beck 
Depression Inventory; PANAS +: Positive and Negative Affect Schedule – Positive Affect; 
PANAS -: Positive and Negative Affect Schedule – Negative Affect; QLI: Quality of Life 
Inventory 
175 
Table 15. In general, within-group effect sizes were large to very 
large for the OASIS, the BDI-II, and the QLI in both treatment groups. 
Regarding the PANAS-PA, within-group effect sizes were mainly large in 
both groups, with overall larger effect sizes in the TP + PA group than in 
the TP group at posttreatment and at the follow-up. However, the effect 
size for the TP group at posttreatment was in the moderate range (g  = –
.77). For the PANAS-NA, within-group effect sizes were all in the large 
range, with slightly larger effect sizes found in the TP + PA group than in 
the TP group at posttreatment and at the follow-up. Regarding 
comparisons between conditions (between-group effect sizes), a small 
effect size was observed at posttreatment and at the follow-up on all 
measures, including the PANAS-PA. To explore the statistical significance 
of the treatment gains and the differences between conditions, a two-way 
repeated-measures ANOVA was performed. The ANOVA showed a 
significant time effect on all measures: PANAS-PA: F (1.72, 37.88) = 
15.47, p < .001, PANAS-NA: F (1.54, 33.85) = 44.13, p < .001, BDI-II: F 
(1.22, 26.82) = 49.84, p < .001, OASIS: F (1.72, 37.91) = 23.25, p < .001, 
and QLI: F (1.57, 34.57) = 36.21, p < .001. The participants significantly 
improved from pre- to posttreatment on all outcomes, and these 
improvements were maintained at the 3-month follow-up. Nevertheless, 
the analysis failed to find a significant interaction effect (Time x Group) on 
any of the measures (p > .05). Thus, no significant differences were found 
between the two groups. 
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Table 25. Within- and between-group effect sizes for all measures 
Within-group effect size, g 
[95% CI] 
Between-group effect size, g 
[95% CI] 
Pre-post Pre-F/U Post-T   F/U 





























































Note. Pre: Pre-treatment; Post: Post-treatment; F/U: 3-month follow-up. TP+PA: Transdiagnostic Protocol + Positive Affect regulation component; TP: 
Transdiagnostic Protocol; OASIS: Overall Anxiety Severity and Impairment Scale; BDI-II: Beck Depression Inventory; PANAS +: Positive and Negative Affect 
Schedule – Positive Affect; PANAS -: Positive and Negative Affect Schedule – Negative Affect; QLI: Quality of Life Inventory. Positive effect sizes denote a 
decrease in scores, negative effect sizes denote an increase. 
177 
Diagnostic Status 
Results assessed by the MINI interview showed that seven 
participants (58%) in the TP + PA condition and eight participants in the 
TP condition (67%) no longer met the diagnostic criteria for any disorder at 
posttreatment. At the 3-month follow-up, eight participants in the TP + PA 
condition no longer met the diagnostic criteria for any ED (67%), whereas 
seven participants in the TP condition (58%) no longer met these criteria. 
A chi-square test did not reveal any statistical difference in the proportion 
of diagnosis-free participants at posttreatment and at follow-up. 
Acceptability of the Treatment 
Means and standard deviations for expectations and opinions about 
treatment are depicted in Table 16. In the TP + PA condition, results 
indicate that participants reported high scores on all the items measuring 
treatment expectations (scores between 7.83 and 8.58): logic of the 
treatment, satisfaction with the treatment, recommendation of the 
treatment to other people with similar problems, usefulness of the 
treatment for other psychological problems, and usefulness of the 
treatment for one’s specific problem. After receiving the intervention, 
scores for treatment opinions improved compared with scores for 
treatment expectations (scores between 8.08 and 8.83). Overall, the 
results for expectations and opinions in the TP condition were higher than 
in the TP + PA condition, ranging between 8.83 and 9.17 for expectations, 
and between 8.58 and 9.67 for opinions. As indicated by a two-way 
repeated-measures ANOVA, no significant differences were found 
between the two groups on any of the items assessing expectations and 
opinions. 












7.83 (1.80) 8.25 (1.82) 9.08 (.90) 9.42 (.67) 
Satisfaction with 
the treatment 
8.08 (1.73) 8.08 (2.23) 9.08 (.79) 9.50 (.67) 
Recommend to 
others 









7.83 (1.70) 8.25 (1.66) 9.17 (.94) 9.42 (.79) 





The aim of the present study was to evaluate the feasibility, in terms 
of preliminary efficacy and acceptability, of a new transdiagnostic 
treatment protocol for ED that includes a specific therapeutic component 
to directly upregulate PA. To do so, two versions of the same protocol 
were developed and tested in a randomized pilot study. One treatment 
protocol includes strategies that focus on the regulation of NA alone (TP), 
and the other protocol adds these strategies to a treatment component to 
upregulate PA (TP + PA). To the best of our knowledge, this is the first 
study to empirically investigate a TP for ED that integrates a specific 
component to directly upregulate PA. 
One aim was to assess the effect of both interventions on a set of 
clinical measures. Overall, the analyses showed that both interventions 
resulted in significant improvements in all measures at posttreatment, and 
that the clinical gains were maintained at the 3-month follow-up. Both 
interventions were effective in reducing depression and anxiety, and these 
gains were maintained at the follow-up assessment. In addition, both 
treatment protocols led to significant improvements in quality of life at 
posttreatment and at the 3-month follow-up. However, the analyses did not 
reveal any significant differences between groups on any of the scales. 
We were also interested in studying the differential effects of the 
two interventions on PA. The first hypothesis was that the TP + PA would 
lead to significantly higher PA outcomes than the TP. The effect sizes for 
PA were larger in the TP + PA group than in the TP group at posttreatment 
(g = 1.34 vs. g = 0.77) and at the 3-month follow-up (g = 1.30 vs. g = 
0.85). Although not significant, these findings suggest that the inclusion of 
a treatment component to upregulate positive affectivity might be 
important in enhancing PA outcomes. This component has already been 
empirically tested in a randomized controlled trial (RCT) exploring the 
efficacy of a web-based intervention for depression (Mira et al., 2017). As 
in the present study, this RCT examined an intervention that combined 
CBT techniques (i.e., psychoeducation about emotions, cognitive 
restructuring, behavioral activation) and PPIs, reporting significant 
improvements in NA and PA compared with a waitlist control group. 
Although there is a body of literature on PPIs, it is difficult to relate the 
results of this study to those of previous meta-analyses (e.g., Bolier et al., 
2013; Sin & Lyubomirsky, 2009; Weiss et al., 2016) of these types of 
interventions, mainly because these meta-analyses utilized well-being as 
the main outcome measure, rather than PA. Furthermore, the samples 
included in the aforementioned meta-analyses are rather heterogeneous, 
making the comparisons between this study and previous research on 
PPIs even more difficult. In any case, the treatment approach followed in 
the present work is consistent with recommendations about the 
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importance of well-being and positive emotional functioning (Fava, 2016; 
Hasler, 2016) and the need for further research on these interventions. 
Finally, although the main focus of this study was on PA, future research 
should study whether adding treatment components designed to 
upregulate PA to transdiagnostic treatments for ED may result in better NA 
outcomes, compared with treatments where these components are 
absent. In any case, these results should be interpreted considering the 
pilot nature of this study. 
Regarding diagnostic status, the number of patients who met the 
diagnostic criteria for a principal disorder decreased at posttreatment, and 
this proportion was maintained at the 3-month follow-up. There were no 
significant differences between groups in the number of participants who 
no longer met the diagnostic criteria for any disorder after the treatment, 
and these changes were maintained at the follow-up. 
Another objective was to explore the participants’ acceptability of 
the intervention. Results showed that participants in both groups had high 
expectations about the treatment protocol before receiving it. Moreover, 
after receiving the intervention, scores on their opinions improved 
compared with scores for treatment expectations. Attrition rate was low in 
both groups (one patient dropped out in each group), which also suggests 
the feasibility of this intervention for a sample of patients with ED. Taken 
together, the results support the acceptability of both interventions. 
Although the acceptability of the PA regulation component was not 
specifically assessed in this study, the results for adherence and 
acceptability are consistent with those found by Mira et al. (2017) for a 
web-based intervention for depression that also included the same 
component based on PPIs.  
In summary, these results suggest that both interventions were 
equally effective for the treatment of several ED. Moreover, acceptability 
did not differ significantly between conditions, suggesting that both 
interventions were similarly accepted by participants. The main strength of 
this study is the inclusion of a treatment component that directly addresses 
PA regulation (i.e., by increasing and maintaining PA). This protocol differs 
from other transdiagnostic treatments in that it addresses the regulation of 
PA in a more direct way, whereas other transdiagnostic treatments only 
integrate treatment strategies essentially aimed to downregulate NA (e.g., 
Ellard et al., 2010; Norton, 2012; Titov, Andrews, Johnston, Robinson, & 
Spence, 2010; Titov et al., 2011). Previous research has proposed some 
directions to address both the assessment and treatment of PA regulation 
from a transdiagnostic perspective (e.g., Carl, Fairholme, Gallagher, 
Thompson-Hollands, & Barlow, 2014; Carl et al., 2013), but this field is 
quite new, and more research is needed on this topic. Questions remain 




regulation in TPs: what the most effective strategies are; in what 
proportion; how and when each treatment component (regulation of PA 
and regulation of NA) should be present in TPs; who this treatment 
approach might benefit the most (e.g., depression vs. anxiety disorders); 
and what the incremental effect of these strategies is on other relevant 
treatment outcomes such as anxious and depressive symptomatology and 
quality of life. 
This study has limitations that bear mention. First, it is a pilot study 
with a low number of participants and no waiting list control group. 
Second, the high effect sizes observed in this study must be interpreted in 
light of the nonsignificant confidence intervals shown at most 
measurement points. Third, this study does not allow us to separate the 
effects of the NA and PA regulation components. Improvements in PA 
might be partly due to a carryover effect, as participants underwent the PA 
regulation sessions (Sessions 12-15) after 11 sessions of NA regulation 
(Sessions 1-11), which makes it difficult to draw conclusions about the 
specific contribution of each of these treatment components. Fourth, 
although we assessed the effect of the intervention on both PA and NA, 
we did not include any measure focused on the underlying emotion 
regulation mechanisms that are hypothesized to be responsible for these 
changes. Five, most of the therapists involved in the study delivered both 
versions of the treatment (TP and TP + PA) and were not blind to the 
treatment conditions. Finally, the addition of a treatment component to one 
of the treatments tested in this study (TP + PA) resulted in a treatment with 
more sessions in one condition than in the other. For these reasons, future 
research should focus on exploring to what extent each of the different 
treatment components accounts for the improvement in measures of PA 
and NA and other clinical measures. One possible strategy to do so is 
conducting dismantling studies. Our research group is currently 
conducting a dismantling study to explore the specific contribution of 
different therapeutic components in the treatment of depression: a protocol 
that combines different components (i.e., CBT and PPIs), a protocol based 
on behavioral activation only, and a protocol based on PPIs only (the 
study protocol is available in https://clinicaltrials.gov/show/NCT03159715). 
In conclusion, this study represents an attempt to contribute to the 
existing gap in transdiagnostic treatments for ED by adding a treatment 
component that more directly addresses the regulation of PA. Preliminary 
efficacy and acceptability results indicate that both interventions are 
feasible to be tested in a larger RCT. Although we were unable to find a 
significant difference in PA due to the impact of the PA regulation 
component, the results found in this study suggest the potential impact 
that including treatment components to directly target PA regulation may 
have on this temperament dimension. 
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General discussion  
To date, most transdiagnostic Internet-delivered treatments have 
been conducted in community and primary care settings, with no studies 
of this kind carried out in public specialized mental health care (González-
Robles et al., 2018). Based on the advantages of both the transdiagnostic 
approach (e.g. lower costs, better management of comorbidity) and 
Internet-delivered formats (e.g. increased reach of evidence-based 
treatments), we decided to conduct a randomized controlled trial (RCT) to 
test the effectiveness of a transdiagnostic Internet-delivered protocol 
(EmotionRegulation) designed to address a wide range of anxiety and 
depressive disorders in this particular setting. Therefore, the principal aim 
of the current doctoral thesis was to develop a transdiagnostic Internet-
based protocol for emotional disorders to be tested in public specialized 
mental health care, compared to treatment as usual (TAU), using an RCT 
design. The RCT protocol was first registered at Clinicaltrials.gov 
(NCT02345668). The details about the study protocol were published, and 
then the RCT was conducted and the results analyzed. In addition, a 
number of secondary studies were conducted in relation to the RCT. First, 
a systematic review was carried out to summarize the state-of-the-art with 
regard to transdiagnostic treatments for emotional disorders. More 
specifically, the review sought to answer how the assessment of 
comorbidity is approached in published transdiagnostic protocols for 
emotional disorders, and what the most commonly targeted specific 
diagnoses are in these interventions. Second, the psychometric properties 
of the online versions of the Overall Anxiety Severity and Impairment 
Scale (OASIS) and the Overall Depression Severity and Impairment Scale 
(ODSIS) were analyzed in Spanish clinical samples with anxiety and 
depressive disorders. The Spanish validation of these scales allowed us to 
include them in the RCT in order to evaluate the progress (or stagnation) 
of each patient module by module, throughout the entire treatment 
process. Finally, given the importance of promoting protective factors such 
as positive affectivity to improve mental health, a randomized pilot study 
was conducted to study the utility of adding treatment modules for the 
regulation of positive affectivity to a transdiagnostic protocol with 
traditional components for the regulation of negative affectivity.   
In the following sections, a general discussion is presented, 
structured as follows. First, a brief summary of the most important findings 
and implications of each study are presented. Next, the main strengths 
and limitations of the studies are discussed. The last section is devoted to 







1) What is the state-of-the-art of transdiagnostic treatments for 
emotional disorders with regard to the assessment of 
comorbidity, and what are the most commonly targeted 
diagnoses in these interventions? 
 
Research has systematically shown that high rates of comorbidity 
are the rule rather than the exception in anxiety and depressive disorders 
(e.g. Brown & Barlow, 2009; Kessler et al., 2005a, 2005b). Furthermore, 
individuals with comorbidity usually exhibit greater severity, chronicity, and 
disability than individuals with no comorbid disorders (Hofmeijer-Sevink et 
al., 2012; Rapaport, Clary, Fayyad, & Endicott, 2005). Unlike disorder-
specific protocols, each of which is designed to treat symptom-specific 
variations of particular disorders, transdiagnostic treatments focus on their 
commonalities, and so they may be a more optimal solution for the 
treatment of comorbid presentations. Moreover, because the number of 
transdiagnostic treatments has grown considerably in the past 15 years, 
we thought there would be enough studies to synthesize the trends in the 
research regarding the most commonly targeted diagnoses in these 
interventions. With these ideas in mind, a systematic review was 
conducted with the following objectives: a) to analyze whether treatment 
response in comorbid disorders is evaluated in transdiagnostic treatments 
for emotional disorders; b) to explore what diagnoses are targeted in 
transdiagnostic treatments for emotional disorders; and c) to explore what 
the real distribution of the diagnoses is at baseline in these treatments. 
Regarding the assessment of comorbidity, the results showed that the 
assessment of the clinical change in comorbidity was not typically 
performed in transdiagnostic treatments, with only 40% of the studies 
conducting assessments of the comorbid disorders. Regarding the 
distribution of diagnoses, the most significant finding was that the most 
commonly targeted diagnoses in these treatments were GAD, PD/AG, 
SAD, and depression, and that other diagnoses such as PTSD, OCD, and 
Anxiety NOS were marginally included in these studies. On the other 
hand, this review also analyzed both the settings and delivery formats, and 
the comparison groups of these studies. We concluded that most 
transdiagnostic treatments to date have been conducted in the community 
and in an individual format. Regarding the delivery format, 27 out of 52 
studies (52%) were Internet- or computerized-delivered treatments. 
Finally, only 8 of the 52 studies (15%) used disorder-specific protocols as 
comparison groups, which highlights the gap in the relative efficacy of 
transdiagnostic treatments compared to disorder-specific treatments. 
Although transdiagnostic treatments have been shown to be effective 
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when compared to control groups, these results led us to conclude that 
studies comparing these two treatment approaches are particularly 
necessary, especially because transdiagnostic treatments offer a number 
of advantages in terms of dissemination and implementation (e.g. lower 
training costs) that could make them superior to disorder-specific 
treatments for practical purposes.  
 
2) What are the psychometric properties of two brief scales for 
the assessment of the severity and impairment associated with 
anxiety and depression? 
 
 The psychometric properties of two brief scales for the assessment 
of the severity and impairment associated with anxiety and depression 
were analyzed in Chapters 4 and 5. The first study focused on the OASIS, 
whereas the second addressed the ODSIS. For these studies, the 
psychometric properties of the online versions were analyzed. Therefore, 
contributions to the literature about the online versions of these 
instruments were made through these studies. As far as we know, only 
two prior studies have analyzed the psychometrics of both instruments 
using online surveys (Ito et al., 2015a, 2015b). However, unlike in the 
studies by Ito et al., which relied on patients’ self-reports to establish a 
formal diagnosis, in our study the diagnoses were performed more 
rigorously, using a structured diagnostic interview. Overall, both 
instruments demonstrated adequate psychometric properties in Spanish 
patients with emotional disorders, with good to excellent reliability and 
evidence found for both convergent and divergent validity. Moreover, the 
unidimensional factor structure reported in previous validations of these 
studies (e.g. Bentley et al., 2014; Campbell-Sills et al., 2009; Norman et 
al., 2006) was confirmed in both studies using Confirmatory Factor 
Analysis. In addition, cutoff scores were obtained for both scales, 
indicating that they may be used as screening instruments. Finally, 
evidence for sensitivity to change was shown for the OASIS. These 
characteristics, along with their brevity and transdiagnostic nature, make 
these scales particularly well-suited instruments for testing psychological 
or psychiatric interventions or collecting data in large-scale research (e.g. 








3) What was the effectiveness and acceptability of 
EmotionRegulation compared to TAU in public specialized 
mental health care?  
 
Chapters 3 and 6 presented the study protocol and the results of an 
RCT comparing a transdiagnostic Internet-based protocol 
(EmotionRegulation) to TAU in specialized mental health care. The results 
revealed that EmotionRegulation was more effective than TAU in reducing 
anxiety and depression, and in improving health-related quality of life. 
These findings have implications for both research and clinical practice. 
Regarding research, this study demonstrated that a transdiagnostic 
Internet-delivered CBT protocol can effectively be deployed in specialized 
care. With regard to clinical practice, the results showed that a 
transdiagnostic Internet-delivered protocol was more effective than TAU, 
which in our country is currently the best treatment alternative that patients 
can expect from the national public care system. Moreover, high scores on 
expectations and opinions were observed among participants, which 
indicated the acceptability of EmotionRegulation for participants. Although 
some methodological issues arose (e.g. rather than 200, 178 participants 
were recruited and, therefore, some of the results were underpowered), 
taken together, the results of this RCT were very promising and encourage 
us to keep exploring the potential of transdiagnostic Internet-based 
interventions in this specific setting. On the other hand, because no 
inferences about the effectiveness of EmotionRegulation on disorder-
specific measures (e.g. OCI-R for OCD symptoms, SIAS for social anxiety 
symptoms, etc.) can be drawn, more research with adequate levels of 
statistical power is needed to study the effectiveness of this type of 
therapy, compared to disorder-specific CBT, for each of the anxiety and 
depressive disorders. Likewise, the lack of research testing 
transdiagnostic Internet-delivered protocols in public specialized mental 
health care warrants the study of predictors and moderators of treatment 
outcomes in this specific population.  
 
4) What is the feasibility of including treatment modules for the 
regulation of positive affectivity in a transdiagnostic protocol 
for emotional disorders? 
 
Most research on transdiagnostic treatments to date has focused 
on alleviating the deficit and psychopathological factors, with little attention 
paid to the promotion of positive protective factors. For these reasons, in 
Chapter 7 we addressed a randomized pilot study aimed at analyzing the 
feasibility, in terms of differential efficacy and acceptability, of a 
transdiagnostic protocol with a treatment component for the regulation of 
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positive affectivity (TP+PA). This treatment was compared to a 
transdiagnostic protocol that only included traditional components 
targeting the regulation of negative affect (TP). In spite of the pilot nature 
of the study, in general, greater improvements were shown by the TP+PA 
group on all measures, in particular with regard to positive affectivity. In 
addition, low attrition rates were observed for both groups, and 
acceptability was high across conditions. In sum, the results obtained in 
this study suggested the feasibility of testing the intervention in a larger, 
sufficiently powered RCT.  
 
Strengths and limitations  
The findings of the studies contained in the current doctoral thesis 
should be interpreted in light of their strengths and limitations. The first 
section outlines the strengths, and the second section summarizes the 
limitations.  
Strengths  
The systematic review (Chapter 2) presents both methodological 
and clinical strengths. With regard to the methodological strengths, it was 
registered in the International Prospective Register of Systematic Reviews 
(PROSPERO) (CRD42018088138). Moreover, the most relevant 
databases were used (i.e. PsycINFO, PubMed, EMBASE, and the 
Cochrane Register of Controlled Trials), which allowed us to conduct a 
comprehensive search of the literature about RCTs focused on 
transdiagnostic treatments. Finally, the PRISMA guidelines were followed 
to ensure that the minimum criteria for conducting systematic reviews 
were met. Regarding the clinical strengths, to our knowledge, this is the 
first study to systematically approach the topic of the assessment of 
comorbidity in transdiagnostic treatments for emotional disorders. 
Furthermore, it also highlights that some emotional disorders (e.g. PTSD, 
OCD, anxiety NOS) commonly found in clinical practice are 
underrepresented in trials about transdiagnostic treatments, in spite of the 
fact that they are theoretically appropriate for transdiagnostic treatment.  
Regarding the validation studies (Chapters 3 and 4), the following 
strengths are worth noting. First, to our knowledge, these are the first 
studies to analyze the psychometric properties of the OASIS and the 
ODSIS in Spanish clinical samples with depression and anxiety. Both 
validation studies showed good to excellent internal consistency, adequate 
construct validity, and a latent structure consistent with prior validations of 
the instruments. In addition, cut-off scores were provided for both 
measures. Thus, because both instruments showed adequate 




clinical practice with Spanish patients. Second, large samples of patients 
with anxiety and depressive disorders were used in both studies, with 
results that are more generalizable to these populations. Finally, the online 
versions of these instruments were validated. With the continuous 
increase in research on Internet interventions, assessment instruments 
that are delivered online are increasingly demanded by researchers in this 
field. Thus, these studies contribute to the realm of online evidence-based 
assessment. 
With regard to the RCT (Chapters 3 and 6), both clinical and 
methodological strengths are underscored. First, to the best of our 
knowledge, this was the first RCT to explore the effectiveness of a 
transdiagnostic Internet-delivered protocol for emotional disorders in the 
context of public specialized mental health care. Moreover, promising 
results were shown for both the effectiveness and the acceptability of this 
intervention, compared to TAU, opening up avenues for further research, 
such as the study of predictors and moderators of treatment, or the 
comparison of transdiagnostic Internet-delivered treatments with disorder-
specific protocols in this specific population. With regard to the 
methodological strengths, the study protocol was registered at 
Clinicaltrials.gov (NCT02345668) and published in an indexed open-
access journal (Trials). Furthermore, an RCT design was used, and we 
adhered to all the relevant guidelines and recommendations about 
reporting and conducting clinical research and RCTs: the CONSORT 
statement (Moher et al., 2010; Moher, Schulz, & Altman, 2001), the 
CONSORT-EHEALTH guidelines (Eysenbach, 2011), the Declaration of 
Helsinki, and good clinical practice. 
Finally, a randomized pilot study was conducted (Chapter 7) to 
study the utility of adding components for the regulation of positive affect 
to a transdiagnostic face-to-face protocol, with the following strengths, 
both clinical and methodological. With regard to the clinical strengths, this 
was the first study to acknowledge the importance of including treatment 
components for the regulation of positive affect in existing transdiagnostic 
treatments for emotional disorders. Thus, a randomized design was 
selected to compare a traditional transdiagnostic protocol (i.e. with 
components for the regulation of negative affect) to an extended version of 
this protocol that added intervention modules targeting the regulation of 
positive affect. The protocols were compared in terms of both relative 
efficacy and acceptability. Although preliminary, the results suggested 
more favorable results for the transdiagnostic protocol with components 
for the regulation of positive affect and equal acceptability across 
conditions, suggesting the feasibility of testing this study in a larger RCT. 
On the other hand, regarding the methodological strengths, a randomized 
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design was selected, and the study protocol was registered in 
ClinicalTrials.gov (NCT02790398) prior to being conducted and published.  
 
Limitations 
In this section, the main limitations of the studies are discussed. 
First, although a comprehensive search was conducted, only 
studies written in English and developed in Western countries were 
included in the systematic review (Chapter 2). Moreover, although aspects 
of the methodology were not reported or unclear in some of the included 
studies, we did not contact the authors of these studies to clarify these 
details. Therefore, these studies were rated as unclear. However, we have 
observed from prior systematic reviews conducted by our research team 
that contacting the authors is often unfruitful and, thus, has little practical 
value. Finally, publication bias could not be ruled out. Therefore, some 
relevant studies might not have been included in the review.  
Second, although the OASIS showed good psychometric 
properties, test-retest reliability was not examined in this study (Chapter 
3). Moreover, the sample size used to explore the sensitivity to change of 
the instrument was low, and it was not analyzed in relation to other 
measures for the assessment of anxiety. However, it is important to note 
that these limitations are largely due to the fact that participants were 
derived from trials with assessment instruments and measurement points 
that were already predetermined. Finally, rather than a sample of non-
clinical control individuals, a cutoff from a self-report questionnaire (Beck 
Anxiety Inventory) was selected to classify the participants in the Receiver 
Operating Characteristic analysis. However, unlike previous validations of 
the OASIS, which only rely on parameters such as sensitivity and 
specificity (e.g. Campbell-Sills et al., 2009; Norman et al., 2006, 2009), a 
wider array of criteria were used in our study to select the most optimum 
cutoff score.  
Third, regarding the validation of the ODSIS (Chapter 4), the same 
procedure as in the OASIS validation was employed to determine the 
cutoff score (i.e. cut points on the Beck Depression Inventory – BDI-II), but 
the selection of the cutoff point was based on several criteria, as in the 
OASIS validation. In addition, although the BDI-II is one of the most 
validated and accepted measures for the assessment of depression, 
conclusions about the construct validity of the instrument could only be 
drawn in relation to this measure because no other instruments to 
evaluate depression were included in the study. Finally, as in the OASIS 




However, some important properties such as test-retest reliability were not 
explored.  
Fourth, regarding the RCT (Chapters 3 and 6), a sample size of 200 
participants was determined in the study protocol in order to reach 
conclusions that met the minimum levels of statistical power. However, 
because of time and funding restraints for this study, we were only able to 
recruit 178 participants. As a consequence, some results were slightly 
underpowered, limiting the generalizability of the findings. Furthermore, 
the long-term effects of EmotionRegulation could not be reported because 
follow-up assessments (3- and 12-month follow-ups) are still being 
conducted and, thus, were not available. However, because the 
maintenance of the effects over time is of vital importance, we plan to 
report the results of follow-up assessments once they are completed. In 
addition, attrition was high in both conditions (around 35%), consistent 
with what is commonly observed in the field of Internet Interventions 
(Andrews, Cuijpers, Craske, McEvoy & Titov; Van Ballegooijen et al., 
2014). However, intention-to-treat analyses were performed to handle 
missing data. On the other hand, the effects of the intervention on 
disorder-specific measures (e.g. PSWQ for generalized anxiety, PDSS for 
panic disorder, and so on) were underpowered due to the low sample size 
of each of the diagnosis subgroups.  
Fifth, although the randomized pilot study yielded results that 
suggested the feasibility of a transdiagnostic protocol with components for 
the regulation of positive affect (Chapter 7), the sample size in this study 
was low, which led to underpowered results that kept us from drawing 
conclusions about the efficacy of the intervention. Moreover, two active 
treatments were compared in this study, with the absence of a control 
group (e.g. waiting list control group or attention control). Finally, carryover 
effects in the group with components for the regulation of positive affect 
(TP+PA) cannot be ruled out, which makes it difficult to draw conclusions 
about the specific contribution of each treatment component to the 
outcomes.  
 
Recommendations and directions for future research 
The findings in this doctoral thesis, as well as its strengths and 
limitations, open up avenues for future research. Several 
recommendations for research are discussed in the following section.  
First, one of the aims of this doctoral thesis was to conduct a 
systematic review focused on transdiagnostic treatments for anxiety and 
depressive disorders (Chapter 2). We concluded that the existing RCTs 
testing transdiagnostic protocols do not typically evaluate the effects of 
these treatments on the comorbid disorders, in spite of the clear 
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association between comorbidity and several indicators of morbidity (e.g. 
clinical severity, greater chronicity, and poorer clinical course) (Hofmeijer-
Sevink et al., 2012; Kessler et al., 2005b; Bruce, Machan, Dyck, & Keller, 
2001). For this reason, further empirical data are needed to conclusively 
demonstrate the assumed superiority of these treatments in addressing 
comorbidity. Therefore, future studies examining transdiagnostic 
treatments should make efforts to include assessment instruments that 
analyze the effect of these treatments on the comorbid disorders. In this 
vein, one important concern when developing protocols to evaluate new 
interventions is the selection of the most relevant assessment tools. 
However, because there are many aspects susceptible to evaluation (e.g. 
broad and specific symptoms, quality and life, work and social functioning, 
psychopathological processes, and so on), if not chosen carefully, the 
assessment protocol might end up with an excessive number of scales. In 
our experience, a common solution for this problem is to evaluate some 
aspects at the expense of others. In the field of transdiagnostic treatments, 
the data from the systematic review (Chapter 2) seem to indicate that 
instruments for anxiety and depression are selected as principal outcomes 
in most studies, whereas less attention is paid to the inclusion of 
measures for the assessment of more specific, but also important, 
measures, such as disorder-specific instruments to assess treatment 
effects on comorbid disorders. A possible alternative to this problem may 
be the inclusion of shorter scales in these trials that allow reliable and valid 
assessment of the comorbid disorders. For instance, in a recent study, 
Staples et al. (2018) analyzed the GAD-2, a shorter version of the 
Generalized Anxiety Disorder Scale (GAD-7), for the assessment of 
generalized anxiety symptoms, showing good psychometric properties 
such as discriminant validity, internal consistency, and sensitivity to 
change. Consequently, it might be worthwhile to develop shorter versions 
of these scales because they may ease the inclusion of measures for the 
assessment of comorbidity in studies evaluating transdiagnostic 
treatments.  On the other hand, the systematic review showed that some 
emotional disorders that are theoretical targets for transdiagnostic 
treatment (e.g. PTSD, OCD, and anxiety/depression not otherwise 
specified) are underrepresented in RCTs on these treatments, in spite of 
their high prevalence rates. Thus, more attention should be paid to these 
disorders in future research on transdiagnostic interventions.  
Second, the RCT (Chapters 3 and 6) conducted in the current 
doctoral thesis represents, to our knowledge, the first attempt to test a 
transdiagnostic Internet-delivered protocol in the context of public 
specialized mental health care. Although encouraging results were found, 
further research should be carried out in this particular setting to extend 




be reached in this context have more ecological value. In our RCT, an 
Internet-delivered format was selected to test a transdiagnostic protocol. 
The advantages of using the Internet to provide treatments have been 
highlighted throughout this doctoral thesis (e.g. regarding dissemination). 
However, the literature in general, and our RCT in particular, has shown 
that dropout rates in Internet-delivered treatments are notably high 
(Andrews et al., 2010; Richards & Richardson, 2012). Therefore, more 
research focused on dropout rates should be conducted with patients 
attending public specialized care. To this end, both quantitative and 
qualitative methods should be undertaken to address the study of dropout 
in these treatments. For instance, the study of predictors can help to shed 
light on the characteristics of the patients (e.g. sociodemographic and 
clinical) that make them more prone to dropout (Karyotaki et al. 2015), 
whereas qualitative research can explore the opinions and attitudes of 
these patients in a more profound way. Some research has been 
conducted in this regard (Fernández-Álvarez et al., 2017; Johansson, 
Michel, Andersson, & Paxling, 2015), showing the importance of taking 
into account the patients’ perspectives in identifying both the barriers and 
facilitators of Internet-delivered treatments. However, the number of 
qualitative studies analyzing these aspects is still low, and so more 
research of this kind is needed to achieve a deeper understanding of this 
phenomenon. On the other hand, the literature has shown that there is still 
considerable room for improvement in the attitudes and perceptions of 
users toward Internet interventions (e.g. Apolinário-Hagen, Vehreschild, & 
Alkoudmani, 2017; Klein & Cook, 2010; Musiat, Goldstone, & Tarrier, 
2014). Although we did not explore the relationship between attitudes and 
attrition in our RCT, this aspect is of vital importance because attitudes 
can significantly determine the patients’ willingness to engage with these 
interventions (Mohr et al., 2010), as well as their likelihood of dropping out 
of them (Fernández-Alvarez et al., 2017). Thus, research efforts should be 
made to educate the population about the true value of these interventions 
in improving mental health, specifically with regard to anxiety and 
depressive disorders. Moreover, although we did not assess the attitudes 
and opinions of the clinicians involved in the RCT (i.e. psychiatrists and 
clinical psychologists), it is worth mention that many of them refused to 
participate in the recruitment process, which might be reflecting negative 
attitudes towards Internet-delivered interventions among these 
professionals. The reasons for these negative attitudes might include 
concerns about the efficacy, privacy, and safety of these treatments 
(Rochlen, Zack, & Speyer, 2005). Moreover, the possibility of establishing 
a good therapeutic alliance with the patients in digital interventions is also 
a matter of concern among clinicians (Sucala, Schnur, Brackman, 
Constantino, & Montgomery, 2013). However, there is research indicating 
that Internet-delivered CBT leads to therapeutic alliance levels that are 
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comparable to face-to-face treatments (Berger, 2016). In this scenario, 
research efforts to educate the population about the benefits of empirically 
supported Internet-delivered interventions should also be extended to 
clinicians, especially because they are seen as authority figures and, 
therefore, their attitudes can have a major impact on patients’ perceptions. 
Likewise, along with the study of patients’ attitudes, more research should 
be conducted with clinicians to examine their opinions and attitudes about 
Internet-delivered treatments. In this attempt to measure attitudes toward 
Internet interventions, different scales have been developed and applied to 
different populations, such as the Attitudes towards Psychological Online 
Interventions Questionnaire (APOI) (Schröder et al., 2015) for patients, 
and the Computer-assisted Therapy Attitudes Scale (CATAS) for clinicians 
(Becker & Jensen-Doss, 2013). In order to identify barriers and improve 
the quality of Internet-delivered treatments, future studies should strive to 
collect data about the attitudes of both users and providers towards these 
interventions, and scales like the aforementioned may help in this 
endeavor. 
Along the same lines, the results of the RCT showed that, overall, 
patients in the EmotionRegulation condition improved to a greater degree 
than patients in the TAU condition. However, as expected, differences 
between participants emerged when we analyzed the significance of the 
clinical gains using Jacobson and Truax’s (1991) method, with a 
proportion of these patients showing deterioration at post-treatment. In this 
vein, there is research indicating that most published trials on Internet-
delivered treatments for anxiety and depressive disorders fail to report 
data about potential negative effects, such as harm, side effects, and 
deterioration rates (Arnberg, Linton, Hultcrantz, Heinzt, & Jonsson, 2014). 
Therefore, efforts should be made to report these aspects in order to draw 
more precise conclusions about the safety of these interventions. In this 
regard, a few recent meta-analyses have examined predictors of 
deterioration in Internet-delivered treatments (Ebert et al., 2016; Karyotaki 
et al., 2018; Rozental, Magnusson, Boettcher, Andersson, & Carlbring, 
2017), concluding that, in general, deterioration rates are lower in these 
treatments compared to control conditions. However, studies focused on 
this aspect are still scarce, and so more research is needed exploring 
potential predictors and moderators of deterioration in Internet-delivered 
treatments. 
In this regard, although Internet-delivered treatments have been 
found to be effective across numerous mental health problems 
(Andersson, 2016), they may not work equally for everyone. Internet-
delivered treatments can be either completely self-guided, guided 
(differing in the types and amount of guidance provided), or combined with 




Blended treatments represent an innovative treatment modality that 
combines face-to-face and Internet-delivered psychotherapy (Kooistra et 
al., 2014). Because blended treatments require a lower number of face-to-
face sessions, they fit properly in routine care settings (e.g. public 
specialized mental health care). Thus, an interesting future line of 
research may be to explore how transdiagnostic treatments work when 
they are provided using distinct delivery modalities (e.g. self-guided 
Internet-delivered treatments, guided Internet-delivered treatments, or 
blended treatments) in specialized care. Another possibility is to combine 
the advantages of both transdiagnostic and group approaches to 
significantly increase the number of people who receive treatment in public 
specialized mental health care, as in the ongoing study by Osma et al. 
(2018). Because the combination of these two approaches 
(transdiagnostic and group) may provide considerable advantages for both 
patients and clinicians (e.g. reduction of mental health waiting times, lower 
costs in training clinicians), we hope that this work will encourage other 
researchers to conduct similar studies in this particular context.  
On the other hand, the individualization or personalization of 
treatment (or the lack of it) has been found to be a relevant aspect of 
transdiagnostic Internet-delivered treatments. For instance, Fernández-
Álvarez et al. (2017) found that one of the main reasons patients gave for 
dropping out of a transdiagnostic Internet-based protocol was that the 
treatment was too general, and, as a result, their specific demands and 
needs were often not met. Consequently, efforts to personalize treatments 
may contribute to decreasing dropout rates from these treatments. For 
instance, in order to develop a more personalized treatment, instead of 
applying a generic, “one-size-fits-all” transdiagnostic treatment, some 
authors have proposed choosing among a number of treatment modules 
to address the specific set of “strengths and weaknesses” presented by 
each individual (Black et al., 2018; Sauer-Zavala, Cassiello-Robbins, 
Ametaj, Wilner, & Pagan, 2018). Because this approach has potential 
benefits for both patients (by focusing on “what really matters” for them) 
and providers (a more cost-effective treatment strategy), and it is closer to 
what clinicians typically do in routine care settings (i.e. deliver evidence-
based psychological treatments in a flexible way) (Black et al., 2018), 
future studies should be conducted to explore this approach in public 
specialized care. In this regard, a more personalized treatment could also 
be achieved by using the information about predictors of treatment 
outcome in order to provide the therapeutic option that best matches the 
sociodemographic and clinical profile of each patient (DeRubeis et al., 
2014). In sum, more research efforts should be devoted to the 
personalization and optimization of current evidence-based treatments in 
order to increase their (cost) effectiveness.  
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Another implication of the RCT is related to the study of the effects 
of transdiagnostic treatments on disorder-specific measures. Along with 
generic measures of anxiety and depression, the study of the efficacy of 
these treatments on more specific symptoms is necessary in order to shed 
light on their relative efficacy for each distinct emotional disorder. Although 
we included measures to assess the effects of the intervention on the 
different diagnoses (e.g. PSWQ for GAD symptoms, OCI-R for OCD 
symptoms, and so on), the sample size for each of the diagnostic 
subgroups was too low, and, therefore, acceptable levels of statistical 
power could not be met. Therefore, further trials with larger sample sizes 
are warranted to explore the effects of transdiagnostic Internet-delivered 
interventions in each of the different emotional disorders. For instance, 
transdiagnostic treatments may be compared to disorder-specific protocols 
for each of the different emotional disorders. A number of RCTs using this 
strategy have already been attempted in community samples, showing 
equivalent effects between these two treatment approaches for depression 
(Titov et al., 2015), panic disorder (Fogliati et al., 2016), social anxiety 
disorder (Dear et al., 2016), and generalized anxiety disorder (Dear et al., 
2015). However, the number of studies comparing these two treatment 
approaches is still very low (González-Robles et al., 2018; Newby et al., 
2015, 2016). Additionally, because a) transdiagnostic treatments may be 
more advantageous than disorder-specific treatments in terms of costs 
and ease of dissemination, and b) comparing these two treatments 
approaches can provide data that strengthen the notion of a common 
transdiagnostic psychopathology underlying anxiety and depressive 
disorders, further studies comparing these two treatment approaches are 
warranted, especially in real-world settings (e.g. primary or specialized 
care), where these aspects are of the highest importance.  
Furthermore, in order to ascertain how transdiagnostic treatments 
modulate the different core processes underlying anxiety and depressive 
disorders, clinical research should strive to include assessment 
instruments focused on the evaluation of transdiagnostic cognitive, 
behavioral, and emotional processes such as neuroticism (Barlow, Allen, 
& Choate, 2004), rumination (Ehring & Watkins, 2008), anxiety sensitivity 
(Boswell et al., 2013), and safety behaviors (Schmidt et al., 2012). For 
instance, in our RCT we included the BISBAS (Carver & White, 1994; 
Caseras, Ávila, & Torrubia, 2003), a scale to assess the transdiagnostic 
constructs of behavioral inhibition and behavioral activation. In this vein, 
the inclusion of measures to assess transdiagnostic mechanisms might be 
particularly relevant when these treatments are studied in comparison with 
disorder-specific protocols. Theoretically, because transdiagnostic 
treatments target deeper and more stable common core processes (e.g. 




effects might be expected compared to disorder-specific treatments 
(Sauer-Zavala et al., 2017). Therefore, the inclusion of scales to assess 
transdiagnostic mechanisms is warranted in future clinical research, 
particularly when these treatments are compared to disorder-specific 
protocols. On the other hand, transdiagnostic treatments are rarely 
explored in public specialized care (González-Robles et al., 2018). 
Because the sociodemographic and clinical characteristics of patients 
attending public mental health services may differ substantially from that of 
other settings like the university or community samples (e.g. regarding 
educational level, Internet usage skills, use of medication, and so on), 
more studies focused on searching for predictors and moderators of 
treatment outcome are needed in this particular context.  
Third, the online versions of two brief scales for the assessment of 
anxiety and depression were validated in Spanish clinical samples with 
heterogeneous anxiety and depressive disorders (Chapters 4 and 5). 
Taken together, the results showed good internal consistency, construct 
validity and a factor structure in accordance with previous validations of 
the scales. However, some important properties such as test-retest 
reliability were not evaluated. Moreover, although the sensitivity to change 
of the OASIS was explored, this aspect was not analyzed in the ODSIS. 
Thus, future validations of both scales should be performed that analyze 
the test-retest reliability of both scales, as well as the sensitivity to change 
of the ODSIS. Finally, because we focused on patients with anxiety and 
depressive disorders, research on the psychometric properties of these 
questionnaires in other populations, such as nonclinical individuals or 
patients with more severe psychopathology (e.g. individuals with bipolar or 
psychotic disorders), is warranted.  
Finally, a randomized pilot study was conducted to explore the 
feasibility of adding treatment modules for the regulation of positive affect 
in a transdiagnostic protocol with traditional components for the regulation 
of negative affect (Chapter 7). Although promising results were found, the 
study presented limitations that warrant further research to more precisely 
determine the contribution of this component to treatment outcome. The 
main limitations were the low sample size and the fact that carryover 
effects could not be ruled out, affecting the understanding of the true 
contribution of this component to the clinical change. Therefore, future 
studies are needed with designs that make it possible to draw safer 
conclusions about the true contribution of these components for the 
regulation of positive affectivity, such as dismantling studies (Papa & 
Follette, 2014) or single-case experimental designs (Barlow, Nock, & 
Hersen, 2009). Another research strategy that may help to ascertain the 
contribution of each component to outcomes is to collect clinical data 
conducting assesments at different points throughout the entire 
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intervention process, and analyze them in relation with the different 
components integrated in the treatment, such as the post-module 
measurements included in our RCT to assess anxiety, depression, and 
positive/negative affectivity. Using this strategy, the results of a recent 
study by Mira et al. (2018) suggested that positive affectivity only improved 
after introducing a component based on positive psychology interventions. 
In summary, further research should be conducted to more accurately 
determine the extent to which each of these treatment components 
contributes to clinical outcomes.  
 
Conclusions 
The studies in this doctoral thesis contribute to the field of 
transdiagnostic treatments, showing the effectiveness of a transdiagnostic 
Internet-delivered protocol for emotional disorders in public specialized 
mental health care, compared to TAU. To our knowledge, this is the first 
time that a transdiagnostic Internet-delivered protocol has been tested in 
this setting, with results that raise the question of whether patients in the 
Spanish public mental health care system are receiving the most adequate 
treatment alternatives for anxiety and depressive disorders. Moreover, a 
systematic review was conducted to synthesize the state-of-the-art of 
transdiagnostic treatments, highlighting the importance of assessing the 
comorbid disorders in these interventions. At the same time, contributions 
to the field of online evidence-based assessment were made through the 
validation of the OASIS and the ODSIS in clinical samples with emotional 
disorders. Finally, the importance of promoting protective factors in 
transdiagnostic treatments was underscored by showing the feasibility of a 
transdiagnostic treatment that included treatment components for the 
regulation of positive affect, opening the door to large-scale efficacy and 
effectiveness studies. Although the results hold promise, we hope that the 
findings and recommendations discussed in the current doctoral thesis 
encourage other researchers to continue to explore the possibilities of 
transdiagnostic Internet-delivered treatments to reduce the burden of 
emotional disorders. In this endeavor, future research is warranted to 
improve the effectiveness and acceptability of transdiagnostic Internet-
delivered interventions among users, clinicians, and policy makers, in 
order to increase their dissemination and implementation in current mental 
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Contacto con Investigadores: Alberto González   vrobles@uji.es    964387649 
Cuestionario de recogida de datos 
(CRD USM)   
PROCEDIMIENTO A SEGUIR: 
 Evaluar criterios inclusión/ exclusión al estudio.
 Recabar datos personales.
 Mostrar y comentar hoja de información al paciente (HIP)
Documentos necesarios adicionales a este: 
 Hoja de Información al paciente
CRITERIOS DE INCLUSIÓN: 
1. Edad: tener 18 años o más.
2. Entender español hablado y escrito.
3. Padecer un Trastorno Emocional  (Trastorno Depresivo Mayor, Distimia, Trastorno de
Ansiedad Generalizada, Trastorno Obsesivo-Compulsivo, Trastorno de Pánico,
Agorafobia, Trastorno de Ansiedad Social, Trastorno de ansiedad no especificado,
Trastorno del estado de ánimo no especificado).
4. Acceso a Internet con cuenta de correo electrónico.
CRITERIOS DE EXCLUSIÓN: 
1. Padecer un trastorno mental grave. Se excluirán los trastornos siguientes: esquizofrenia,
trastorno bipolar.
2. Presencia de riesgo de suicidio.
3. Diagnóstico de dependencia de alcohol y/o sustancias.
4. Enfermedad médica de consideración que impida la realización del tratamiento
psicológico.
5. Recibir otro tratamiento psicológico mientras dure el estudio.
6. En el caso de estar recibiendo tratamiento farmacológico, el incremento de dosis y/o cambio
del tipo de medicación significará la exclusión del participante del ensayo.
DATOS DEL PACIENTE 
NOMBRE: __ _______________APELLIDOS:________________________________ 
 EDAD:  TELÉFONO: 
CORREO ELECTRÓNICO (en mayúsculas): 
POSIBLE DIAGNÓSTICO: ___________ 
TRATAMIENTO FARMACOLÓGICO PRESCRITO (Si está recibiendo 




EN CASO DE RECHAZO/ABANDONO DEL ESTUDIO, especificar causa: 
 No lo necesita
 No cree en su utilidad
 Falta de tiempo
 Falta de habilidad para el
manejo del programa
 No le gustan los ordenadores
 No le gusta el programa / no se
siente a gusto con su manejo 
 Prefiere un trato personal
 Falta de confianza en la
seguridad de los datos
Otros motivos (especificar): 
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DISEÑO, DESARROLLO Y PUESTA A PRUEBA DE UN PROTOCOLO DE 
TRATAMIENTO TRANSDIAGNÓSTICO PARA LOS TRASTORNOS 
EMOCIONALES ADMINISTRADO ONLINE  
Hoja de información al paciente (presentada por el centro de salud) 
INFORMACIÓN PARA EL PACIENTE 
Apreciado Sr./Sra.: 
Antes de confirmar su participación en el estudio es importante que entienda en qué 
consiste. Por favor, lea detenidamente este documento y haga todas las preguntas 
que le puedan surgir. 
Objetivo del estudio: 
El objetivo principal de este estudio es desarrollar un programa de psicoterapia 
aplicado a través de Internet para el tratamiento de los trastornos emocionales 
(trastorno depresivo mayor, distimia, trastorno de ansiedad generalizada, trastorno de 
pánico, agorafobia, trastorno de ansiedad social, trastorno obsesivo-compulsivo, 
trastorno de ansiedad no especificado, trastorno del estado de ánimo no especificado) 
y evaluar su eficacia.  
Desarrollo del estudio: 
En una primera fase del estudio se evaluará si los pacientes pueden participar o no en 
el mismo, aquellos pacientes que puedan participar en el estudio (fase 2) serán 
adscritos a una de estas dos condiciones: 
a) Tratamiento habitual (el tratamiento psiquiátrico y/o psicológico que se administre
de forma regular en el centro de salud).
El tratamiento habitual consistirá en el tratamiento psiquiátrico y/o psicológico de 
referencia más adecuado a la problemática de cada paciente, y será administrado 
por un especialista del ámbito clínico (psiquiatra y/o psicólogo clínico) en el centro 
de salud mental.  
b) Protocolo de tratamiento transdiagnóstico aplicado online.
El tratamiento transdiagnóstico aplicado online consistirá en un programa vía 
internet e interactivo que el paciente puede realizar desde su casa compuesto por 
un total de 12 módulos de periodicidad semanal. Estos distintos módulos o 
componentes terapéuticos tienen como objetivo fundamental: 1) incrementar la 
conciencia emocional; 2) facilitar la flexibilidad cognitiva; 3) identificar patrones de 
evitación comportamental y emocional; y; 4) promover la exposición interoceptiva 
y situacional. 
Es posible que, de forma paralela a este estudio, se realicen grupos de discusión 
formados por los pacientes participantes en el mismo, cuyo contenido será transcrito y 
analizado, con el objetivo de identificar las barreras y dificultades del uso del programa 
de psicoterapia. Al ser una posibilidad al margen del estudio, si se diera la 
oportunidad, se solicitaría la firma de un nuevo consentimiento informado.  
Participantes: 
Los participantes de este estudio son personas diagnosticadas de trastornos 
emocionales (trastornos de ansiedad, trastornos depresivos). 
Los participantes deben tener una edad mínima de 18 años y disponer de una 
conexión a Internet. 
Participación del paciente en el estudio: 
En esta primera fase del estudio se recogerá la siguiente información que nos ayudará 
a conocer si cumple los criterios para ser incluido en el estudio: 
CRITERIOS DE INCLUSIÓN: 
1. Tener 18 años o más.
2. Entender español hablado y escrito.
3. Padecer un Trastorno Emocional (Trastorno Depresivo Mayor, Distimia, Trastorno
de Ansiedad Generalizada, Trastorno Obsesivo-Compulsivo, Trastorno de Pánico,
Agorafobia, Trastorno de Ansiedad Social, Trastorno de ansiedad no especificado,
Trastorno del estado de ánimo no especificado).
4. Disponer de acceso a Internet y cuenta de correo electrónico.
CRITERIOS DE EXCLUSIÓN: 
1. Padecer esquizofrenia.
2. Padecer trastorno bipolar.
3. Presentar alto riesgo de suicidio.
4. Presentar dependencia de sustancias y/o de alcohol.
5. Padecer enfermedad médica de consideración que impida la realización del
tratamiento psicológico.
6. Recibir otro tratamiento psicológico mientras dure el estudio.
7. En el caso de estar recibiendo tratamiento farmacológico, incremento de dosis
y/o cambio del tipo de medicación.
El investigador responsable se pondrá en contacto con usted una vez finalizada esta 
primera fase para indicarle su inclusión en el estudio y las indicaciones para participar 
en la segunda fase del estudio.  
Beneficios/riesgos: 
El beneficio para los pacientes será un seguimiento sobre su enfermedad más 
constante, de forma que cualquier problema será más rápidamente detectado con lo 
que se remitirá a recibir el tratamiento más adecuado.  
No existen riesgos en la realización de estudio.  
Participación voluntaria: 
Su participación en el estudio es enteramente voluntaria. Usted decide si quiere 
participar o no. Incluso si decide participar, puede retirarse del estudio en cualquier 
momento sin tener que dar explicaciones. En ningún caso esto afectará su atención 
médica posterior.  
Confidencialidad: 
El estudio se llevará a cabo siguiendo las normas deontológicas reconocidas por la 
Declaración de Helsinki (52ª Asamblea General Edimburgo, Escocia, Octubre 2000), 
las Normas de Buena Práctica Clínica y cumpliendo la legislación vigente y la 
normativa legal vigente española que regula la investigación clínica en humanos (Real 
Decreto 1720/2007 que desarrolla la ley orgánica 15/99 y Ley 14/2007 de 
Investigación Biomédica).  
Los datos serán protegidos de usos no permitidos por personas ajenas a la 
investigación y se respetará la confidencialidad de los mismos de acuerdo a la Ley 
Orgánica 15/1999, de 13 de diciembre, sobre la Protección de Datos de Carácter 
Personal y la ley 41/2002, de 14 de noviembre, ley básica reguladora de la autonomía 
del paciente y de derechos y obligaciones en materia de información y documentación 
clínica. Por tanto, la información generada en este ensayo será considerada 
estrictamente confidencial, entre las partes participantes.   
Revisión Ética: 
Un comité ético independiente ha revisado los objetivos y características del estudio y 
ha dado su aprobación favorable. 
Preguntas/Información: 
Si usted o su familia tienen alguna pregunta con respecto al estudio puede contactar 
con el profesional de su centro de salud o bien con el Investigador Principal.  
Si precisa más información, por favor, pregunte en su centro de salud o a: 
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DISEÑO, DESARROLLO Y PUESTA A PRUEBA DE UN PROTOCOLO DE 
TRATAMIENTO TRANSDIAGNÓSTICO PARA LOS TRASTORNOS EMOCIONALES 
ADMINISTRADO ONLINE  
Hoja de información al paciente (presentada por evaluadores) 
INFORMACION PARA EL PACIENTE 
Apreciado Sr./Sra.: 
Antes de confirmar su participación en el estudio es importante que entienda en qué 
consiste. Por favor, lea detenidamente este documento y haga todas las preguntas 
que le puedan surgir:  
Objetivo del estudio: 
El objetivo principal de este estudio es desarrollar un programa de psicoterapia 
aplicada a través de Internet para el tratamiento de los trastornos emocionales 
(Trastorno depresivo mayor, trastorno de ansiedad generalizada, trastorno de pánico, 
agorafobia, trastorno de ansiedad social y trastorno obsesivo-compulsivo) y evaluar su 
eficacia.  
Desarrollo del estudio: 
En una primera fase del estudio se evaluará si los pacientes pueden participar o no en 
el mismo, aquellos pacientes que puedan participar en el estudio (fase 2) serán 
adscritos a una de estas dos condiciones: 
a) Tratamiento habitual (el tratamiento psiquiátrico y/o psicológico que se administre
de forma regular en el centro de salud).
El tratamiento habitual consistirá en el tratamiento psiquiátrico y/o psicológico de
referencia más adecuado a la problemática de cada paciente, y será administrado
por un especialista del ámbito clínico (psiquiatra y/o psicólogo clínico) en el centro
de salud mental.
b) Protocolo de tratamiento transdiagnóstico aplicado online.
El tratamiento transdiagnóstico aplicado online consistirá en un programa vía
internet e interactivo que el paciente puede realizar desde su casa compuesto por
un total de 12 módulos de periodicidad semanal. Estos distintos módulos o
componentes terapéuticos tienen como objetivo fundamental: 1) incrementar la
conciencia emocional; 2) facilitar la flexibilidad cognitiva; 3) identificar patrones de
evitación comportamental y emocional; y; 4) promover la exposición interoceptiva
y situacional.
Es posible que, de forma paralela a este estudio, se realicen grupos de discusión 
formados por los pacientes participantes en el mismo, cuyo contenido será transcrito y 
analizado, con el objetivo de identificar las barreras y dificultades del uso del programa 
de psicoterapia. Al ser una posibilidad al margen del estudio, si se diera la 
oportunidad, se solicitaría la firma de un nuevo consentimiento informado 
Participantes: 
Los participantes de este estudio serán personas diagnosticadas de trastornos 
emocionales (trastornos de ansiedad, trastornos depresivos).  
Los participantes deben tener una edad mínima de 18 años y disponer de acceso a 
internet desde su domicilio.  
Participación del paciente en el estudio: 
En esta segunda fase del estudio se recogerá la siguiente información: 
- Variables sociodemográficas, como género, edad, estado civil, nivel educativo, 
socioeconómico, y ocupación. 
- Variables psicológicas:  
a) Entrevista diagnóstica psiquiátrica.
b) Entrevista de utilización de servicios médicos
Beneficios/riesgos: 
El beneficio para los pacientes por su participación en el estudio será un seguimiento 
sobre su enfermedad más constante, de forma que cualquier problema será más 
rápidamente detectado con lo que se remitirá a recibir el tratamiento más adecuado.  
No existen riesgos en la realización de estudio.  
Participación voluntaria: 
Su participación en el estudio es enteramente voluntaria. Usted decide si quiere 
participar o no. Incluso si decide participar, puede retirarse del estudio en cualquier 
momento sin tener que dar explicaciones. En ningún caso esto afectará su atención 
médica posterior.  
Confidencialidad: 
El estudio se llevará a cabo siguiendo las normas deontológicas reconocidas por la 
Declaración de Helsinki (52ª Asamblea General Edimburgo, Escocia, Octubre 2000), 
las Normas de Buena Práctica Clínica y cumpliendo la legislación vigente y la 
normativa legal vigente española que regula la investigación clínica en humanos (Real 
Decreto 1720/2007 que desarrolla la ley orgánica 15/99 y Ley 14/2007 de 
Investigación Biomédica).  
Los datos serán protegidos de usos no permitidos por personas ajenas a la 
investigación y se respetará la confidencialidad de los mismos de acuerdo a la Ley 
Orgánica 15/1999, de 13 de diciembre, sobre la Protección de Datos de Carácter 
Personal y la ley 41/2002, de 14 de noviembre, ley básica reguladora de la autonomía 
del paciente y de derechos y obligaciones en materia de información y documentación 
clínica. Por tanto, la información generada en este ensayo será considerada 
estrictamente confidencial, entre las partes participantes.   
Revisión Ética: 
Un Comité Ético Independiente ha revisado los objetivos y características del estudio y 
ha dado su aprobación favorable. 
Preguntas/Información: 
Si usted o su familia tienen alguna pregunta con respecto al estudio puede contactar 
con el profesional de su centro de salud o bien con el Investigador Principal.  
Si precisa más información, por favor, pregunte en su centro de salud o a: 
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CONSENTIMIENTO INFORMADO 
Título del PROYECTO: DISEÑO, DESARROLLO Y PUESTA A PRUEBA DE UN 
PROTOCOLO DE TRATAMIENTO TRANSDIAGNÓSTICO PARA LOS 
TRASTORNOS EMOCIONALES ADMINISTRADO ON-LINE. 
Yo,   
(Nombre y apellidos del participante) 
He leído la hoja de información que se me ha entregado. 
He podido hacer preguntas sobre el estudio y he recibido suficiente información sobre 
el mismo. 
He hablado con:   
(Nombre del investigador/médico) 
Comprendo que mi participación es voluntaria. 
Comprendo que puedo retirarme del estudio: 
1) Cuando quiera.
2) Sin tener que dar explicaciones.
3) Sin que esto repercuta en mis cuidados médicos.
Presto libremente mi conformidad para participar en el estudio. 
Deseo ser informado sobre los resultados del estudio:  sí  no   (marque lo que
proceda) 
Doy mi conformidad para que mis datos clínicos sean revisados por personal ajeno al 
centro, para los fines del estudio, y soy consciente de que este consentimiento es 
revocable. 
He recibido una copia firmada de este Consentimiento Informado. 
Firma del participante: 
Fecha: 
He explicado la naturaleza y el propósito del estudio al paciente mencionado 
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PROTOCOLO DE APOYO POR PARTE DEL TERAPEUTA 
A LA CONDICIÓN DE TRATAMIENTO TRANSDIAGNÓSTICO ONLINE 
1. 2 SMSs DE APOYO A LA SEMANA
2. UNA LLAMADA DE TELÉFONO A LA SEMANA DE UN MÁXIMO DE 10 MINUTOS: EL
CONTENIDO DE LA LLAMADA VARIARÁ DEPENDIENDO DE CÓMO VAYAN
AVANZANDO EN LOS MÓDULOS.
1. Si en una semana no ha cambiado de módulo (ANIMAR)
2. Si en una semana realiza un módulo (REFORZAR)
3. Si hace dos módulos en una semana. (REFORZAR Y FRENAR)
4. Si en una semana hace más de dos módulos. (¡¡¡FRENAR!!!)
Estructura de las llamadas: 
a) Saludar y preguntar si ha tenido algún problema.
b) Resolver dudas concretas sobre el uso del protocolo (p. ej., no entiendo cómo tengo
que hacer la tarea “registro de conductas impulsadas por las emociones”), si las 
hubiera. 
b) 1 (animar), 2 (reforzar), 3 (reforzar y frenar) o 4 (¡¡frenar!!):
- 1 (animar): Te animo a que sigas adelante, recuerda que aunque puedes hacer el 
programa a tu ritmo, sacarás el máximo beneficio realizando un módulo a la semana.  
- 2 (reforzar): ¡Muy bien! Estás avanzando a buen ritmo, lo ideal es un módulo a la semana,  
recuerda  que es muy importante realizar las tareas que te propone el programa” 
- 3 (reforzar y frenar): Bien, has finalizado otro módulo. Vas algo deprisa. No sigas 
avanzando y repasa las tareas que te ha propuesto el programa. Recuerda que lo mejor es 
que realices un módulo por semana. 
- 4 (frenar): Estas avanzando demasiado deprisa, recuerda que para que las estrategias 
que te propone Sonreír es Divertido se conviertan en habilidades es muy importante que 
vayas realizando las tareas y practiques mucho por lo recomendable es que realices un 
módulo semanalmente. 
c) Recordar/animar a que repasen el contenido de los módulos si lo consideran
necesario. 
d) Recordar la importancia de realizar las tareas.
Esquema orientativo del apoyo recibido a lo largo de la semana: 
Lunes Martes Miércoles Jueves Viernes Sábado Domingo 
SMS Teléfono SMS 
*Importante: todas las llamadas, así como su duración exacta (minutos y segundos) deben
registrarse SIEMPRE en el documento Excel correspondiente. 
